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Wer nichts prüft, entdeckt nichts. 
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Abstract 
Abstract 
Within this Ph.D. thesis, capillary electrophoresis (CE) and inductively coupled plasma mass 
spectrometry (ICP-MS) were applied to investigate the pharmacokinetic aspects of metal-
based anticancer compounds with Ru or Pt as central atoms. Furthermore, both techniques 
were used for the first time to characterize the interaction between anti-diabetic complexes 
with serum proteins.  
An important factor in antineoplastic chemotherapy is the cellular uptake of drugs. The more 
lipophilic a compound is, the easier it can pass the membrane by passive diffusion and 
accumulate in the cell. A higher accumulation of the anticancer drug in the tumor tissue 
normally results in higher antitumor activity. The lipophilicity of a set of Pt compounds was 
determined by the shake-flask method as well as indirectly by microemulsion electrokinetic 
chromatography (MEEKC). During these investigations the hybrid technique MEEKC-ICP-
MS was established for the first time. This new method is characterized by a low detection 
limit and enables the determination of the capacity factor (log k) of UV/vis-silent compounds. 
A good correlation between log k obtained by MEEKC and MEEKC-ICP-MS and the 
corresponding octanol-water-partition coefficient (log P) was observable for complexes with 
minor structural differences. To confirm the structure-activity relationship, the log P and log k 
values were set in correlation with the accumulation of the Pt complexes in cancer cell lines 
and their cytotoxicity. It was found that the more lipophilic the compound is, the higher is the 
cellular uptake and the lower is the IC50 value.  
The influence of the lipophilicity on the biodistribution of oxaliplatin and its methyl derivatives 
KP1537 and KP1691 was also studied in tumor-bearing mice. The analysis of the Pt content 
in different tissue samples indicated that KP1691 is quickly accumulated in the tumor but 
also the efflux is rather rapid. No differences in the tumor accumulation were seen for 
oxaliplatin and KP1537 in a time frame of 6 h. 
A further focus of this thesis was the interaction of therapeutic metal complexes with serum 
proteins. The binding of drugs to serum proteins has a big impact on their biodistribution and 
modes of action. With the help of the hybrid technique CZE-ICP-MS, it was shown that 
albumin is the main binding partner for the Ru complex sodium trans-[tetrachloridobis-(1H-
indazole)ruthenate(III)] (KP1339), currently undergoing clinical trials, as well as for Zn-based 
anti-diabetic compounds. The experimental data for the Zn complexes confirmed theoretical 
calculations based on stability constants. Additionally to the plasma distribution of KP1339, 
the accumulation in different tissues was investigated. High concentrations in lung and 
thymus make this compound interesting for the treatment of lung cancer and lymphoblastic 
leukemia.
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Abstract 
Concluding, bioanalytical methods can significantly contribute to a better understanding of 
the properties and biological behavior of novel remedies. This enables the development of 
compounds with defined pharmacological mechanism, which could improve treatment 
efficacy and reduce side effects. 
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Zusammenfassung 
Zusammenfassung 
 
Im Rahmen dieser Dissertation wurden Kapillarelektrophorese (CE) und induktiv gekoppeltes 
Plasma-Massenspektrometrie (ICP-MS) zur Untersuchung pharmakokinetischer Aspekte von 
metallbasierenden Krebsmedikamenten mit Ru und Pt als Zentralatom eingesetzt. Des 
Weiteren wurden beide Techniken zum ersten Mal zur Charakterisierung der 
Wechselwirkungen zwischen Antidiabetika und Serumproteinen verwendet.  
Die zelluläre Aufnahme ist ein wichtiger Faktor in der antineoplastischen Chemotherapie. Je 
lipophiler eine Verbindung ist, desto leichter kann sie passiv die Membran passieren und in 
der Zelle angereichert werden. Eine höhere Akkumulation des Chemotherapeutikums im 
Tumorgewebe resultiert oft in einer verbesserten Antiproliferation. Die Lipophilie für 
verschiedene Pt Verbindungen wurde sowohl mit der Shake-Flask Methode als auch indirekt 
mit elektrokinetischer Chromatographie mit Mikroemulsionen (MEEKC) bestimmt. Im Zuge 
dieser Untersuchungen wurde die Hybridtechnik MEEKC-ICP-MS etabliert. Diese neuartige 
Technik zeichnet sich durch ein niedriges Detektionslimit aus und ermöglicht auch die 
Kapazitätsfaktor (log k) Bestimmung von UV/vis-inaktiven Verbindungen. Eine gute 
Korrelation zwischen den log k Werten, die mit MEEKC bzw. MEEKC-ICP-MS bestimmt 
wurden, und den dazugehörigen Oktanol-Wasser-Verteilungskoeffizienten (log P) wurde bei 
Komplexen mit geringen strukturellen Unterschieden beobachtet. Zur Bestätigung der 
Struktur-Wirkungs-Beziehung wurden die log P und log k Werte in Korrelation mit der 
Akkumulation der Pt-Komplexe in verschiedenen Zelllinien und deren Zytotoxizität gebracht. 
Es zeigte sich, dass je lipophiler der Komplex ist desto größer ist die zelluläre Aufnahme und 
umso kleiner der IC50 Wert. 
Der Einfluss der Lipophilie auf die Verteilung von Oxaliplatin und dessen Methylderivaten 
KP1691 und KP1537 in tumortragenden Mäusen wurde ebenfalls untersucht. Die Analyse 
des Platingehaltes in verschiedenen Geweben zeigte, dass KP1691 zum einem sehr schnell 
im Tumor angereichert wird, aber auch sehr schnell wieder ausgeschieden wird. Zwischen 
Oxaliplatin und KP1537 wurden keine großen Unterschiede in der Tumorakkumulation im 
beobachteten Zeitraum festgestellt.   
Ein weiterer Schwerpunkt dieser Doktorarbeit war die Untersuchung der Wechselwirkung 
von therapeutischen Metallkomplexen mit Serumproteinen. Die Anbindung an Serumproteine 
hat einen entscheidenen Einfluss auf die Bioverteilung und den Wirkmechanismus von 
Arzneimitteln. Mit Hilfe der Hybridtechnik CZE-ICP-MS konnte gezeigt werden, dass Albumin 
den Hauptbindungspartner im Blut für den zur Zeit in klinischen Studien getesteten Ru-
Komplex Natrium trans-[tetrachloridobis-(1H-indazol)ruthenat(III)] (KP1339) wie auch für 
Antidiabetika auf Zinkbasis darstellt. Die experimentellen Daten für die Zn-Komplexe 
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Zusammenfassung 
bestätigten theoretische Berechnungen der Stabilitätskonstanten. Zusätzlich zu der 
Verteilung im Blut wurde für KP1339 die Akkumulation in diversen Mausorganen untersucht. 
Hohe Konzentrationen in Lunge und Thymus machen diese Verbindung möglicherweise 
interessant für die Behandlung von Lungenkrebs und lymphoblastischer Leukämie. 
Zusammenfassend kann gesagt werden, dass bioanalytische Methoden signifikant zu einem 
besseren Verständnis des Verhaltens und der Eigenschaften von neuen Medikamenten 
beitragen können. Dies wiederum ermöglicht die Entwicklung von Verbindungen mit 
definierten pharmakologischen Wirkungsmustern, die die Effektivität von Therapien 
verbessern und Nebenwirkungen minimieren könnten. 
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Abbreviations 
Abbreviations 
 
API atmospheric pressure ionization 
BGE background electrolyte 
CE capillary electrophoresis 
CEC capillary electrochromatography 
CGE capillary gel electrophoresis 
CI chemical ionization 
CIEF capillary isoelectric focusing 
CITP 
CTR1 
capillary isotachophoresis 
copper transporter-1 
CZE capillary zone elctrophoresis 
DNA 2„-deoxyribonucleic acid 
e.g. exempli gratia (for example) 
EOF electroosmotic flow 
ESI electrospray ionization 
et al. et alii (and others) 
etc. 
FE 
et cetera (and other things) 
electrical force 
FF frictional force 
FDA 
FOLFIRI 
 
 
FOLFOX4 
 
 
5-FU 
Food and Drug Administration 
chemotherapy with 5-fluorouracil, leucovorin and 
irinotecan 
chemotherapy with 5-fluorouracil, leucovorin and 
oxaliplatin 
5-fluorouracil 
GC gas chromatography 
HPLC high performance liquid chromatography 
HSA human serum albumin 
ICP inductively coupled plasma 
KP1019 indazolium trans-[tetrachloridobis(1H-indazole)-
ruthenate(III)] 
KP1339 
KP1537 
 
 
KP1691 
 
sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] 
(SP-4-2)-[(1R,2R,4R)-4-Methyl-1,2-diaminecyclohexane-
κ2N,N’][ethanedioato(2-)-κ2O1,O2]platinum(II)  
(SP-4-2)-[(1R,2R,4S)-4-Methyl-1,2-diaminecyclohexane-
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Abbreviations 
 
LA 
κ2N,N’][ethanedioato(2-)-κ2O1,O2]platinum(II) 
laser abalation 
LADME liberation, absorption, distribution, metabolism and 
excretion 
log k capacity factor 
log P octanol-water partition coefficient 
LV leucovorin 
MALDI matrix-assisted laser desorption ionization 
MEEKC microemulsion electrokinetic chromatography 
MEKC micellar electrokinetic chromatography 
MS mass spectrometry 
MSA mouse serum albumin 
m/z mass-to-charge   mass-to-charge ratio 
NAMI-A imidazolium trans-[tetrachlorido(S-dimethylsulfoxide)(1H-
imidazole)ruthenate(III)] 
RF radio frequency 
SDS sodium dodecyl sulphate 
Tf transferrin 
UV ultra violet 
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Introduction 
1. Introduction 
 
1.1. Epidemiology 
 
Worldwide 10.9 million people are diagnosed with cancer each year and there are 
approximately 6.7 million deaths due to this disease [1]. Malignant neoplasms are 
responsible for around 12% of deaths worldwide, but the percentage of all deaths due to 
cancer in the different regions of the world varies from only 4% in Africa to 23% in Northern 
America (Figure 1). 
 
 
 
Figure 1. Proportion of all deaths caused by cancer in the world in 2008 [1]. 
 
 
This means that in industrial countries nearly one in four deaths is due to malignant 
neoplasms. In these countries, most deaths are still related to cardiovascular diseases. A 
closer look at age-adjusted mortality rates indicates that deaths related to the cardiovascular 
system have declined markedly since 1970 whereas cancer mortality shows only a slight, 
gradual downtrend (Figure 2) [2]. This will probably continue in the next years and in 15-20 
years cancer will be the most frequent cause of death. When mortality of malignant 
neoplasms is more closely inspected, lung, colorectal and prostate cancer are the most 
frequent types responsible for death in the male population, while breast, colon and lung 
cancers are predominant for women [3]. Statistics for Europe indicate an increase in total 
cancer cases since 1975 but the death rates have fallen by 25% for males and 18% for 
females for all cancers since 1990 (Figure 3) [4]. This can be explained by the development 
of improved cancer therapeutics as well as by improved prevention and early diagnosis. 
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Figure 2. The most common causes of death in Germany for men and women [2].
 
 
 
 
 
 
Figure 3. Age-standardized (European) incidence and mortality rates for all cancers [4]. 
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1.2. Malignant transformation 
 
The first reports of cancer are traceable to the time of the old Egyptians [5]. The term 
“cancer” was introduced by Hippocrates (ca. 460-370 BC) which also was searching for the 
cause of this illness. He suggested that an imbalance in the bodily fluids is the cause of 
cancer. This theory remained the conventional wisdom for generations, but with the 
improvements in medicine and clinical diagnostic his suggestion was rapidly discarded in 
favor of more evidence-based models [6, 7]. Nowadays cancer is recognized as a cell-based 
disease caused by sequential accumulation of mutations. In a lifetime, in any human 
individual being, 1010 DNA mutations occur, but a single mutation is not enough to lead to the 
development of cancer [8]. Analysis of the genome sequence in breast and colorectal 
cancers indicated that individual tumors accumulate an average of circa 90 mutant genes but 
only a subset of these contribute to the neoplastic process [9]. Especially alterations in genes 
called tumor suppressor genes and proto-oncogenes are critical [10]. Tumor suppressor 
genes like p53, Rb and BRCA1 encode proteins that are responsible for control processes 
essential to limiting cell proliferation. They act upon pathways involved in growth control and 
cell cycle regulation. If e.g. p53 detects DNA damage, it will stop cell cycle progression and 
allow time for DNA repair. If the repair mechanisms fail, it will activate the expression of 
several genes involved in apoptosis. 50%  of all human cancers have a mutated p53 gene 
[11]. Cancers with this mutation are generally aggressive and show resistance to radiation 
and chemotherapy which result in poor prognosis [12]. Oncogenes are genes which lead to 
modified proteins, which are unable to exert they function correctly and provide a selective 
growth advantage to the cell. They arise through the mutation of normal cellular genes with 
growth regulation called proto-oncogenes, such as growth factors (sis, hst-1, int-2), growth 
factor receptor tyrosine kinases (EGFR, Her2) or non-receptor tyrosine kinases (abl, src) [7].  
The damage of the genetic material can arise spontaneously through mistakes in somatic 
recombination events or through endogenous factors like oxidative stress or DNA replication 
errors. Mutations can be induced also exogenously by physical (e.g., ionizing radiation and 
UV light), chemical (e.g., polycyclic hydrocarbons and heavy metal salts) and biological 
carcinogens (e.g., bacteria, viruses and mycotoxins).   
Tumorgenesis follows the Darwinian evolution theory, mutations which lead to selective 
growth advantages result in a progressive conversion of normal human cells into cancer cells 
[13]. Further mutations in the offspring of these already modified cells result then in even 
faster growth. Malignant cells are characterized by self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless 
replicative potential, sustained angiogenesis, tissue invasion and metastasis [13]. 
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Carcinogenesis is a multistage process and therefore the majority of incidences appears at 
an age > 65 because it takes decades for these multiple mutations to happen [14, 15]. 
 
 
 
 
1.3. Cancer treatment 
 
There are five standard methods of treatment for cancer: surgery, chemotherapy, 
radiotherapy, immunotherapy and biological therapy. The choice of therapy depends of 
cancer state and type as well as patient‟s age, sex, physical and psychological conditions. 
Until 1960 surgical methods and radiotherapy dominated the field of cancer therapy but the 
cure rates also after even more radical local treatments just achieved 33% [16]. The reason 
for the low rate is that these two methods just can cure cancers that are confined to specific 
areas and have not spread, but often tumors are diagnosed when the patients already 
developed metastases. In these cases chemotherapy is required, which affects the entire 
body, not just a specific part. The use of chemotherapy to treat cancer began in the early 20th 
century and nowadays there are more than 50 chemotherapeutics available for the over 200 
different types of cancer, which can be given in various ways (Figure 4) [17]. The major 
categories of chemotherapeutic agents are alkylating agents (e.g., ifosfamide and 
cyclophoshamide), antimetabolites (e.g., 5-fluorouracil and gemcitabine), anthracyclines 
(e.g., epirubicin and mitoxantrone), plant alkaloids (e.g., irinotecan and etoposide), antitumor 
antibiotics (e.g., bleomycin), taxanes (e.g., docetaxel), monoclonal antibodies (e.g., 
cetuximab and herceptine) and Pt-based drugs. Despite of this variety of organic drugs, the 
three worldwide approved Pt drugs, cisplatin, carboplatin and oxaliplatin play a major role in 
contemporary medical oncology [18, 19]. 
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Figure 4. Key advances in the history of cancer chemotherapy [16]. 
 
 
 
1.3.1. Platinum-based anticancer compounds 
 
A new era of chemotherapy started in the 1960ies with the accidental discovery of the 
anticancer properties of cisplatin (cis-[diamminedichloridoplatinum(II)]; Figure 5) [20-23]. 
Cisplatin is a very effective cancer drug which is used against epithelial malignancies of 
ovaries, testes, head and neck, esophageal and lung [24]. With the introduction of cisplatin-
containing regimens the cure rate for men with metastatic testicular cancer rised from 5% to 
80% [25]. The antineoplastic activity results primarily from the interaction of the drug with the 
DNA, leading to adducts which induce apoptosis in cells [26]. Despite the great success at 
treating certain kinds of cancer, cisplatin has some limitations. First of all, a number of severe 
5
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side effects such as nephrotoxicity, neurotoxicity, nausea, vomiting, ototoxicity and alopecia 
accompany the use of cisplatin [27, 28]. In addition to its toxic side effects, the major 
limitations of cisplatin chemotherapy are acquired and intrinsic resistance [19]. Acquired 
resistance results from the reduction in cisplatin accumulation inside cancer cells either by 
reduced drug uptake or enhanced efflux [29-31], the increased capability of cells to repair 
cisplatin adducts [32-36], the modulation of apoptotic pathways in various cells, the up-
regulation in transcription factors, the loss of p53 and other protein functions and an 
increased detoxification by reaction with intracellular thiols [37-40].  
To overcome these negative aspects, several thousands of new Pt complexes have been 
synthesized in the last 35 years in order to identify compounds with superior efficacy, 
reduced toxicity, lack of cross-resistance or improved pharmacological characteristics [41]. 
So far 35 complexes have entered clinical trials as anticancer agents but in addition to 
cisplatin only carboplatin and oxaliplatin were approved for worldwide clinical use (Figure 5) 
[42]. 
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Figure 5. Pt-based drugs in worldwide clinical use: cisplatin (left), carboplatin (center) and oxaliplatin 
(right). 
 
 
Carboplatin {(SP-4-2)-[diammine(1,1-cyclobutanedicarboxylato-κO(2-))platinum(II)]; Figure 5} 
was introduced in 1981. Compared to the parent compound cisplatin, it has a lower reactivity 
and is therefore less toxic to the kidneys and the nervous system and causes less nausea 
and vomiting. However, myelosuppression is increased and was identified as the dose-
limiting factor [43]. The mode of action is analogous to cisplatin with identical DNA lesions 
formed. Thus, it has not enlarged the spectrum of Pt-treatable cancers, nor has it proved 
active in cisplatin-resistant cancers [37].  
 
Oxaliplatin {(SP-4-2)-[((1R,2R)-cyclohexanediamine-κ2N,N’)(ethanedioato(2-)-κ2O1,O2)-
platinum(II)]; Figure 5} has a broad spectrum of antineoplastic activity and has demonstrated 
lack of cross-resistance with cisplatin and carboplatin [44]. The reasons for the different fields 
of application of cisplatin and carboplatin on the one side and oxaliplatin on the other are: 
6
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formation of different DNA adducts, mismatch repair recognition proteins do not recognize 
oxaliplatin-induced DNA adducts [32] and the cellular uptake of oxaliplatin seems to be less 
dependent on the copper transporter CTR1 [45]. Nowadays oxaliplatin is used in the clinic in 
combination with 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOX4) as first-line treatment 
against metastatic colorectal carcinoma [46-48]. The FOLFOX4 regimen improves the 
response rate and increases median time to progression as well as median survival times {} 
[49]. The limiting factor of dosage is chronic neurotoxicity and is usually seen in patients who 
have received total doses >780 mg/m2 [50]. 
 
In order to find Pt-based drugs with better therapeutic properties than cisplatin, carboplatin 
and oxaliplatin, the focus of interest has moved to octahedral Pt(IV) compounds. Due to their 
increased inertness and consequently reduced toxicity and possibility of oral administration 
they could improve the living quality of cancer patients significantly [41, 42, 51]. Several 
examples of Pt(IV) complexes underwent clinical trials including satraplatin {(OC-6-43)-
[bis(acetato)amminedichlorido(cyclohexylamine)]platinum(IV); Figure 6} and LA-12 {(OC-6-
43)-[bis(acetato)(1-adamantylamine)amminedichlorido]platinum(IV); Figure 6} and show 
promising activity.  
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Figure 6. Chemical structures of satraplatin (left) and LA-12 (right). 
 
 
Satraplatin was investigated in advanced phase III clinical trials in hormone refractory 
prostate cancer in combination with prednisone [52, 53], and is currently in a phase II trial 
against non-small cell lung carcinoma. The main in vivo metabolite of satraplatin is 
cis[amminedichlorido(cyclohexylamine)]platinum(II) [54]. This satraplatin metabolite binds in 
a similar manner to the DNA as cisplatin [55], but its cellular uptake is not dependent on 
CTR1 and shows therefore also activity in cisplatin resistant cancer cells [56, 57]. The 
satraplatin derivative LA-12 has finished phase I clinical trials and has shown promising in 
vivo activity in ADJ/PC6 plasmacytoma and A2780 ovarian carcinoma tumor mice models 
[53, 58, 59]. 
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1.3.2. Ruthenium-based anticancer compounds 
 
Although Pt complexes are now widely used as anticancer agents, the development of drug 
resistance, the toxic side effects and the lack of activity against several types of cancer are 
problems which need to be overcome. This has motivated the search for anticancer activity 
amongst complexes of other metals. In the last years many research groups focused on 
metal complexes of Fe, Ru, Ga, Ti and Rh [60-62]. 
Ru compounds appear well-suited for medicinal applications. They have been investigated 
as immunosuppressants (e.g., cis-[Ru(NH3)4(Im)2], Im is imidazole), nitric oxide scavengers 
(e.g., Ru(III) polyaminocarboxylates such as AMD6245 and AMD1226), antibiotics (e.g., 
Ru(III) derivative of thiosemicarbazone) and antimalarials ([RuCl2(chloroquine)]2) [63-65]. 
Clarke observed at first the anticancer properties of Ru compounds in 1980 [66, 67]. But the 
Ru(III) ammines (e.g., [RuCl3(NH3)3]) with which he was working, were too insoluble for 
clinical use. To date just two Ru(III) complexes, namely imidazolium trans-[tetrachlorido(S-
dimethylsulfoxide)(1H-imidazole)ruthenate(III)], more commonly known as NAMI-A, and 
indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019), have completed 
phase I clinical trials (Figure 7). Despite their structural and chemical similarities, these two 
complexes show distinctly different antitumor behaviors. 
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Figure 7. Chemical structures of NAMI-A (left) and KP1019 (right). 
 
 
NAMI-A (“New anti-tumor metastasis inhibitor A”) was the first Ru-based anticancer drug that 
entered clinical trials. Phase I clinical trials showed that the drug was well-tolerated in 
patients [68]. Dose-limiting toxicity was the formation of painful blisters on hands and feet 
which persisted for weeks and months [69]. Other side effects of NAMI-A were anemia, 
lymphopenia, fatigue, anorexia, stomatitis, peripheral edema, alopecia, nausea, diarrhea, 
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tinnitus, and infusion-site phlebitis. The NCI anticancer drug discovery screen as well as 
several other in vitro studies indicated the absence of the direct cytotoxicity of NAMI-A for 
tumor cells. But in vivo NAMI-A has shown selective activity against the development and 
growth of pulmonary metastases from a variety of primary tumors [70]. The mechanism of 
metastasis control seems to be attributable to combined anti-angiogenic and anti-invasive 
effects on tumor cells and blood vessels. The high activity of NAMI-A against lung metastasis 
results from its about eight times longer half-life of elimination in the lungs compared to other 
tissues, probably due to the high content of collagen to which NAMI-A binds efficiently [71]. 
 
KP1019 demonstrated exciting anticancer activity in a pilot clinical phase I study. It was well-
tolerated, no dose-limiting toxicity was observed and five out of six patients treated achieved 
disease stabilization (duration of stable diseases reached up to 10 weeks). Due to its higher 
water solubility, the sodium salt of KP1019, sodium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)] (KP1339), has been selected as a lead candidate for further clinical 
development, and is currently in a phase I/IIa study. A comparison of the modes of action 
and activity pattern showed similar cytotoxic activity and drug accumulation profiles for 
KP1019 and KP1339 [72]. The mode of action of KP1019 is different to that of NAMI-A. It is 
significantly cytotoxic in vitro against colorectal cell lines (SW480, HT29) and is also highly 
effective in reducing tumor growth in vivo. Chemically induced colorectal tumors in rats 
treated with KP1019 showed a higher decrease in tumor volume than with 5-FU, the most 
effective drug in clinical use against colorectal cancer. Also complete remission of tumors 
was observed [73]. It appears that KP1019 induces caspase-mediated apoptosis via the 
mitochondrial pathway. 
 
Besides NAMI-A, KP1019 and KP1339 a large number of other Ru complexes have been 
prepared and tested for antitumor activity. RAPTAs, a class of organometallic Ru(II) 
complexes, characterized by the presence of a 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane 
(pta) ligand and a η6-arene ligand, are very promising. As NAMI-A they show weak 
cytotoxicity against tumor cells in vitro and failed the NCI screening process [74]. But in vivo 
they selectively reduced the growth of lung metastases. A benefit of RAPTAs is that they are 
free of toxicity to healthy cells even with prolonged exposure at millimolar concentrations and 
this makes them highly attractive as drugs [71]. 
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1.4. Pharmacokinetics 
 
Pharmacology is the study of the interactions that occur between drugs and a living 
organism. It can be divided into the two main areas pharmacodynamics and 
pharmacokinetics [75]. Pharmacodynamics deals with the physiological effects of drugs on 
biological systems and involves receptor binding, postreceptor effects and chemical 
interactions [76]. Pharamacokinetics on the other hand describes the effects of biological 
systems on drugs. Pharmacokinetic processes are described by liberation, absorption, 
distribution, metabolism and excretion (LADME scheme) [76, 77], and are strongly 
dependent of individual physiology. Factors like genetic make up, sex, age, renal and hepatic 
failure, obesity, dehydration, etc. can change pharmacokinetics dramatically [78]. 
 
Liberation 
Liberation is defined as the release of the drug from its dosage form. This process has a big 
influence on the pharmacokinetics of solid dosage forms (tablets, granules, capsules, etc.). 
Solid forms must be able to disintegrate in the respective desired environment before the 
drug can be absorbed.  
 
Absorption 
Absorption deals with the passage of a drug from its site of administration into the plasma. In 
all routes of administration, except intravenous injections, a drug must cross various 
semipermeable cell membranes before it reaches the systemic circulation (Figure 8) [79]. 
Membranes consist of phospholipid bilayers with embedded proteins. There are four ways by 
which drugs can cross these barriers: passive diffusion, facilitated passive diffusion, active 
uptake or endocytosis. Passive diffusion is based on the concentration gradient for a drug 
across the cell membrane and is mainly dependent of a molecule‟s lipophilicity, size and 
charge [80]. Lipid soluble drugs and small molecules penetrate cell membranes most rapidly. 
Weak acids or bases can cross the lipid matrix only in the uncharged form. Facilitated 
passive diffusion is important for compounds with low lipid solubility. Driven by the 
concentration gradient, trans-membrane proteins transport molecules across the membrane 
without consumption of energy. When energy (e.g., ATP hydrolysis) is necessary for carrier-
mediated passage, the process is called active transport. Active uptake is important for drugs 
with structures similar to endogenous substances like ions, vitamins, sugars and amino acids 
[79]. Endocytosis plays a minor role in drug uptake. It is an active transport in which 
molecules are enclosed in vesicles formed by an invagination of the cell membrane and 
released inside the cell. 
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Figure 8. The main routes of drug administration and distribution, adapted from [81]. 
 
 
Distribution 
Distribution deals with the transfer and diffusion of a drug from the intravascular to the 
extravascular space. The distribution of a drug in the body is not uniform, the accumulation of 
a molecule in a certain tissue depends on blood perfusion, binding within the tissue, regional 
pH and permeability of the membranes. An important role in the distribution of drugs plays 
the binding to serum proteins. Only unbound drugs are able to cross cell membranes by 
passive diffusion and therefore the effect of a drug is highly affected by the free 
concentration of the drug in plasma rather than total concentrations [82, 83]. Binding to 
serum proteins results mostly in an inactivation of the drug but on the other side if the binding 
is reversible drug-protein complexes in plasma could serve as drug reservoir for free drug 
concentration and prolong the duration of drug action. The interaction between drugs and 
serum proteins could also result in a selective accumulation of some chemotherapeutics in 
cancer cells. Neoplastic cells differ from normal cells by a high Fe requirement and an 
overexpression of transferrin receptors. Therefore, anticancer drugs with high affinity to 
transferrin (Tf) would selectively accumulate in tumor cells [84]. Albumin (HSA) is the main 
protein in plasma and is responsible for the transport of various molecules. Malignant tissue 
have an enhanced HSA uptake due to angiogenesis, hypervasucularization, a defective 
vascular architecture and an impaired lymphatic drainage [85]. Stehle et al. have supposed 
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that HSA is a major energy and nutrition source for tumor growth [86] and therefore 
therapeutic agents bound to HSA would be delivered specifically to cancer cells. 
 
Metabolism 
Metabolism is defined as the transformation of drugs into compounds which are easier to 
eliminate. Chemical reactions like oxidation, reduction, hydrolysis, hydration, condensation, 
and isomerization are involved in the metabolism of drugs [87]. Metabolism occurs mainly in 
the liver with the help of the cytochrome P450 system. Depending on the molecule, it can 
lead to an inactivation or activation of the drug. 
 
Excretion 
Under excretion the elimination of unchanged drug or metabolite from the body via renal, 
biliary or pulmonary processes is understood. The principal organ of extraction is the kidney. 
Elimination of drugs in this way is limited to water-soluble substances and therefore lipophilic 
molecules need to be metabolized to more polar products before they can be renally 
excreted. Lipophilic drugs can also be excreted by the hepatobiliary system. Elimination via 
the lungs is restricted to highly volatile compounds.  
 
 
 
 
1.5. Drug Development 
 
The development of a single new medicine from a research-based concept to a fully 
marketed product is lengthy, increasingly challenging and extremely costly (Figure 9). The 
entire process ranges from 12 to 20 years and costs approximately 800 million USD [88]. 
Before a drug can be tested in humans, laboratory and animal tests have to be performed to 
investigate the LADME properties, the mode of action and the side effects of a compound. 
The steps between discovery and approval are known to be critical. A novel agent had only 
an 8% chance for clinical application in 2000, down from the historical success rate of 14% in 
1985 [89]. The critical steps are the clinical phase I to III trials which are described in the 
following paragraphs according to the U. S. Food and Drug Administration (FDA) [90]. 
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Figure 9. The drug development process [91]. 
 
 
Phase I Clinical Trials 
In phase I trials the drug is tested in humans for the first time. This initial phase of testing is 
designed to determine the effects of the drug candidate on humans including 
pharmacokinetics and pharmacodynamics as well as side effects that occur as dosage levels 
are increased. This phase of testing takes several months and is conducted with 20 to 100 
volunteers.  
 
 
Phase II Clinical Trials 
The second phase of testing is designed to confirm safety, determine efficacy and side 
effects over a short time and to find the optimal dose and administrations schemes for phase 
III study. It can last from several months to two years and involves about 100 to 500 patients. 
Most phase II studies are placebo-controlled and double-blinded. Only a third of the clinically 
tested compounds successfully complete phase I and II trials. 
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Phase III Clinical Trials 
This part of the clinical trials is very expensive and lengthy. Phase III studies are typically 
double-blinded and placebo-controlled, and involve 1000-5000 patients over many months 
usually years. Safety profiles and adverse effects are studied to determine the benefit-risk 
relationship. Due to the large test group researchers and physicians have the opportunity to 
identify rare side effects of treatment. Phase III trials are the principle criterion for FDA 
approval. Nowadays, 50% of the experimental drugs that make it through phase I and II of 
clinical studies fail in phase III, compared to a 20% failure rate 10 years ago. 
 
 
Drug development and sponsors of clinical trials are nowadays under increasing pressure. 
The investment required for one successful therapeutic launch rised more than 55% in less 
than a decade [89]. Many of the scientific tools used to predict and estimate safety and 
effectiveness are outdated. They are time-consuming and imprecise, and fail often in 
prediction of safety problems in the early state of the critical path [92]. There is a large 
economical interest to develop new in vitro methods and techniques which aid in the 
prediction of the activity of a compound in vivo. The earlier a product can be brought to 
market, the longer a company may sell the product without any competition. 
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2. Bioanalytical Techniques 
 
2.1. Capillary Electrophoresis 
 
Electrophoresis as a separation technique was introduced by Tiselius in 1937 (1948 Nobel 
Prize) and is defined as the movement of charged colloidal particles or polyelectrolytes, 
immersed in a liquid, under the influence of an external electric field [93, 94]. Tiselius‟ 
separation technique in free solution was limited by thermal diffusion and convection. The 
modern era of capillary electrophoresis (CE), which led to current instrumentation, was 
developed over the years and the theory was first described in 1981 by Jorgenson and Lukas 
[95, 96]. They demonstrated that the use of fused silica capillaries produced highly efficient 
electrophoretic separations. CE has now become a mature analytical technique with 
advantages like short analysis time, high separation efficiency, easy and predictable 
selectivity, low sample and electrolyte consumption, low waste generation, automation and 
reproducibility. These remarkable advances have benefits in application fields like food 
analysis, pharmaceutical analysis, bioanalysis and environmental pollutant analysis. 
A schematic diagram of a typical CE system is shown in Figure 10. The basic instrumental 
set-up consists of a fused silica capillary, two buffer reservoirs, two electrodes, a high voltage 
power supply and an on-column detector.   
 
Figure 10. Schematic representation of a CE system, adapted from [97]. 
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The separation of compounds by CE is dependent on the differential migration of analytes in 
an electric field. The electrophoretic migration velocity (v) of an analyte is defined by 
Equation 1: 
 
v = μE · E                                                                                                                  Equation 1 
 
where             v  =  ion velocity 
                       μE = electrophoretic mobility 
                       E = applied electric field 
 
 
During the separation, two contrary forces act on an ionic species: on the one side the 
electrical force (FE) and on the other the frictional force (FF). 
 
 
where             η    = solution viscosity 
                       rSt  = Stokes radius 
                       q   =  ion charge 
 
After a short transient period a steady state, defined by the balance of FF and FE, is attained: 
 
-FF = FE 
6π · η · rSt · v = q · E                                                                                                 Equation 2                                                          
 
Solving for velocity and substituting Equation 2 into Equation 1 yields μE which is then 
described in terms of physical parameters: 
 
                                                                          Equation 3 
 
Equation 3 shows that only charged ions are affected by the electric field, neutral analytes 
are poorly separated by CE and require additives. Small, highly charged species exhibit high 
mobilities whereas large, minimally charged species have low mobilities. 
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The velocity of migration of an analyte in CE is also dependent of the electroosmotic flow 
(EOF) of the buffer solution. The EOF is the bulk movement of the liquid in the capillary as a 
consequence of the surface charge of the interior capillary wall [98]. In fused silica capillaries 
the interior wall is negatively charged because the silanol (Si-OH) groups are deprotonated 
at pH > 3. The cations of the buffer solution are attracted to the silanol anions and form a 
diffuse double-layer (Figure 11). The inner or fixed layer is held tightly to the silanoate 
groups. The outer layer is further from the silanoate groups and called the mobile or diffuse 
layer. When a positive potential is applied at the injection end of the capillary the cations 
forming the mobile layer migrate toward the cathode and drag along anions and neutrals, 
which results in the separation of positively, neutral and negatively charged species. 
Because of the potential, the EOF has a flat flow velocity profile which does not contribute to 
the broadening of solute zones. This is in contrast to a laminar or parabolic flow velocity 
profile which is generated by pressure. 
 
 
Figure 11. Graphical depiction of the capillary walls in the presence of a buffer solution, adapted from 
[99]. 
 
 
The electroosmotic mobility can be determined by measuring the retention time of a neutral 
analyte and is defined as: 
 
                                                                                                                Equation 4 
where             μEOF  = EOF mobility                                             
                       ε         = solution dielectric constant 
                       ξ       = zeta potential 
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The zeta potential in Equation 4 is strongly pH dependent, therefore the EOF can vary by 
more than an order of magnitude between pH 2 and pH 11 [94]. Under basic conditions (pH 
> 11) the surface is highly charged, the EOF is then too rapid to enable separation of the 
analytes before they reach the detector. On the contrary, at pH < 2 the silanol groups are 
protonated and the EOF is zero. Besides the pH of the background electrolyte (BGE), the 
EOF can be controlled by the following variables: electrical field (EOF changes proportionally 
with electrical field), ionic strength or BGE concentration (EOF increases at low ion strength), 
BGE composition (addition of organic modifiers to the electrolyte changes zeta potential and 
electrolyte viscosity), temperature (EOF changes due to viscosity change), and surfactants 
(anionic surfactants increase EOF, cationic surfactants decrease EOF) or coatings (can 
increase, decrease or even reverse the surface charge of the capillary) [94].                  
In a typical CE separation the EOF has an influence on the electrophoretic migration, 
therefore the resultant migration mobility of each species i is: 
 
μeff,i = μEOF + μE,i                                                                                                             Equation 5 
 
If μEOF > μE,i for all i, and this is generally the case for pH > 3, all species move in the same 
direction enabling single point detection of analytes: 
 
μeff,+ = μEOF + μE,+                                    Positive ions 
μeff    = μEOF                                              Neutral molecules   
μeff,- = μEOF - μE,-                                          Negative ions                                                                                                                                                                                                                                                                                                                               
 
From these equations it is evident that small multiply charged cations migrate quickly 
whereas anions are retained longer in the capillary due to their conflicting electrophoretic 
mobilities (Figure 12). 
 
 
Figure 12. Schematic representation of separation in CE using fused silica capillaries [97]. 
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The most widely used detection method is UV-visible absorption spectroscopy. Practically all 
commercial CE systems are equipped with this detector because it is suitable for many types 
of analytes. An optical window in the capillary allows online detection. The sensitivity with UV 
detection is proportional to the path length of the cell (Beer-Lambert law), which in this case 
is the internal diameter of the capillary (10-100 μm). Due to this short path length the 
detection limit with UV/vis absorbance is relatively high. In order to improve the detection 
limit, fluorescence and mass spectrometry are also used as detection techniques. 
Several modes of CE operation have been developed in the last years. They differ in the 
composition of the BGE and can be divided according to their separation modes in the 
following main categories: capillary zone electrophoresis (CZE), micellar electrokinetic 
chromatography (MEKC), microemulsion electrokinetic chromatography (MEEKC), capillary 
gel electrophoresis (CGE), capillary isoelectric focusing (CIEF), capillary isotachophoresis 
(CITP) and capillary electrochromatography (CEC) [94].  
To date, CZE has been the most popular CE mode because of its simplicity of operation and 
versatility. However, more and more sophisticated capillary based separation techniques 
have been developed in recent years and applied for a multitude of analytical problems. 
 
 
 
2.2. Microemulsion Electrokinetic Chromatography  
 
Microemulsion electrokinetic chromatography (MEEKC) is a separation mode applied in CE, 
which offers the possibility of highly efficient separations of both charged and neutral 
analytes. This electrodriven separation technique uses microemulsion buffers to resolve 
solutes based on both their hydrophobicities and electrophoretic mobilities. In general, an oil-
in-water microemulsion is utilized in MEEKC which consists of an aqueous buffer, oil, 
surfactant and co-surfactant. Borate and phosphate are used as typical buffers in the pH 
range 7-9 in MEEKC, because of their relatively high EOF velocities. Octane or heptane are 
most frequently used to generate the oil droplets. These droplets are coated with a surfactant 
to reduce the surface tension between the two liquid layers and which allows the emulsion to 
form. Sodium dodecyl sulphate (SDS) is the most widely utilized emulsifier in MEEKC. The 
surfactant molecules position themselves at the oil-water interface, with the tail groups 
orientated towards the oil droplet and the negatively charged hydrophilic sulphate groups 
orientated towards the aqueous phase (Figure 13). Electrostatic repulsion of the negatively 
charged head groups of SDS prevents highly efficient packing and formation of an emulsion. 
Therefore a co-surfactant, usually a medium chain length alkyl alcohol such as butan-1-ol, is 
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essential for the formation of the microemulsion. Co-surfactant molecules position 
themselves between the sulphate group of the surfactant molecules and reduce the surface 
tension of the system. 
 
Figure 13. Schematic drawing of a surfactant coated oil droplet. 
 
 
SDS induces negative charges to the droplets, which enables them to migrate towards the 
anode when voltage is applied. Under most conditions, however, anionic oil droplets still 
migrate along the separation axis toward the detector (near the cathode) because their 
electrophoretic velocity is usually not large enough to overcome the EOF. The 
chromatographic separation is based on the partition of the solutes between the aqueous 
phase and moving oil droplets. The more hydrophobic the solute is, the more it interacts with 
the oil droplet and the longer the migration time. Conversely uncharged, highly hydrophilic 
solutes reside in the aqueous phase of the microemulsion and migrate quickly with the EOF 
towards the detector. The retention factor (capacity factor k) of a solute in an MEEKC system 
is defined as the ratio nme/naq (nme = total number of moles of solute in the microemulsion 
phase, naq = total number of moles of solute in the aqueous phase) and this mass distribution 
coefficient can be calculated according to: 
 
                                                                                                        Equation 6 
 
where           to  = migration time of an unretained substance (EOF marker) 
                    tme = migration time of the microemulsion 
                    tR  = solute migration time 
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Higher k values indicate slower migration and stronger partitioning of the solute into the oil 
droplet. 
MEEKC is a relatively new technique but is widely applied to a range of application types 
[100, 101]. This method is very useful for the determination of log P values of neutral solutes 
[102, 103], but MEEKC can also be applied to the analysis of vitamins [104], bioanalysis 
[105], natural products [106] and antibiotics [107]. 
 
 
 
2.3. Inductively Coupled Plasma Mass Spectrometry  
 
Inductively coupled plasma mass spectrometry (ICP-MS) is a useful and powerful technique 
for trace element analysis which was commercialized in 1983 [108]. Beside its sub-parts-per 
trillion detections limits, ICP-MS offers further advantages like multi-element and multi-
isotope capability as well as a wide linear dynamic range [109]. Therefore this method has 
found applications in the semiconductor, biomedical, nuclear and pharmaceutical industry. 
ICP-MS is based on the atomization and ionization of the analytical sample in the plasma 
and the separation of the formed ions in the mass spectrometer. An ICP-MS system usually 
consists of six parts: a sample-introduction system, a plasma source, an interface region, an 
ion focusing system, a mass analyzer and a detector (Figure 14). 
 
Figure 14. Schematic representation of an ICP-MS system, adapted from [110]. 
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Depending on the sample, two different introduction systems exist for ICP-MS. For a liquid 
sample an introduction system consisting of a nebulizer and a spray chamber is normally 
used. In the nebulizer the liquid sample is dispersed into a fine aerosol by a pneumatic action 
of gas flow. Only small droplets are transferred into the plasma. Solid samples can be 
introduced into the ICP-MS by two different ways. They can be digested with heat and/or 
strong acids and introduced into the ICP-MS in liquid form. But this process is time 
consuming and the adding of chemicals like hydrofluoric acid to dissolve the sample can give 
rise to matrix-based interferences forming in the plasma. An alternative introduction system 
for solid samples is laser-ablation (LA). This technique requires minimal sample preparation. 
High-energy UV or IR photons are emitted by the laser and release ablation particles as a 
fine dense aerosol which is then transported from the laser cell using a carrier gas to the 
plasma source. The generation of the plasma with a temperature of approximately 6000 K, 
requires a plasma torch, a radio frequency (RF) coil and an RF power supply. A flow of argon 
gas is introduced into a series of concentric tubes of the torch that is wrapped at one end by 
an RF coil [111]. An electrical spark is applied to the gas, which causes some electrons to be 
stripped from their argon atoms. These electrons are accelerated in the magnetic field of the 
induction coil and collide with other argon atoms leading to the emission of electrons. This 
collision-induced ionization of the argon continues in a chain reaction, resulting in what is 
known as an inductively coupled plasma discharge. During their voyage into the plasma the 
sample aerosol goes through a number of physical changes [112]. In the preheating zone the 
liquid droplets are dried and become small solid particles. As the sample moves further into 
the plasma, the solid particles are transferred into the gas phase. These ground state atoms 
are converted to ideally simply charged ions through the collision with energetic argon 
electrons (Figure 15). 
 
 
Figure 15. Conversion of a droplet to an ion in the ICP, adapted from [112]. 
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The ions are transported from the plasma and directed into the interface of the mass 
spectrometer. The interface is responsible for the transport of the ions from the atmospheric 
pressure region of the torch to the mass spectrometer analyzer region, which is at 10-6 Torr 
[113]. Immediately behind the interface a lens focusing system is positioned. It focus the ion 
beam into the mass analyzer and blocks both photons and neutrals from passing any further 
into the spectrometer which results in low background levels, low detection limits and stable 
signals in real-world sample matrices [114]. The ions exiting the lens system are separated 
according to their mass-to-charge (m/z) ratio by the mass analyzer. Quadrupole mass filters, 
double focusing magnetic sector and time-of-flight are the mass analyzers which are used in 
commercial ICP-MS systems. 90% of all ICP mass spectrometers sold are equipped with a 
quadrupole mass analyzers which consists of four cylindrical or hyperbolic metallic rods 
[115]. By placing a direct current field on one pair of rods and a RF field on the other, only 
ions of a selected m/z ratio can reach the detector, whereas ions that do not have the 
selected m/z pass through the spaces between the rods and are ejected from the quadrupole 
(Figure 16). The settings of the quadrupole can be changed quickly, allowing to measure all 
the analytes in a multielement sample. In real-world samples 25 elements can be determined 
in duplicate with precision in 1-2 min [115].   
 
Figure 16. Schematic representation of a quadrupole mass filter [116]. 
 
 
Ions that make it through the mass analyzer are converted into electrical pulses and are 
detected by an electron multiplier. The magnitude of the electrical pulses corresponds to the 
concentration of analyte ions present in the sample. 
 
23
  
Bioanalytical Techniques 
2.4. Capillary Electrophoresis-Inductively Coupled Plasma Mass    
       Spectrometry  
 
Selectivity and sensitivity are important factors in (bio)analysis. Selectivity can be achieved 
by separation techniques like high-performance liquid chromatography (HPLC), gas 
chromatography (GC) and CE. To study proteins CE is one of the techniques of choice. With 
this separation technique protein analysis is carried out under mild conditions and, in contrast 
to HPLC, there is no need of organic solvents or very high salt concentrations. This enables 
the study of proteins under real-world conditions with minor influences on an existing 
equilibrium, i.e., conformational changes or protein degradation are unlikely to occur during 
analysis. Additionally, CE separations are characterized by high resolution, minimal sample 
consumption and short separation times, but CE has a serious drawback by its lack of 
sensitivity when ordinary UV-Vis detectors are used. 
ICP-MS is a multielement, highly sensitive and specific detector. The drawback of ICP-MS 
for bioanalysis lies in the selectivity. During ICP ionization proteins are atomized and ionized, 
owing to this destructive detection principle, no information of the chemical form of a protein 
can be obtained with ICP-MS detection. 
CE and ICP-MS have large potential in bioanalysis and in their combination, limitations of the 
one technique are offset by properties of the other. The hybrid technique CE-ICP-MS was for 
the first time described in 1995 [117] and finds nowadays application in metal-protein binding 
studies, tracing the metabolism of drugs in the human body, metal-speciation analysis, 
isoform analysis of metalloproteins and studies of metal-transmembrane transporation [118]. 
The challenges in the hyphenation of CE to ICP-MS are the adaptation of the low flow rate of 
the CE to the flow rate of the nebulizer of the ICP-MS, the maintenance of the electrical 
connection and the avoidance of laminar flow in the capillary, which could destroy the EOF 
based separation. Since 1995, several interfaces like concentric nebulizers, cross-flow 
nebulizers, oscillating capillary nebulizers and ultrasonic nebulizers were developed [119]. 
One of the most widely distributed interfaces is the microconcentric nebulizer developed by 
Schaumlöffel and Prange [120], which is commercially available as the CEI-100 interface 
from CETAC. The instrument set-up of the CE-ICP-MS system using the CEI-100 interface is 
shown in Figure 17. The CEI-100 interface involves the use of a sheath liquid in order to 
allow closing the electrical circuit for CE and to increase the linear velocity of the flow of CE 
effluent to match the sample flow rate of the ICP-MS. Because of easy clogging and breaking 
of the micronebulizers, on-line CE-ICP-MS analyses are still far from routine. Especially 
quantitative measurements are critical due to changes in sensitivity between runs which lead 
to poor repeatability [121]. Therefore, the addition of a trace element to the make-up-liquid is 
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necessary. The average intensity of the external standard is then used to normalize the 
signals of the analytes.  
Depending on the research topic and the analytes different CE separation modes have to be 
used. So far mostly CZE was combined with ICP-MS and only a few other modes of CE have 
been used hyphenated to ICP-MS. With capillary electrochromatography (CEC) the 
absorption of bio-species on the capillary wall is reduced and the separation efficiency of 
some analytes is improved. Lin et al. used CEC-ICP-MS for the separation of selenoamino 
acids [122]. Capillary isoelectric focusing (CIEF) is known for its extremely high resolving 
power. This CE mode was interfaced to ICP-MS and used by Michalke et al. for the analysis 
of organic Se species [123]. We have developed MEEKC-ICP-MS and used this method for 
the separation of neutral complexes and the analysis of lipophilicity of anticancer platinum 
compounds [124]. 
 
 
 
Figure 17. CE-ICP-MS system with a microconcentric nebulizer, adapted from [120]. 
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2.5. Electrospray Ionization Mass Spectrometry  
 
Electrospray ionization mass spectrometry (ESI-MS) is nowadays a basic tool in different 
research areas including analysis of pharmaceuticals with a relatively small molecular mass 
up to biological macromolecules. It is a soft ionization technique and is therefore especially 
useful in studying labile species such as peptides, proteins, organometallics, coordination 
compounds, oligosaccharides and polymers. Electrospray as an ionization technique for 
mass spectrometry was developed by Dole et al. in the late 1960s [125] and improved by 
Yamashita and Fenn who in 1984 coupled an electrospray source to a quadrupole mass 
analyzer [126-128]. The success of ESI started when Fenn et al. demonstrated that with this 
ionization technique multiply charged ions were obtained from proteins [129, 130]. Before 
this development the mass spectral analysis of proteins and other macromolecules was 
problematic because of limited transfer into the gas phase. Fenn was awarded for this 
contribution with the 2002 Nobel Prize in Chemistry.  
The process of electrospray ionization can be divided in 4 steps: formation of ions, 
nebulization, desolvation and ion evaporation. Ion formation can occur already in solution 
before nebulization. In this case the analyte ion abundance is high as is the electrospray 
sensitivity. Analytes that do not ionize in solution can be charged during the process of 
nebulization, desolvation and ion evaporation. The nebulization starts when the sample 
solution enters the spray chamber through a needle to which a high potential difference is 
applied (Figure 18). The combination of the nebulizing gas, which often enters the spray 
chamber concentrically through a tube that surrounds the needle, and the strong electrostatic 
field forces the spraying of charged droplets from the needle with a surface charge of the 
same polarity as of the needle. As the charged droplets pass down the potential gradient 
toward the source sampling cone on the counter electrode, solvent evaporation occurs. With 
the aid of a counter flow of warm nitrogen gas the charged droplets are continuously reduced 
in size by evaporation of the solvent, leading to an increase of surface charge density and a 
decrease of the droplet radius. When the force of the Coulomb repulsion equals that of the 
surface tension of the droplet (the Rayleigh limit), the droplet is ripped apart. This produces 
smaller droplets with a high surface charge density which can undergo a cascade of 
ruptures, yielding smaller and smaller droplets until the analyte is free of solvent and single 
ions move to the mass analyzer.  
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Figure 18. The spraying process at the nebulizer tip of an ESI-MS instrument [131]. 
 
 
The process of ion formation has been the subject of many scientific investigations but the 
exact mechanism of the process is still discussed controversially. Two different theories exist 
that explain the final production of gas-phase ions: the ion evaporation model that says that 
ions are emitted directly from the charged droplets into the gas phase and the charged 
residue model that suggests that electrospray droplets undergo evaporation leading to 
droplets that contain on average one analyte ion.  
ESI is an example of atmospheric pressure ionization (API). Sample ionization under 
atmospheric pressure has the advantage of a 103-104 times greater ionization efficiency as in 
a reduced-pressure chemical ionization (CI) source [130]. The analyzer compartment is 
situated in the high vacuum region of the mass spectrometer (10-5 Torr) in order to prevent 
unwanted interactions between the molecular ions and atmospheric components which can 
affect the determined m/z ratio. Therefore, the ions have to pass a series of skimmer cones 
and are guided electrostatically into the vacuum of the mass analyzer. There are five types of 
mass analyzers that can be used in ESI-MS systems: quadrupolar analyzers, ion trap 
analyzer, magnetic and electromagnetic analyzers, time-of-flight analyzers and ion 
resonance analyzers. The combination of several analyzers in sequence is also possible 
(tandem mass spectrometry) and is becoming increasingly common.  
As already mentioned above, the great benefit of ESI is the formation of multiply charged 
species which makes the measurement of biological macromolecules possible. Generally it 
can be said that a protein will tend to carry one charge per 1000 Da. This value is dependent 
of the number of basic amino acids in the protein, and the measurement conditions. If there 
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are only few basic amino acids the number of charges decreases [130]. Therefore, nearly all 
proteins can be detected in the mass range up to 3000 m/z, regardless of their actual 
molecular weight. The ESI-mass spectrum of apo-Tf is shown in Figure 19; it is protonated 
between 27 and 35 times and provides individual peaks in the range of 2200-3000 m/z. With 
the help of deconvolution algorithms the multiple peaks can be transformed into a single 
peak given the molecular weight. 
 
 
Figure 19. ESI-mass spectrum of apo-transferrin. The number of charges are indicated on each peak. 
The molecular weight of this glycoprotein is 79570 ± 7 Da. 
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3. Results 
 
This Ph.D.-thesis can be divided in three research topics and is based on the following 
publications/manuscripts: 
  
The influence of lipophilicity on the antiproliferate properties of anticancer 
platinum complexes 
 
The first example of MEEKC-ICP-MS coupling and its application for the 
analysis of anticancer platinum complexes 
Bytzek A.K., Reithofer M.R., Galanski M., Groessl M., Keppler B.K., Hartinger C.G. 
Status: published in Electrophoresis, 2010, 31, 1-7. (Cover article) 
 
The first example of the coupling of MEEKC to ICP-MS was presented and used for the 
separation of Pt(II) and Pt(IV) anticancer drugs and drug candidates. The MEEKC-ICP-MS 
system was found to be more sensitive than MEEKC with conventional UV/vis detection and 
the analysis of UV/vis silent compounds is now achievable. 
To achieve an effective separation of the Pt complexes, I have optimized at first the MEEKC 
method by using different compositions of microemulsions. Afterwards the coupling of 
MEEKC to ICP-MS was performed and the collected data was compared with standard 
ultraviolet/visible (UV/vis) spectroscopy detection. I have drafted the manuscript and 
contributed to the discussion of the data. 
 
 
 
Tuning of lipophilicity and cytotoxic potency by structural variation of 
anticancer platinum(IV) complexes 
Reithofer M.R., Bytzek A.K., Valiahdi S.M., Kowol C.R., Groessl M., Hartinger C.G., Jakupec 
M.A., Galanski M., Keppler B.K. 
Status: published in Journal of Inorganic Biochemistry, 2010, 105, 46-51. 
 
The IC50 values of a series of bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) 
compounds were correlated with the compounds lipophilicity, reduction potential and their 
cellular accumulation in cancer cells in vitro. It was found that the antiproliferative properties 
of the complexes correlated with their lipophilicity as well as their accumulation, whereas 
differences in antiproliferative potency could not be explained by reduction potentials.  
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I have contributed ocantol/water partition coefficient data on the lipophilicity by the shake 
flask method as well as by microemulsion electrokinetic chromatography. Furthermore, a 
significant contribution to the discussion of the results was made during the preparation of 
the manuscript. 
 
 
 
Studies on the biodistribution of oxaliplatin and its methyl derivatives in tumor 
bearing mice 
Bytzek A.K., Jungwirth U., Berger W., Galanski M., Hartinger C.G., Keppler B.K. 
Status: in preparation 
 
The influence of the lipophilicity of Pt- complexes on the anticancer activity in vivo was 
studied in tumor-bearing mice. Oxaliplatin and its methyl derivatives KP1537 and KP1691 
were administered intravenously and their biodistribution and especially their accumulation in 
the tumor were determined 1 and 6 h post-injection. 
I have mineralized the tissue samples by microwave digestion and analyzed them for their Pt 
content by ICP-MS. Data analysis and correlation with biophysical properties of the 
enantiomeric compounds was done. 
 
 
 
Understanding the behavior and properties of the ruthenium drug candidate 
KP1339 in vivo 
 
LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug 
candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) 
in mouse plasma 
Bytzek A.K., Boeck K., Hann S., Herman G., Keppler B.K., Hartinger C.G., Koellensperger G. 
Status: submitted to Metallomics 
 
To improve the understanding of the mode of action of the drug candidate KP1339, the Ru 
complex was given intravenously to mice. CZE and SEC-IC (size exclusion/anion exchange 
chromatography) were coupled to ICP-MS in order to characterize the interaction of KP1339 
with mice plasma proteins in vivo. The samples of the mice terminated after 24 hours showed 
a 2-2.5 lowered albumin content as compared to the untreated control group and the mice 
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which were terminated after 7 days. It was found that KP1339 bind to a high degree to 
albumin. At a dose higher then 50 mg/kg the formation of albumin aggregates was observed 
and confirmed by matrix-assisted laser desorption ionization mass spectrometry (MALDI 
MS).  
My contribution to this paper was the optimization of a CZE-ICP-MS method for the 
measurement of Ru in the plasma samples as well as the investigation of the interaction with 
serum proteins. Additionally, I performed MALDI measurements of the fractionated plasma 
samples and drafted significant parts of the manuscript, especially the discussion with regard 
to the mode of action of the drug candidate. 
 
 
 
Biodistribution of the anticancer drug candidate sodium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) 
Bytzek A.K., Koellensperger G., Keppler B.K., Hartinger C.G. 
Status: in preparation 
 
The Ru complex KP1339 is a promising anticancer agent, currently undergoing clinical trials. 
In this work package, pharmacokinetic aspects of KP1339 in non-tumor bearing mice in a 
time frame of 24 h were investigated. KP1339 was administered intravenously and the 
accumulation in tissues was determined at several time points. The highest Ru levels were 
found in colon, lung, liver kidney and thymus. The peak Ru concentrations in these tissues 
were reached 1-6 h after administration and declined slowly over time. Apart from the Ru 
content in the blood also the interaction with serum proteins was investigated. It was found 
that a large majority of the total Ru content was attached to mouse serum albumin (MSA). 
Beside the MSA adduct, a higher molecular weight species was observed probably 
stemming from MSA conjugates. 
I contributed the mineralization of the tissue samples by microwave digestion and the 
analysis of their Ru content by ICP-MS to this paper. The partition of the Ru between the 
major serum proteins was investigated by CZE-ICP-MS. Additionally, I performed an NCI 
anticancer drug discovery screen compare analysis for the parent compound KP1019 which 
indicated that the mode of action of this Ru compound is different from those of established 
drugs. 
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Serum protein binding of zinc complexes 
 
Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro 
protein-binding studies by means of CZE-ICP-MS 
Bytzek  A.K., Enyedy E.A., Kiss T., Keppler B.K., Hartinger C.G. 
Status: published in Electrophoresis, 2009, 30, 4075-4082. 
 
Zn(II) compounds are under development as insulin-enhancing drugs with potential use in 
the treatment of diabetes. Herein, CZE-ICP-MS studies on the interaction of Zn(II)-maltolato, 
-2-picolinato and -2,6-dipicolinato complexes with human serum proteins were performed 
and modeling calculations were confirmed by these experimental results. The investigated 
Zn(II)-complexes showed a high affinity to albumin.  
For this study I adapted a CZE-ICP-MS method for the measurement of the Zn content 
attached to proteins. In vitro incubation of the Zn(II) complexes with transferrin, albumin and 
human serum were performed and the interaction with this proteins was determined.
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3.1. The first example of MEEKC-ICP-MS coupling and its 
application for the analysis of anticancer platinum 
complexes 
 
Bytzek A.K., Reithofer M.R., Galanski M., Groessl M., Keppler B.K., Hartinger C.G. 
Status: published in Electrophoresis, 2010, 31, 1-7. (Cover article) 
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Research Article
The first example of MEEKC-ICP-MS
coupling and its application for the analysis
of anticancer platinum complexes
MEEKC is a powerful electrodriven separation technique with many applications in
different disciplines, including medicinal chemistry; however, up to now the coupling to
highly sensitive and selective MS detectors was limited due to the ion suppressive effect
of the commonly used surfactant SDS. Herein, the first example of the coupling of
MEEKC to ICP-MS is presented and an MEEKC method for the separation of Pt(II) and
Pt(IV) anticancer drugs and drug candidates was developed. Different compositions of
microemulsions were evaluated and the data were compared with those collected with
standard ultraviolet/visible (UV/vis) spectroscopy detection. The MEEKC-ICP-MS system
was found to be more sensitive than MEEKC-UV/vis and the analysis of UV/vis silent
compounds is now achievable. The migration behavior of the Pt(II) and Pt(IV)
compounds under investigation is correlated to their different chemical structures.
Keywords:
Anticancer drugs / CE / Inductively coupled plasma MS / Microemulsion
electrokinetic chromatography / Platinum complexes
DOI 10.1002/elps.200900522
1 Introduction
Commercially available CE instruments have been tradi-
tionally equipped with ultraviolet/visible (UV/vis) detectors,
at best with a DAD device. These detectors provide sufficient
sensitivity for many applications, however, with the
disadvantage of low selectivity. In the last decade, CE
hyphenated to mass spectrometers has gained considerable
attention and the number of applications has increased
steadily [1–3]. CE can be operated in different separation
modes and more and more of these techniques are coupled
to MS detectors, though some of these separation modes,
especially when containing non-volatile components, have
initially been considered as limited in their compatibility to
MS coupling. Today, CE-MS is applied in many different
fields of research, including, e.g. the analysis of pharmaceu-
ticals and their metabolites, often in difficult biological
matrices, environmental samples or technical products
[4, 5].
One of such applications is the analysis of platinum(II)
compounds, often used in the chemotherapeutic schemes of
cancer patients [6]. Platinum complexes have been applied for
more than 30 years in the clinic but yet their mode of action
has not unambiguously been identified [7]. The most impor-
tant part in their activity appears to be related to the binding to
DNA, whereas attachment to proteins, in particular to plasma
proteins, being the first potential binding partners after intra-
venous administration, is believed to contribute to their side
effects [8]. These adverse effects comprise nephrotoxicity,
ototoxicity, vomiting, etc., which are often observed during
chemotherapy. However, the major limitation of healing
tumor patients appears to be intrinsic and acquired resistance
[7]. Oxaliplatin 1 (SP-4-2)-[(1R,2R)-]cyclohexane-1,2-diamine-
k2N,N](oxalato-k2O,O)platinum(II) (Fig. 1) has been used in
clinics for several years and more recently Pt(IV) compounds
also moved into the focus of interest, due to potential oral
administration which would improve the living quality of
cancer patients significantly [9, 10]. Several examples of Pt(IV)
complexes underwent clinical trials, most recently satraplatin
[(OC-6-43)-bis(acetato-kO)amminedichlorido(cyclohexylamine-
kN)platinum(IV); formerly JM216], but so far none of them
made it to clinical application. One of the chemical features of
the compound class exploitable for drug development is that
they are relatively inert and are not significantly metabolized
with respect to ligand substitution reactions after administra-
tion, but can be reduced in the hypoxic environment of the
tumor, consequently enhancing the selectivity of the chemo-
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therapeutics. The axial ligands were found to influence the
redox potential of the PtIV/II couples and eventually after
reduction structurally related compounds to those used in
clinics are formed. Recently, the synthesis of a series of such
Pt(IV) compounds was reported (Fig. 1) and promising in vitro
anticancer activity was demonstrated [11–13].
In recent years, CE has become an established technique
in metallodrug research [14–16], especially for metallo-
drug–protein-binding studies [17–22]. Initially, hydrolysis of
the established anticancer agents such as cisplatin, carboplatin
and oxaliplatin (neutral compounds which become positively
charged after the exchange of the chlorido or biscarboxylato
ligands by aqua groups) was studied in CZE mode [16]. Other
major CE-based investigations include the binding of such
compounds and related non-platinum anticancer metallodrug
candidates to DNA building blocks [16], i.e. nucleotides and
proteins under conditions, often chosen to resemble the
physiological situation [16, 18, 23, 24]. Although the use of
unspecific UV/vis detection appears limited, coupling to MS,
in particular to element-specific ICP-MS (which also becomes
of increasing importance in proteomics [25]), provides an
additional degree of selectivity and also outstanding sensitivity
[17, 26]. Hyphenation to the soft and ICP-complementary
ionization technique ESI-MS yields structural information,
not available from ICP-MS [17, 26, 27].
An important feature in the modes of action of (metal-
lo)drugs is the cellular uptake [28]. This process is often
influenced by active transport into the cell but also passive
accumulation by diffusion is known to play an important
role, especially in the case of the platinum compounds [29].
The diffusion of drugs through the cell membrane is related
to the lipophilicity of a compound, which can be related to
log k values in MEEKC. The separation in MEEKC mode
relies on the different partition of the analytes in micro-
emulsions (oil droplets suspended in an aqueous buffer,
stabilized by a surfactant and co-surfactant) and a chroma-
tography-type separation is achieved [30], thus enabling the
efficient separation of neutral species as recently shown for
different isomers of new oxaliplatin derivatives [31]. The
more lipophilic a compound is the higher will be its inclu-
sion into the oil droplet [32]. Many different applications
have been reported for this separation technique, including
vitamins, proteins, peptides, drug compounds and agro-
chemicals [30].
To the best of our knowledge, no coupling of MEEKC to
ICP-MS was reported so far. Herein, this new methodology
was applied in anticancer metallodrug research in a proof of
principle study and the potential was evaluated in the
analysis of oxaliplatin and several new neutral Pt(IV) anti-
cancer drug candidates.
2 Materials and methods
2.1 Instrumentation
CE separations were carried out on an HP3D CE system
(Agilent, Waldbronn, Germany) equipped with an on-column
DAD. Detection was carried out either by UV/vis at 200 nm or
with an Agilent 7500ce ICP-MS interfaced utilizing a CETAC
CEI-100 microconcentric nebulizer [33]. For all measurements
with UV-detection, capillaries of 48.5 cm total length (40 cm
effective length; 50 mm id) were used (Polymicro Technolo-
gies, Phoenix, AZ, USA), in the case of ICP-MS detection the
capillary length was extended to 60 cm. Capillary and sample
tray were thermostatted at 371C. The sample injection was
carried out by hydrodynamic injection at 10mbar for 15 s or at
25mbar for 4 s for UV/vis and ICP-MS detection, respectively,
and the separation voltage was 20–25 kV. New capillaries were
conditioned with 0.1M HCl, water, 0.1M NaOH, and again
with water (10min each). As a daily routine, the capillary was
flushed with 0.1M NaOH, water, and BGE for 5min each
before the first run. Before each injection, the capillary was
purged with 0.1M NaOH, water and the BGE for 2min each.
The operational values for the MEEKC-ICP-MS interface are
listed in Table 1. The nebulizer was employed in self-
aspiration mode with the sheath liquid closing the electrical
circuit and spraying a fine aerosol. Analyses were started only
if a sufficiently stable signal (RSD 115Ino5%) was attained.
Instrument control as well as data analysis was carried out
using ChemStation software (B.03.07).
2.2 Reagents and solutions
SDS, dodecanophenone, 1-bromododecane, 1-butanol and
sodium monohydrogenphosphate were purchased from
Sigma-Aldrich (Vienna, Austria). Sodium hydroxide solu-
tion (0.1 M), hydrochloric acid, heptanes and sodium
dihydrogenphosphate were obtained from Fluka (Buchs,
Switzerland) and DMSO from Fisher Scientific, Austria.
The ICP-MS tuning solution containing lithium, yttrium,
cerium, thallium and cobalt in 2% HNO3 (each 10 mg/L)
was obtained from Agilent Technologies (Vienna, Austria)
and the 115In standard was from CPI international (Santa
Figure 1. Structures of the platinum anticancer drug oxaliplatin
1 and Pt(IV) drug candidates 2–11. chxn5 cyclohexanediamine
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Rosa, USA). High-purity water used throughout this study
was obtained from a Millipore Synergy 185 UV Ultrapure
Water system (Molsheim, France). Oxaliplatin 1 and the
Pt(IV) compounds 2–11 (Fig. 1) were synthesized as
described elsewhere [11–13, 34].
2.3 Preparation of the microemulsion
For the preparation of the MEEKC solutions, different ratios
of SDS, 1-butanol, heptane and a small portion of buffer
(mass%) were mixed by sonication for 5 min. The residual
buffer was then slowly added to the mixture. Phosphate
buffer (20 and 10mM for MEEKC-UV/vis and -ICP-MS,
respectively; pH 7.4) was used for the preparation of the
microemulsions. The solution was kept for 24 h at room
temperature before use.
2.4 Sample preparation
The analytes were dissolved in the microemulsions to give
concentrations between 0.4 and 0.6mg/mL (UV/vis detection)
and ca. 0.1 mg/mL (ICP-MS detection). For the MEEKC-UV/
vis studies, DMSO and dodecanophenone were used as
markers for the EOF and the microemulsion droplets,
respectively; to 1mL of the sample solution, 1 mL DMSO
and 10 mL dodecanophenone (18mg/mL in methanol) were
added. In the case of ICP-MS detection, DMSO (34S) and 1-
bromododecane (79Br) were used as markers (1mL of the
sample contained 3 mL DMSO and 1 mL 1-bromododecane
(diluted 1:1 with 1st issue correction1-butanol)).
2.5 Calculations
The capacity factor, k, is defined as the ratio nme/naq
(nme5 total number of moles of solute in the microemul-
sion phase, naq5 total number of moles of solute in the
aqueous phase) and this mass distribution coefficient can be
calculated according to Eq. (1) (to5migration time of an
unretained substance (EOF marker), tme5migration time
of the microemulsion, tR5 solute migration time).
k ¼ tR  t0
tnð1 tR=tmeÞ ð1Þ
The LODs and LOQs for ICP-MS and UV/vis detection were
calculated using Eqs. (2) and (3) (s5 residual standard
deviation of the calibration curve, S, its slope).
LOD ¼ 3:3s
s
ð2Þ
LOQ ¼ 10s
s
ð3Þ
3 Results and discussion
Oral administration of drug compounds does not only
require a certain degree of chemical inertness but also
sufficient bioavailability, a factor, which depends at least
partly on the lipophilicity of a drug. In a recent report, the
lipophilicity of oxaliplatin derivatives was related to the k
factors determined by an MEEKC-UV/vis method [31]. It is a
few years since MEEKC-MS has been introduced, as the
coupling with ESI-MS is limited due to the suppressive
effect of the commonly used surfactant SDS on ESI [35].
However, the development of atmospheric pressure photo
ionization with ionization by high-energy photons [36]
enabled the hyphenation of the two methods [37], and
different pharmaceuticals have been analyzed with this
technique [38, 39]. ICP-MS is an element specific and highly
sensitive method [25, 26], which is in contrast to ESI-MS not
influenced by ion suppression.
3.1 Analysis of oxaliplatin by MEEKC-ICP-MS,
method development and initial performance tests
Many parameters such as the choice of oil phase, surfactant
and co-surfactant, pH of the BGE, and the hydrophobicity of
the analytes influence the separation performance of an
MEEKC system and the complexity of the microemulsion
allows optimization in several directions. Since the devel-
oped method is aimed to be eventually used in the analysis
of samples in biological environment, the pH of the
buffer composition was set to 7.4 and a phosphate buffer
was used for the preparation of the microemulsion with the
surfactant SDS. In order to generate the oil droplets,
heptane was added and 1-butanol was used as the co-
surfactant. Before injection, the sample was diluted with the
microemulsion in order not to disrupt the separation system
[32].
A satisfying result for the analysis of 1 was obtained with
an MEEKC system consisting of 1.43% SDS, 0.85% heptane,
6.57% 1-butanol and 91.15% phosphate buffer (10mM, pH
7.4; Fig. 2). Microemulsions of such composition were
demonstrated to possess high stability in other reports [40].
Due to the low flow through the capillary, the interface
Table 1. ICP-MS operational parameters
Sampler Ni (0.1 mm orifice)
Skimmer Ni (0.4 mm orifice)
Plasma RF power, W 1500
Isotopes recorded 34S, 79Br, 115In, 195Pt
Nebulizer gas flow
rate (L/min)
1.14
Sheath liquid 10 mM phosphate buffer with
20 mg/L In
BGE Microemulsion: 1.43% SDS, 91.15%
phosphate buffer (10 mM, pH 7.4),
0.85% heptane, 6.57% butanol
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between the CE system and the ICP-MS requires addition of
a sheath liquid (phosphate buffer containing 20 mg/L In),
which is also used to close the electrical circuit of the CE
system and to introduce an external standard in order to
monitor the stability of the spraying conditions. The oxali-
platin sample was spiked with DMSO and 1-bromododecane
to mark the EOF and the microemulsion droplets, respec-
tively, and the ICP-MS was operated to record in parallel
195Pt, 34S and 79Br, in order to detect all three sample
components. Furthermore, the capacity factors for 1 and the
Pt(IV) complexes 2, 5, 9 and 10 were determined for MEEKC-
UV/vis and -ICP-MS. These compounds were chosen due to
their different structures and therefore expected differing log
k values. The data obtained for all compounds were found to
be very similar with the two detection systems (Table 2; the
small differences might be related to inaccuracies stemming
from broad S and Br signals); however, 9 and 10 were not
separable with the applied method. These results also prove
that 1-bromododecane is a suitable but UV/vis-silent marker
for the microemulsion droplets. It appears that the presence
of the surfactant does not influence the ionization efficiency
of the ICP-MS and the analysis is not altered by such
processes.
In order to determine the LOD and LOQ for the MEEKC-
UV/vis and the -ICP-MS systems, calibration curves with
oxaliplatin samples were prepared. Linear calibration curves
with high correlation coefficients were obtained for both
detection methods: in the case of UV/vis detection, the stan-
dards covered the range of 0.35–5mM (Fig. 3), in the case of
ICP-MS detection 0.125–1.000mM. The LODs and LOQs
were slightly lower when ICP-MS detection was used
(Table 3); however, addition of an internal standard was
required in that case (the peak area of oxaliplatin was divided
by the peak area of 1-bromododecane as a function of the
analyte concentration), whereas the MEEKC-UV/vis system
was easier to handle in terms of operation. Furthermore, high
recovery rates of about 90% were obtained.
3.2 Separation of oxaliplatin and platinum(IV)
complexes with MEEKC and UV/vis detection
In order to maintain the stability of the separation system,
oil-in-water microemulsions require specific ratios of the
respective components. These ratios can only be varied
within a very narrow range and a standard microemulsion
consists of approximately 90% aqueous buffer, 3% surfac-
tant, 6% co-surfacant, and 1% oil [32]. The separation
conditions of 1, its Pt(IV) precursor 11 and a series of Pt(IV)
anticancer drug candidates, were optimized by changing the
composition of the microemulsion (Fig. 4; the differing
intensities of the peaks are due to using freshly prepared
sample mixtures). The microemulsion consisting of 1.44%
SDS, 6.48% 1-butanol, 0.82% heptane and 91.26% phos-
phate buffer was identified as a good compromise (over 1.89
and 0.85% SDS in the microemulsion) between separation
performance and analysis time for the separation of 1–8, 10
Figure 2. MEEKC-ICP-MS of oxaliplatin 1. Shown are the traces
of 195Pt, the EOF marker (34S) and the marker of the microemul-
sion droplets (79Br).
Table 2. Comparison of the log k values obtained for 1, 2, 5, 9
and 10 by MEEKC-UV/vis and -ICP-MS with 1.44% SDS,
6.48% 1-butanol, 0.82% heptane, 91.26% phosphate
buffer as microemulsion (n5 3)
Compound Detection method
UV/vis ICP-MS
Oxaliplatin 1 0.86370.004 0.89070.025
2 1.13070.004 1.10070.171
5 0.55370.003 0.61670.035
9 0.09870.002 0.17070.015
10 0.10570.002 0.06170.023
Figure 3. Calibration graph for the
quantification of oxaliplatin 1 with
the MEEKC-UV/vis and -ICP-MS
systems.
Electrophoresis 2010, 31, 1144–1150 CE and CEC 1147
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
37
and 11 (9 was not added to the sample mixture due to
expectable overlaps based on the log k determination;
Fig. 5). Higher SDS concentrations resulted in a lower
EOF and therefore significantly longer analysis times as well
as peak broadening [41]. In contrast, lowering of the SDS
concentration to 0.85% reduced the separation efficiency
and lead to partially unresolved peaks. These studies have to
be considered as preliminary studies with regard to the
biological applications (therefore all experiments were
carried out at 371C, and the phosphate buffer was adjusted
to pH 7.4), e.g. for the detection of oxaliplatin and its
potentially orally administerable Pt(IV) precursor in biolo-
gical tissue.
In an attempt to correlate the structure of the analytes
with the log k values, as determined from analyses with three
different MEEKC systems, no clear-cut relationship was
observed (Fig. 5). All MEEKC systems show the same order of
migration, and the separation of the compounds in structu-
rally related groups allows drawing the following conclusions:
in the case of compounds 2–5, the increase of lipophilicity by
changing from the methyl ester to ethyl, propyl and butyl
residues is clearly reflected by increasing log k values, as was
also observed for the methyl and ethyl esters 8 and 9. In the
case of the propyl amides of the succinate 6 and glutarate 7
derivatives, the latter possesses, as expected, a more lipophilic
character. Compounds 10 and 11 are difficult to compare with
any of the other compounds due to their structural difference.
However, the Pt(IV) precursor 11 for 1 is significantly more
lipophilic than the clinically established compound.
3.3 Analysis of platinum(IV) complexes with
MEEKC-ICP-MS
In order to assay the separation performance of MEEKC-
ICP-MS (1.43% SDS, 91.15% phosphate buffer (10 mM, pH
7.4), 0.85% heptane, 6.57% butanol), mixtures of Pt
compounds were analyzed consisting of the complexes
2–5, 7 and 10, varying only in the aliphatic ester
functionality and with widely differing log k values in the
MEEKC-UV/vis experiment (Fig. 6). Peak tailing leading to
partial peak overlapping, possibly caused by the dilution of
the sample in the CE-MS interface and a memory effect of
the ICP-MS detection, was observed in these studies, which
limits the number of compounds to be analyzed. However,
the separation is sufficient to determine the log k values of
the compounds studied on basis of these results.
Table 3. LOD and LOQ as determined by MEEKC-UV/vis and -
ICP-MS for the anticancer drug oxaliplatin 1
Method CE-UV/vis CE-ICP-MS
LOD (mM) 0.39 0.25
LOQ (mM) 1.18 0.76
Figure 4. Effect of the SDS surfactant concentration on the
migration of the platinum complexes 1–8, 10 and 11 in MEEKC-
UV/vis mode (D, dodecanophenone). (A) 1.89% SDS, 5.94%
1-butanol, 0.59% heptane, 91.59% phosphate buffer; (B) 1.44%
SDS, 6.48% 1-butanol, 0.82% heptane, 91.26% phosphate buffer;
(C) 0.85% SDS, 6.68% 1-butanol, 1.06% heptane, 91.41%
phosphate buffer.
Figure 5. log k values for 1–11 as obtained by MEEKC analysis
with different microemulsion compositions ((A) 1.89% SDS,
5.94% 1-butanol, 0.59% heptane, 91.59% phosphate buffer; (B)
1.44% SDS, 6.48% 1-butanol, 0.82% heptane, 91.26% phosphate
buffer; (C) 0.85% SDS, 6.68% 1-butanol, 1.06% heptane, 91.41%
phosphate buffer). For all log k values SDs of about 5% or less
were determined (n5 3).
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4 Concluding remarks
MEEKC was found to be an efficient separation system for the
analysis of Pt(II) and Pt(IV) anticancer agents, which were
assigned according to the migration times (both with UV/vis
and ICP-MS detection). The application of MEEKC was for a
long time limited in the choice of detectors and only recently it
was hyphenated to MS detectors with atmospheric pressure
photo ionization. In this article, the coupling of MEEKC with
the element-specific ICP-MS is presented for the first time.
The high selectivity and sensitivity of the ICP-MS was used to
detect in parallel the platinum compounds and the EOF and
microemulsion droplet markers DMSO and 1-bromodode-
cane, respectively. Initial performance tests revealed slightly
higher sensitivity of the ICP-MS system as compared with
UV/vis, which in addition suffers from unspecificity, espe-
cially when analyzing clinical samples with complex matrix.
However, MEEKC-UV/vis was the more stable system in
terms of operation; high linearity of the calibration curve was
obtained without addition of internal standards. An advantage
of the ICP-MS technology is that UV/vis-silent compounds
(such as 1-bromododecane) can be detected without prior
derivatization.
When comparing the lipophilicity of the Pt compounds,
a clear-cut trend is only observable as long as minor struc-
tural changes are made, e.g. from methyl 2 to ethyl 3, propyl
4 and butyl esters 5. To establish a more general rule, a
broader series of compounds is required. Additionally,
further studies on the correlation of octanol–water coeffi-
cients, a widely used indicator for the distribution of a drug
within an organism, with the log k values obtained by ICP-
MS detection are desirable and would broaden the area of
application of the method.
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The successful story of metal containing anticancer drugs started
more than 40 years ago with the discovery of the antiproliferative
activity of cisplatin (cis-diamminedichloridoplatinum(II)) by Barnett
Rosenberg [1]. Besides cisplatin, two further platinum-based anticancer
drugs are used routinely in the clinics today, namely carboplatin, cis-
diammine(cyclobutane-1,1-dicarboxylato)platinum(II), andoxaliplatin,
(R,R)-cyclohexane-1,2-diamine(oxalato)platinum(II) [2]. Along with
the discovery of cisplatin, platinum(IV) compounds were found to act
aspotential anticancer drugs. In this context it isworthwhilementioning
that platinum(IV) compounds show some advantages over their
platinum(II) analogs. Firstly, platinum(IV) compounds exhibit a higher
coordination number (six vs. four) than their platinum(II) counterparts,
and therefore theﬁne-tuningof pharmacologically important properties
such as kinetic stability, lipophilicity and reduction potential can be
performed more easily [3]. Secondly, platinum(IV) compounds are
kinetically inert compared to platinum(II) complexes, which puts forth
the possibility of oral drug administration [4,5]. The ﬁrst platinum(IV)
anticancer drugs which were investigated in clinical trials, tetraplatin
and iproplatin (Fig. 1), were both abandoned, because of unfavorable
pharmacological properties.
In the case of tetraplatin, the toxicity was too high [6], whereas
iproplatin was found to be not active enough [7]. In this context it hasto be mentioned that platinum(IV) compounds act as prodrugs,
whereby the biologically more active platinum(II) species is obtained
via reduction of its platinum(IV) analog (activation by reduction)
[5,8]. Thus the different biological activity of tetraplatin and iproplatin
(systemic toxicity vs. low efﬁcacy) can be explained based on their
reduction potentials. The use of chloride as axial ligands results in a
high reduction potential (tetraplatin: Ep=−90±20 mV vs. Ag/AgCl)
[9], therefore tetraplatin is reduced easily in the bloodwithin seconds.
Complexes having axial hydroxido ligands display a much lower
reduction potential (iproplatin: Ep=−730±100 mV vs. Ag/AgCl),
therefore reduction to the active platinum(II) compound is slow in the
body and as a result, the compounds are not properly activated.
A breakthrough was achieved with the carboxylation of trans-
dihydroxidoplatinum(IV) compounds, resulting in bis(carboxylato)
platinum(IV) analogs, which showed a reduction potential situated
between compounds with either chlorido or hydroxido axial ligands.
So far, two bis(carboxylato)platinum(IV) compounds, namely satra-
platin, (OC-6-43)-bis(acetato)amminedichlorido(cyclohexylamine)
platinum(IV) (formerly JM216) and LA-12, (OC-6-43)-bis(acetato)
adamantylamine(ammine)dichloridoplatinum(IV) (Fig. 1), have been
investigated in clinical trials. Satraplatin was investigated in advanced
phase III clinical trials in hormone refractory prostate cancer in
combination with prednisone [10], and is currently in a phase II trial
against non-small cell lung carcinoma. The satraplatin derivative
LA-12 has ﬁnished phase I clinical trials and has shown promising in
vivo activity in ADJ/PC6 plasmacytoma and A2780 ovarian carcinoma
tumor mice [11–13].
Recently, platinum(IV) chemistry has made considerable progress
due to a new carboxylationmethod. The use of succinic,maleic, glutaric,
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Fig. 1. Chemical structures of tetraplatin, iproplatin, satraplatin and LA-12.
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(carboxylato)platinum(IV) complexes, displaying two free and unco-
ordinated carboxylic acid groups, therefore opening up the possibility
for further functionalization of the axial ligands. Derivatization of the
axial ligands is of great importance,when taking into account, that these
ligands are released during the activation of the platinum(IV) complex
in the body. A speciﬁc targeting of established platinum(II) drugs (e.g.
cisplatin) via their platinum(IV) analogs seems now promising, since a
derivatization of the equatorial ligands is no longer necessary [20–22].
Recently, we reported on the synthesis, characterization and
cytotoxicity of a series of bis(carboxylato)platinum(IV) complexes
with exceptionally high antiproliferative properties using succinic and
glutaric anhydride as carboxylation agents [17–19]. Further derivati-
zation was performed using amines and alcohols, which resulted in
formation of the corresponding amides or esters, respectively. With
the aim of gaining a deeper insight into the mechanism of action and
in order to understand the structure–activity relationships and to
optimize the effects achievable with this class of compounds, we
determined the lipophilicity, the reduction potential as well as the
cellular accumulation of the respective platinum(IV) complexes and
compared them with their cytotoxic properties.
2. Experimental section
2.1. Compounds and reagents
The platinum(IV) complexes were synthesized following a
published procedure [17–19]. Sodium dodecyl sulfate (SDS), dodeca-
nophenone, 1-butanol and sodium monohydrogenphosphate were
purchased from Sigma-Aldrich (Vienna, Austria). Sodium hydroxide
solution (0.1 M), hydrochloric acid, and heptane sodium dihydrogen-
phosphate were obtained from Fluka (Buchs, Switzerland) and DMSO
was from Fisher Scientiﬁc. High purity water used throughout this
work was obtained from a Millipore Synergy 185 UV Ultrapure Water
system (Molsheim, France).
2.2. Electrochemistry
Cyclic voltammograms were measured in a three-electrode cell
using a 2.0 mm-diameter glassy carbon disc working electrode, a
platinum auxiliary electrode, and a Ag|Ag+ reference electrode
containing 0.10 M AgNO3, the potential of which was corrected
using an internal standard of ferrocenium/ferrocene. Measurements
were performed at room temperature using an EG & G PARC 273A
potentiostat/galvanostat. Deaeration of solutions was accomplished
by passing a stream of argon through the solution for 5 min prior to
the measurement and then maintaining a blanket atmosphere of43argon over the solution during the measurement. The potentials were
measured at a scan rate of 100 mV s−1 in 0.20 M [n-Bu4N][BF4]/DMF
(dimethylformamide), using [Fe(η5-C5H5)2] (E1/2=+0.72 V vs. NHE)
[23] as the internal standard, and were quoted relative to the normal
hydrogen electrode (NHE).
2.3. log k determination
The log k values were determined by MEEKC (microemulsion
electrokinetic chromatography) carried out with an HP3D CE system
(Agilent, Waldbronn, Germany) equipped with an on-column diode-
array detector. Detection was carried out by UV at 200 nm. For all
measurements, capillaries of 48.5 cm total length (40 cm effective
length; 50 μm ID) were used (Polymicro Technologies, Phoenix, AZ,
USA). Capillary and sample tray were thermostatted at 37 °C. The
sample injection was carried out by hydrodynamic injection at
10 mbar for 15 s and the separation voltagewas 25 kV. New capillaries
were conditioned with 0.1 M HCl, water, 0.1 M NaOH, and again with
water (10 min each). As a daily routine, the capillary was ﬂushed with
0.1 M NaOH, water, and BGE (background electrolyte) for 5 min each
before the ﬁrst run. Before each injection, the capillary was purged
with 0.1 M NaOH, water and the BGE for 2 min each.
The microemulsion was prepared using the following component
ratios (wt.%) to establish a stable microemulsion: 91.26% sodium
phosphate buffer (20 mM, pH 7.4), 0.82% heptane, 1.44% SDS, and
6.48% 1-butanol. For the preparation of the MEEKC solutions,
surfactant, alcohol, oil, and a small portion of buffer were mixed by
ultrasonication for 5 min. The residual buffer was then slowly added
to the mixture. Afterwards, the solution was let to stand for 30 min at
the room temperature before use.
The analytes were dissolved in the microemulsion to give
concentrations between 0.45 and 0.6 mg/ml. DMSO and dodecano-
phenone were used as markers for the EOF (electroosmotic ﬂow) and
the microemulsion droplets, respectively: to 1 ml of the sample
solution 1 μl DMSO and 10 μl dodecanophenone (18 mg/ml in
methanol) were added.
The retention factor, k, is deﬁned as the ratio nme/naq (nme = total
number of moles of the solute in the microemulsion phase, and naq =
total number of moles of the solute in the aqueous phase) and this
mass distribution coefﬁcient can be calculated according to Eq. (1)
[to = migration time of an unretained substance (EOF marker), tme =
migration time of themicroemulsion, and tR= solutemigration time].
k =
tR−t0
t0 1− tR=tme
  ð1Þ2.4. log P determination
For the log P determination, the guidelines for the shake ﬂask
method described recently in Ref. [24] were slightly modiﬁed.
Weighted amounts of platinum complexes were dissolved in HPLC-
grade water, which was pre-saturated with octanol, and mixed by
sonication for 5 min. Afterwards, the solutions were centrifuged for
5 min and the concentration of Pt was determined by ICP-MS
(inductively coupled plasma-mass spectrometry). Weighted amounts
of that solutions were mixed with the same volume of octanol and
shaken for 15 min. After phase separation, the Pt concentration in the
aqueous phase was again determined by ICP-MS and the partition
coefﬁcients were calculated.
The platinum content in the aqueous phase was determined by
ICP-MS (Agilent 7500ce, Waldbronn, Germany), equipped with a
CETAC ASX-520 autosampler (Neuss, Germany), a Scott double pass
spray chamber, and a MicroMist nebulizer. For the analysis, the
samples were diluted 1:1000 with 2.5% HCl. Every sample contained
0.5 ppb In as the internal standard (CPI International, Santa Rosa, CA,
USA).
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SW480 cells (colon carcinoma, human) were kindly provided by
BrigitteMarian (Institute of Cancer Research, Department of Medicine I,
Medical University of Vienna, Austria). Cells were grown in 75 cm2
culture ﬂasks (Iwaki/Asahi Technoglass) as adherent monolayer
cultures in complete culture medium, i.e., minimal essential medium
(MEM) supplemented with 10% heat-inactivated fetal bovine serum,
1 mMsodiumpyruvate, 4 mM L-glutamine, and 1% non-essential amino
acids (100×) (all purchased from Sigma-Aldrich Austria) without
antibiotics. Cultures were maintained at 37 °C in a humidiﬁed
atmosphere containing 5% CO2 and 95% air. For cellular accumulation
experiments, exponentially growing cells were harvested from culture
ﬂasks by trypsinization and seeded in complete culture medium in
densities of 3×105 cells/well in 6-well plates (3 plates per substance).
Corresponding adsorption blanks were located on the same plate. Cells
were allowed to settle and resume adherent characteristics for 24 h at
37 °C. Then, 0.278 ml/well of 10× solutions of the test compounds were
added, followed by incubation for 2 h at 37 °C. In themeantime, the cell
number was determined in 3 wells, and the average cell number per
well was calculated. After exposure, the medium was removed
completely and wells were washed twice with PBS, followed by
solubilization of cells by addition of 0.5 ml/well of subboiled HNO3 for
N1 h. Subsequently, aliquots of 400 μl/well were transferred into 15 ml
polypropylene tubes, ﬁlled to a total volume of 8 ml with Milli-Q water
and internally standardized with In (0.5 ppb). The amount of Pt was
determined by ICP-MS (Agilent 7500ce, Waldbronn, Germany),
equipped with a CETAC ASX-520 autosampler (Neuss, Germany), a
Scott double pass spray chamber, and aMicroMist nebulizer, at a sample
delivery rate of approx. 0.25 mlpermin. Platinumand indiumstandards
were obtained from CPI International (Amsterdam, The Netherlands).
The instrument was tuned with a solution containing 1 ppb each of
lithium, yttrium, cerium, thallium, and cobalt in 2% HNO3 (Agilent
Technologies, Vienna, Austria).
3. Results and discussion
Bis(carboxylato)Pt(IV) compounds are among the most promising
platinum-based drug candidates for the treatment of cancer. In order
to rationalize the observed cytotoxic activity of a series of Pt(IV)
complexes reported recently, the compounds were evaluated with
regard to their lipophilicity, redox potentials, in vitro antiproliferative
properties, and cellular accumulation. For these studies, a series of
nine bis(carboxylato)platinum(IV) complexes (Fig. 2) was chosen
that covers a broad range of cytotoxicity and lipophilicity [17–19].H2
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Fig. 2. Chemical structures of dichlorido(ethane-1,2-diamine)platinum(IV) complexes.
44The complexes feature ethane-1,2-diamine and chloride as equato-
rial ligands and either succinate (Fig. 2, n=0)or glutarate (n=1) esters
and amides in axial positions.
3.1. log P and log k determination
A good estimate for a drug's ability to accumulate in (cancer) cells
is its lipophilicity, which is generally expressed by the octanol–water
partition coefﬁcient, log P, and a number of direct and indirect
methods can be applied for its determination. An electrokinetic
chromatography method used in determining the lipophilicity is
microemulsion electrokinetic chromatography (MEEKC) [25,26]. The
separation in MEEKC occurs not only due to the electrophoretic
mobility of the analytes but is also based on their hydrophobic
interaction with microemulsion droplets. The migration times of the
analytes in comparison to those of the electroosmotic ﬂow (EOF) and
microemulsion droplet markers can be used to calculate capacity
factors as a measure of the lipophilicity. Additionally, log P values
were determined using the traditional shake ﬂask method [24]. log k
and log P values of complexes 2–9 are listed in Table 1. Complex 1
equipped with a carboxylic acid functionality could not be included in
the investigations, since its lipophilicity is dependent on the pH value.
Correlating the MEEKC data with the chemical structures of
compounds 2–6 bearing ester moieties, it appears that with the length
of the alkyl ester group, the lipophilicity as expressed by the capacity
factors increases (compound 4 is a special case with an additional
methylene group separating the dicarboxylic acid functionalities,
being situated in terms of capacity factor between 3 and 5; order of
lipophilicity: 2b3b4b5b6).
In the case of amides the situation is a bit more complicated since
the structures of terminal groups vary signiﬁcantly. Complex 7 with
the hydroxyethyl moiety showed the smallest capacity factor and it
was also the least lipophilic compound (of both ester and amide
series). Increased lipophilicity was found for the propyl (8) and the
cyclopentylamine (9) derivatives, respectively.
The shake ﬂask method yielding the log P values for the compounds
drew a similar picture as observed by theMEEKCmethod. Correlation of
capacity factors with octanol–water partition coefﬁcients of the ester
derivatives (2–6), resulted in a linear dependency (R2=0.99089, Fig. 3),
showing that, within this class of complexes, the methods are
complementary to each other.
3.2. Electrochemistry
Since platinum(IV) compounds act as prodrugs (activation by
reduction), the reduction potential is an important pharmacological
parameter to estimate the reactivity/activity of the drugs. When the
reduction potential is high (e.g. tetraplatin: Ep=−90±20mV vs. Ag/
AgCl or +110±20mV vs. NHE) [9] reduction occurs rather fast in the
blood, resulting in a number of severe side effects as in the case of
tetraplatin. On the other hand, if the reduction potential is too low
(iproplatin: Ep=−730±100 mV vs. Ag/AgCl or −530±100 mV vs.
NHE), the drug is not reduced fast enough in the body and is excretedTable 1
log P values determined via the shake ﬂaskmethod and log k values obtained byMEEKC
measurements.
Complex log k log P
Ester derivatives 2 −1.14 −0.81±0.02
3 −0.60 −0.32±0.01
4 −0.26 0.24±0.01
5 −0.04 0.70±0.01
6 0.59 1.69±0.02
Amide derivatives 7 −1.94 −1.45
8 −0.47 −0.43±0.04
9 0.09 0.61±0.03
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Fig. 3. Plot of log P values, obtained via the shake ﬂask method, vs. log k derived from
MEEKC experiments for ester derivates 2, 3, 4, 5, and 6.
Table 2
Summary of the electrochemical data.
Functional group Compound Ep/PtIV→PtII
COOH 1 −0.56
Amide derivatives CH2OH 7 −0.56
– 8 −0.63
– 9 −0.63
Ester derivatives – 2 −0.65
– 3 −0.65
– 4 −0.65
– 5 −0.63
– 6 −0.64
Potentials in V±0.02 vs.NHEmeasured at a scan rate of 100 mV s−1 in 0.20 M [n-Bu4N]
[BF4]/DMF.
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the reduction potential are the consequence of different axial ligands
(chlorido vs. hydroxido). Thus, to reach a balance of an appropriate
(medium-scale) degree of reactivity, a change of the axial ligands to e.g.
carboxylate, resulting in complexes with an intermediate reduction
potential, is required.
All compounds were investigated by cyclic voltammetry in DMF
solution at a scan rate of 100 mV s−1 using 0.20 M [n-Bu4N][BF4] as
supporting electrolyte. Since the solubility of these compounds was too
low in water, DMF was the solvent of choice (stability for several days
wasdemonstratedby1H-NMRspectroscopy). The cyclic voltammogram
displayed only one irreversible reduction peak corresponding to PtIV/II
reduction (Fig. 4), which is common for Pt(IV) compounds. This fact can
be explained by loss of the axial ligands, which results in a change of the
coordination geometry (octahedral vs. square planar). Reduction
potentials of all compounds are given in Table 2. With the exception
of compounds 1 and 7, the reduction potentials of all other compounds
are very similar (Table 2). Thus, the chain length of the carboxylato
ligand does not inﬂuence the reduction potential. However, a polar end
group (COOH in 1 and CH2OH in 7) leads to an increase in the reduction
potential by about 0.07 V.Table 3
Cellular accumulation of platinum(IV) complexes upon 2 h of exposure of SW480 cells
and antiproliferative activity in four human cancer cell lines. Values are means±3.3. Cytotoxicity
The cytotoxicity of all compounds was determined in four different
cell lines, representingboth, cisplatin sensitive (CH1,HeLa) and cisplatin
resistant (SW480, SK-OV-3) cancer cells, yielding the IC50 values listed
in Table 3 [18,19]. Generally, there is a fairly good inverse correlation
between IC50 and log P values (themore lipophilic a complex, the lower
its IC50 values). This correlation is particularly strongwithin the series of
ester derivatives featuring the succinate residue (2, 3, 5, and 6) and
within the series of amide complexes (7, 8, and 9).-1.3 -0.8 -0.3 0.2 0.7
5 µA
E / V vs. NHE
Fig. 4. Cyclic voltammogram of 6 in DMF containing 0.20 M [n-Bu4N][BF4] at a scan rate
of 0.10 V s−1 using a glassy carbon working electrode.
45As expected, the methylester derivative 2 is the least cytotoxic of
the ester derivatives, whereas the butylester derivative 6 shows the
highest cytotoxicity in all four cell lines. In the case of complex 4
(containing a glutarate instead of a succinatemoiety), the lipophilicity
is intermediate between those of complexes 3 and 5, but its cytotoxic
properties, in particular in the more sensitive CH1 and HeLa cells, are
lower than might be expected on the basis of lipophilicity (Fig. 5).
Therefore, it may be argued that an ethyl spacer is more favorable for
cytotoxicity than a propyl spacer.
Taking into account the small changes in the reduction potentials
of 1–9, cytotoxicity obviously depends mainly on the lipophilic
properties of the complexes, which should reﬂect in different extents
of cellular accumulation. Consequently, cellular platinum accumula-
tion in one of the cell lines was investigated.3.4. Cellular accumulation
Cellular platinum content upon 2 h of exposure of SW480 cells to
the complexes could be quantiﬁed by ICP-MS in all cases. Values vary
within two orders of magnitude from 4.9 fg Pt/cell (7) to 541 fg Pt/cell
(6) (Table 3). Assuming an average cell volume of ca. 4200 μm3
(corresponding to the mean diameter of ca. 20 μm measured for
suspended SW480 cells), these values suggest that 6 and 5, the
compounds that are taken up to the highest extent, may even have
been accumulated (about 660 μM and 240 μM, respectively, according
to this calculation) beyond the extracellular concentration (50 μM)
within the short exposure time of 2 h.
Plotting IC50 values of all complexes against cellular accumulation
in the same cell line yields an approximately hyperbolic correlation,
which can roughly be linearized by logarithmic transformation of both
axes (Fig. 6).standard deviations obtained from at least three independent experiments.
Compound Pt
accumulation
(fg/cell)
IC50 (μM)a
SW480 SW480 CH1 HeLa SK-OV-3
1 6.6±0.2 95±5 5.5±2.2 14±4 76±17
2 19.7±1.0 16±1 0.68±0.20 3.6±1.3 17±3
3 59.8±3.8 4.1±0.5 0.34±0.11 0.68±0.04 3.7±1.2
4 61.7±3.3 3.5±0.1 1.1±0.2 2.1±1.0 3.7±1.1
5 197.3±14.0 0.63±0.20 0.068±0.024 0.11±0.01 1.0±0.3
6 541.4±93.5 0.22±0.08 0.018±0.007 0.032±0.007 0.35±0.08
7 4.9±0.7 142±23 24±3 82±2 131±16
8 41.3±13.2 31±15 2.3±1.1 9.2±2.0 66±23
9 9.9±2.2 19±9 1.9±0.2 2.9±1.4 29±5
a 50% inhibitory concentrations in CH1, HeLa, SW480 and SK-OV-3 cells (MTT assay,
96 h of exposure) [18,19].
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Fig. 5. Correlation of cytotoxicity (IC50 in four human cancer cell lines) with lipophilicity (log P) of ester derivatives 2–6. Note that compound 4 (with axial ligands derived from
glutaric acid) deviates from the correlation observed for the other compounds (with axial ligands derived from succinic acid), indicating that cytotoxicity is also dependent on the
position where the carbon chain of the axial ligands is elongated and not on lipophilicity alone.
50 M.R. Reithofer et al. / Journal of Inorganic Biochemistry 105 (2010) 46–51The complexes 5 and 6, which were previously identiﬁed as highly
cytotoxic [19], are accumulated by the cells in the highest amounts.
Thus, the strong biological effects of these compounds are most likely
the consequence of their high capacity of penetrating the cell, which
results from the higher chain length and lipophilicity of the ester
moiety of the axial carboxylato ligands. Whereas elongation of the
ester carbon chain results in an increase of both cellular accumulation
and antiproliferative potencywith each addition of a singlemethylene
moiety (2b3b5b6), chain elongation by one methylene moiety
between the carboxylato carbon atoms has no effect whatsoever
(3≈4).
In the case of amides (7, 8, and 9), an expectedly low accumulation
was found for complex 7 exhibiting a hydroxyethyl moiety.
Surprisingly, the highest accumulation was observed for the propyl
derivative and not for the cyclopentyl congener. In addition, the
difference in accumulation is not reﬂected in the cytotoxicity of those0,1
1
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Fig. 6. Correlation of cellular accumulation of platinum(IV) complexes and their
antiproliferative activity in SW480 cells.
46compounds. One would expect that a higher accumulation results in a
higher cytotoxicity, but compound 9 displays lower IC50 values in all
tested cell lines, consistent with its high lipophilicity, even though
cellular accumulation of this compound is lower than that of
8 (Table 3). However, it should be born in mind that cellular
accumulation was measured after 2 h, whereas the IC50 values were
determined after 96 h of exposure time. Therefore, we cannot exclude
that complex 9 is simply accumulated slower than compound 8.
In the case of the esters (2–6), cellular accumulation is in good
agreement with the IC50 values and with the log P values (cellular
accumulation increases with increasing lipophilicity). Each additional
methylene group in the ester moiety (methyl-, ethyl-, propyl- and
butylester) leads to an approximately threefold increase of cellular
accumulation, which results in a signiﬁcant enhancement of cytotoxi-
city. Since the reduction potentials of compounds 2–6 are very similar,
the differences in cytotoxicity are clearly based on cellular concentra-
tions of the complexes. Consistent with the structure–activity relation-
ships mentioned earlier, an exception is compound 4, which contains a
propyl instead of an ethyl spacer between the carboxylic carbon atoms.
Compound 3 shows almost the same cellular accumulation as
compound 4, but the IC50 values of 3 are about three times lower in
CH1 and HeLa cells than the IC50 values of 4, indicating that cellular
accumulation cannot (just as little as reduction potential) explain why
an ethyl spacer is more advantageous than a propyl spacer in terms of
cytotoxic potency.
4. Conclusions
Novel Pt(IV) complexes have shown to exhibit extraordinary
cytotoxic properties. In order to better understand their chemical
behavior and their effect on the biological activity, a series of
experiments was conducted including determination of lipophilicity,
redox potentials, in vitro antiproliferative activity and cellular
51M.R. Reithofer et al. / Journal of Inorganic Biochemistry 105 (2010) 46–51accumulation. With the selected series of bis(carboxylato)platinum
(IV) compounds, a wide range of cytotoxicity against human tumor
cells (IC50 values from nM to high μM) and lipophilicity (from
relatively hydrophobic to lipophilic) was covered. The cytotoxic
properties of the studied ester derivatives correlated well with the
lipophilicity as well as the accumulation of the complexes in tumor
cells. It appeared that the differences in cytotoxicity of the compounds
are not caused by differences in reduction potentials. Future in vivo
studies will guide us to the development of compounds with
properties ﬁtting in the ideal window of lipophilicity, toxicity and
activity.
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Introduction 
A new era of chemotherapy started with the introduction of cisplatin (cis-
[diamminedichloridoplatinum(II)]) as an anticancer drug. This Pt complex is very effective 
against epithelioid malignancies of ovarian, testes, head and neck, esophageal and lung [1]. 
Due to the serious side effects of cisplatin, carboplatin {(SP-4-2)-diammine[1,1-
cyclobutanediicarboxylato-κO(2-)]platinum(II)} was introduced in the clinic in 1981 as a second 
generation compound with reduced side-effects [2]. The mode of action of carboplatin is 
analogous to that of cisplatin and therefore they share the same spectrum of treatable cancers 
[3]. The last world-wide approved anticancer Pt drug is the third generation complex oxaliplatin 
{(SP-4-2)-[(1R,2R)-cyclohexanediamine-κ2N,N’][ethanedioato(2-)-κ2O1,O2]-platinum(II)}. In 
contrast to cisplatin and carboplatin, it has a different spectrum of activity [4] which can be 
explained by the formation of different DNA adducts due to the bulky cyclohexane ligand [5], 
and by different cellular uptake mechanisms. The accumulation of cisplatin and carboplatin in 
cells occurs mainly by passive diffusion but also facilitated transport plays an important role [6]. 
It was found that for these compounds the copper influx transporter CTR1 (copper transporter 1) 
can act as a transport system [7, 8]. Experiments indicated that deletion of the Saccaromyces 
cerevisiae CTR1 gene lowers accumulation, and increases resistance to cisplatin, and co-
administration with copper inhibits cisplatin uptake in wild-type strains [9, 10]. The cellular 
uptake of oxaliplatin seems to be less dependent on CTR1 [11], but driven by passive diffusion 
and the human organic cation transporters (OCT) [12]. Passive diffusion is based on the 
concentration gradient for a drug across the cell membrane and is mainly dependent on the 
lipophilicity, size and charge of the compound [13]. Several studies investigated the impact of 
the lipophilicity of Pt-complexes on the in vitro anticancer activity. Thereby, higher lipophilicity of 
Pt complexes was frequently related to higher intracellular accumulation and lower IC50 values 
[14-17]. Stewart et al. demonstrated that Pt accumulation is crucial for clinical efficacy. They 
investigated the Pt content in human autopsy samples and found that patients whose tumors 
responded to Pt-containing therapies had higher tumor Pt concentrations than those that failed 
to respond [18]. In recent years, a series of oxaliplatin derivatives were synthesized and tested 
on their anticancer activity. Especially oxaliplatin analogues with an additional methyl-group at 
the cyclohexan ring, namely KP1537 {(SP-4-2)-[(1R,2R,4R)-4-methyl-1,2-diaminecyclohexane-
κ2N,N’][ethanedioato(2-)-κ2O1,O2]-platinum(II)} and KP1691 {(SP-4-2)-[(1R,2R,4S)-4-methyl-
1,2-diaminecyclohexane-κ2N,N’][ethanedioato(2-)-κ2O1,O2]platinum(II)}, exhibited promising 
anticancer activity (Figure 1). The two oxaliplatin derivatives differ only in the orientation of the 
substituted alkyl group. Even though there is only this marginal difference, in vitro tests 
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indicated that the cytotoxic profile of KP1537 is similar to that of oxaliplatin, whereas KP1691 
was more cytotoxic than oxaliplatin in the majority of the tested cell lines [19]. 
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Figure 1. Chemical structures of oxaliplatin (left), KP1691 (middle) and KP1537 (right). 
 
 
Interestingly, KP1537 -the in vitro less cytotoxic compound- was more  active against an in vivo 
murine L1210 leukemia model than oxaliplatin and KP1691. First, it could be shown that 
KP1537 has a greater therapeutic window and can be administered at higher doses than 
oxaliplatin [19]. When equal doses of oxaliplatin and KP1537 were used no differences in the 
efficacy were seen (in accordance to the in vitro results). However, higher KP1537 doses, which 
were toxic in the case of oxaliplatin, had a superior therapeutic effect than oxaliplatin. KP1537 
treatment resulted in five long-term survivors and an increase in life span of more than 200%, 
whereas the optimal oxaliplatin dose led to two long-term survivors and an increase in life span 
of 152% (Figure 2). KP1691, which was the most potent compound in the in vitro tests, showed 
an increased life span of only 122% and was less active than KP1537 and oxaliplatin. The 
mismatch between the in vitro and in vivo experiments on the one side and the differences in 
the activity between the two methyl derivatives on the other might be explained by altered 
transport, drug uptake and/or efflux pumps which might impact on the pharmacological 
characteristics of these stereoisomeric complexes in vivo but not in vitro [19].  
In order to study the biodistribution of the Pt complexes in vivo, tumor and organ samples (brain, 
kidney, lung, liver and spleen) from tumor-bearing BalbC mice were analyzed for their Pt 
content 1 and 6 h post-treatment. As chronic neurotoxicitiy is the dose-limiting factor in 
oxaliplatin therapy [20, 21] the cellular uptake into the sciatic nerve was also investigated.  
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Figure 2: Kaplan-Meier plots demonstrating the survival of tumor-bearing mice treated with different 
doses of oxaliplatin and KP1537 in comparison to untreated controls [19]. 
 
 
Experimental 
 
Animal treatment and sample preparation 
The animals were kept in a pathogen-free environment and every procedure was done in a 
laminar airflow cabinet. The experiments were done according to the regulations of the Ethics 
Committee for the Care and Use of Laboratory Animals at the Medical University Vienna. 
5×10^5 CT-26 cells in 50 μL serum-free RMPI medium were injected subcutaneously into the 
right flank of 6- to 8 weeks old female BalbC mice. Animals were randomly assigned to 
treatment groups and treated after one month with one intravenous bolus injection of oxaliplatin, 
KP1537 or KP1691 (9 mg/kg dissolved in 5% glucose). 1 or 6 h after drug application the 
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animals were sacrificed and blood, brain, kidney, liver, lung, sciatic nerve, spleen and tumor 
were collected and stored at –20 °C until microwave digestion and analysis for the Pt content. 
 
 
 
Tumor platinum content 
Instrumentation. The Pt content in the tissue was determined by ICP-MS (Agilent 7500ce, 
Waldbronn, Germany), equipped with a CETAC ASX-520 autosampler (Neuss, Germany), a 
Scott double pass spray chamber, and a MicroMist nebulizer. The 195Pt and 115In isotopes were 
recorded, the latter as internal standard. Instrument control and data analysis were carried out 
using Agilent ChemStation software (G1834B). The working conditions were optimized daily 
using a 1 μg L-1 tuning solution (Agilent) containing 7Li, 89Y and 205Tl in 2% HNO3. Doubly 
charged ions and oxide levels were minimized by using 140Ce/70Ce and Ce/CeO ratios and were 
typically < 2.5%. The instrument was calibrated daily using Pt standards of 0.5, 1, 5, 12, 23 and 
30 ng Pt/mL in 3.5% HNO3 spiked with 0.5 ppb In as internal standard (CPI International, Santa 
Rosa, CA, USA). 
Sample preparation. Tissue sample aliquots of 10–35 mg were digested with 1 mL nitric acid 
(65% HNO3 p.a. from Sigma Aldrich, further purified with a quartz sub-boiling system from 
Milestone-MLS GmbH, Leutkirch, Germany) and 1 mL water in a microwave system (MLS-
Ethos1600, Milestone-MLS GmbH, Leutkirch, Germany). The samples were diluted with water 
to reach an end mass of approximately 10 g (0.5 ppb In as internal standard). 
 
 
 
 
 
Results and Discussion 
 
The pharmacokinetics and tissue distribution of drug compounds have a major influence on the 
therapeutic efficacy and adverse effects. Three groups of tumor bearing female BALB/c mice 
were treated either with oxaliplatin or its methyl derivatives KP1691 and KP1537 and the 
accumulation and biodistribution of the compounds were compared.  
 
Tissue distribution after 1 h 
One hour after administration of all three compounds, the highest Pt concentrations were found 
in blood. In order to study the distribution in the blood, the plasma was separated from the blood 
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cells by centrifugation. In the blood cells the Pt concentration was approximately 4.5 times 
higher than in the plasma after treatment with all three Pt complexes (Table 1). Similar 
observations were made for oxaliplatin by others. A high content of oxaliplatin in the blood is 
bound in erythrocytes which is supposed to inactivate the Pt complex [22, 23]. Mandal et al. 
investigated the oxaliplatin blood distribution of 19 colorectal cancer patients 1 and 48 h after 
the first infusion [24]. They found that the concentration of protein bound Pt complexes in 
erythrocytes did not change significantly in this time frame but the Pt levels in the plasma were 
reduced by about 50%, which can be attributed to drug transport, metabolism and clearance. 
Generally, the high affinity of Pt complexes to erythrocytes might explain the high Pt levels in 
lung, kidney and spleen which have a  high blood supply and therefore are rich in erythrocytes. 
For example, the spleen is responsible for the filtration of the blood from worn-out erythrocytes. 
In contrast, low Pt levels were found in the brain after treatment with all three Pt complexes 
indicating that these compounds have a low potential to cross the blood brain barrier.  
 
 
Table 1. Organ distribution of KP1691, KP1537 and oxaliplatin after 1 h in tumor bearing mice 
 
 
 
compound 
                       ng Pt / mg tissue 
KP1691 KP1537 oxaliplatin 
blood cells 3.43 ± 0.30 2.71 ± 0.48 2.38 ± 0.13 
brain 0.05 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
kidney 2.90 ± 0.02 2.49 ± 0.26 2.87 ± 0.39 
liver 2.76 ± 0.36 2.28 ± 0.34 2.44 ± 0.14 
lung 1.87 ± 0.15 1.78 ± 0.33 1.99 ± 0.15 
plasma 0.74 ± 0.07 0.51 ± 0.10 0.62 ± 0.12 
sciatic nerve 0.76 ± 0.03 0.37 ± 0.11 0.48 ± 0.05 
spleen 2.64 ± 0.08 2.00 ± 0.43 2.12 ± 0.12 
tumor 1.03 ± 0.02 0.78 ± 0.12 0.72 ± 0.12 
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When comparing the three different drugs to each other, in all analyzed tissues the highest Pt 
levels were found in mice treated with KP1691. The Pt tumor content in the KP1691 group was 
1.03 ng Pt/mg tumor whereas the accumulation for KP1537 and oxaliplatin was similar and only 
0.75 ng Pt/mg tumor. A similar picture was found in all other tissue samples. 
  
 
 
 
Tissue distribution after 6 h 
Tissues collected from mice sacrificed 6 h after drug administration showed for all three 
treatment groups the highest Pt concentrations again in kidney, liver, lung and spleen (Table 2). 
However,  the absolute values after 6 h in comparison with the Pt content in the samples taken 
after 1h changed differently within the three Pt drugs.  The Pt concentration in kidney, liver, lung 
and spleen slightly decreased in mice treated with KP1691, whereas only minor changes were 
found for KP1537 and a slight increase for oxaliplatin.  
  
 
Table 2. Organ distribution of KP1691, KP1537 and oxaliplatin 6 h after treatment with the Pt complexes  
 
 
 
compound 
                          ng Pt / mg tissue 
KP1691 KP1537 oxaliplatin 
brain 0.03 ± 0.01  0.05 ± 0.02   0.06 ± 0.02  
kidney 2.02 ± 0.61  2.62 ± 0.32  3.36 ± 0.51  
liver 1.76 ± 0.53 2.29 ± 0.07  2.58 ± 0.52  
lung 1.47 ± 0.50  1.61 ± 0.19   2.66 ± 0.94  
sciatic nerve 0.39 ± 0.13  0.47 ± 0.11   0.70 ± 0.14  
spleen 1.72 ± 0.56  1.78 ± 0.10    2.40 ± 0.28  
tumor  0.63 ± 0.19   0.83 ± 0.02   0.99 ± 0.04  
 
 
 
A similar trend was observed for all other tissue samples. After 6 h the highest Pt levels were 
found in the oxaliplatin group. Notably, the KP1691 concentration in the tumor decreased an 
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average by 40% whereas the Pt level after treatment with KP1537 remained constant (Figure 
3). It appears as if the drug uptake and efflux are responsible for the different in vitro and in vivo 
anticancer activities of the investigated compounds. Furthermore, the enhanced efflux of 
KP1691 is most probably the reason for the lower anticancer activity in vivo. However, further 
investigations have to be performed to identify possible efflux mechanisms. Even though 
oxaliplatin accumulated over time to higher concentrations it was not more active in vivo and 
there is only a small difference to the in vivo more active KP1537. Taking into account that the 
uptake of oxaliplatin in the sciatic nerve is higher than for KP1537, the methyl derivative seems 
to be beneficial with regard to lower neurotoxicity. 
 
 
 
Figure 3. Pt content in tissue samples taken 1 and 6 h after intravenous administration of KP1691, 
KP1537 and oxaliplatin. The values are average of data from three independent experiments and the 
bars indicate the standard deviations. 
 
 
 
Conclusion 
 
In this study the biodistribution and accumulation of oxaliplatin and its methyl derivatives 
KP1691 and KP1537 were investigated in tumor-bearing mice. KP1691 is quickly accumulated 
in all analyzed tissue samples including the tumor. However, also a rather rapid efflux was 
detected which might explain the low anticancer activity of KP1691 observed in the L1210 
murine leukemia model as compared to KP1537 and oxaliplatin [19]. In the same L1210 murine 
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leukemia model no differences in the anticancer activity between oxaliplatin and KP1537 were 
found when used at equal doses. A similar trend was observed in this study on the 
biodistribution of these two complexes; 6 h after administration the Pt tumor content in the 
KP1537 group was similar to that of oxaliplatin. Interestingly, KP1537 levels did not change 
between 1 and 6 h post-injection taken samples, whereas in the oxaliplatin group a slight 
increase was seen. Future studies should include long-term and repeated drug treatment 
groups to see if the Pt tumor levels for KP1537 and oxaliplatin remain similar or whether 
differences are found. Considering that neurotoxicity is a central problem of clinical application 
of oxaliplatin, the lower accumulation of KP1537 in the sciatic nerve makes it a promising drug 
for further (pre)clinical development.  
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 Abstract 
The ruthenium-indazole complexes are promising anticancer agents undergoing clinical trials. 
KP1339 is administered intravenously (i.v.), where serum proteins are the first available 
biological binding partners. In order to gain a better insight into the mode of action, mice were 
treated with different doses of KP1339 i.v. and sacrificed at different time points. The blood 
serum was isolated from blood samples and analyzed by capillary zone electrophoresis (CZE) 
and size exclusion/anion exchange chromatography (SEC-IC) both combined online to 
inductively coupled plasma-mass spectrometry (ICP-MS). The performance of the analytical 
methodology was compared and the interaction of KP1339 with mouse plasma proteins 
characterized in vivo. Interestingly, the samples of the mice treated with 50 mg/kg and 
terminated after 24 h showed a by 2- to 2.5-fold lowered albumin content and increased 
formation of albumin aggregates as compared to the untreated control group and the 40 mg/kg 
group. The majority of Ru was bound to albumin and the stoichiometry of the KP1339 protein 
binding was determined through the molar Ru/S ratio. In general, good agreement of the data 
obtained with both techniques was achieved and the SEC-IC method was found to be more 
sensitive as compared to the CZE–ICP-MS approach. However, the latter benefits from shorter 
analysis time and lower sample consumption.  
 
 
 
Introduction 
 
Ruthenium compounds have become the best developed representatives of the non-platinum 
complexes with anticancer activity.1-9 So far the two octahedral ruthenium(III) complexes 
indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019; Figure 1) and 
imidazolium trans-[tetrachlorido(S-dimethylsulfoxide)(1H-imidazole)ruthenate(III)] (NAMI-A; 
Figure 1) have been tested in clinical phase I trials.3,6,10,11 Only very moderate toxicities were 
observed in the case of KP1019,3,6,11 and for NAMI-A blister formation was dose-limiting.10 
In preclinical studies, KP1019 was found to be active against primary tumors and metastases in 
animal models, e.g., in an autochthonous colorectal carcinoma of the rat which resembles colon 
cancer of humans,11,12 whereas NAMI-A was shown to inhibit the metastasizing process.13,14 In 
addition, the activity of KP1019 was investigated against more than 50 primary explanted 
human tumors, a model that has high predictability for the clinical situation,15,16 showing activity 
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 in more than 80% of the tumor models. These ruthenium(III) complexes are thought to have a 
distinct mode of action from platinum complexes17,18 with DNA being not the primary target but 
interaction with proteins was demonstrated.19 This behavior might also contribute to the low 
toxicity and side effects of such species, as does the “activation by reduction”, i.e., Ru(III) 
coordination compounds are thought to be activated in the tumor tissue by reduction under 
hypoxic conditions.17,18,20,21 
 
 
 
Figure 1. The structures of the two Ru
III
 complexes in clinical trials: KP1019 (left) and NAMI-A (right). 
 
 
The high affinity of the RuIII compounds to proteins, in particular to transferrin, was thought to 
play a major role in the uptake into cells in vitro,22,23 and the distribution and transport to the 
tumor in vivo.19,24-28 However, the main fraction of the Ru compound was found attached to 
human serum albumin in in vitro and in vivo samples and was estimated to be > 99% of the total 
Ru content.26,27,29 The binding of the ruthenium compound to albumin was considered as a form 
of storage, as also hypothesized for cisplatin.30  
The limitation in the application of KP1019 in the clinic was the low solubility and therefore the 
maximum tolerated dose was not reachable in clinical trials.31 In an approach to obtain a 
compound with high water solubility, the indazolium counterion in KP1019 was replaced by 
sodium (KP1339).3,6 With regard to the mode of action, a comparative study on the protein 
binding behavior of KP1019 and KP1339 revealed similar properties in terms of binding 
kinetics.32 
The adduct formation of metal complexes with proteins was studied by several methods, 
including spectroscopic and separation methods (for recent reviews see refs. 19,33). 
Hyphenated liquid chromatography- (LC) and capillary zone electrophoresis-inductively-coupled 
plasma mass spectrometry (CZE–ICP-MS) methods were applied for the quantification of the 
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 protein loading,26,34-41 based on the metal-to-sulfur ratio as determined by ICP-MS as sensitive 
and element-specific detector.  
Herein, we report the method development for characterization of the in vivo protein binding of 
the Ru anticancer compound KP1339 by LC– and CZE–ICP-MS and a comparison of these 
techniques with regard to detection and quantification limits. Data gained by means of the 
developed methods for the analysis of blood samples obtained from mice treated with KP1339 
are presented.  
 
 
 
Experimental 
 
Mouse samples 
KP1339 was administered i.v. to nude BALB/c mice (3 per group) in single doses of 40 (M40), 
50 (M50) and 60 (M60) mg/kg and compared to the control (M0). When signs of terminal toxicity 
appeared, the experimental animals were terminated (control and M40-7: 7 days; M40-1: 1 day; 
M50-1: 1 day, M60-1: 1 day) and blood samples were taken. The collected blood was added to 
heparin-containing Eppendorf tubes and centrifuged (2500 rpm for 5 min). The obtained plasma 
was stored at -20 °C until analysis. 
 
 
Sample preparation 
Microwave-assisted digestion (MLS-1200-Microwave, MLS GmbH, Leutkirchen, Germany) was 
performed to mineralize the plasma samples for determination of total Ru concentration via ICP-
MS. Therefore 20 mg plasma aliquots were digested according to the microwave user 
instructions. The digested samples were filled up with water to reach an end mass of 10 g. For 
the analysis, the samples were diluted 1 : 2.  
For the elemental quantification by flow injection (FI)–ICP-MS and elemental speciation by 
SEC–ICP-MS the samples were diluted 1 : 20. For the 2D-SEC-IC–ICP-MS determination a 
dilution factor of 10 was applied. Calibration of metal-to-sulfur ratios was performed using FI of 
inorganic ruthenium and sulfur standards (Merck, Germany). 
For CZE–ICP-MS, four sets of standards (incubated for 3 h at 37 °C in 10 mM phosphate buffer 
containing 100 mM NaCl at pH 7.4, in order to simulate physiological conditions) at molar 
KP1339/HSA ratios of 0.5, 1, 2 and 3 were utilized for calibration. The concentration of HSA 
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 was kept constant at 100 μM. The in vivo samples were diluted 1 : 3 with the incubation buffer 
before analysis. 
For protein fractionation, the plasma samples M0 and M60-1 were defrosted and diluted 1 : 10 
with 20 mM Tris buffer containing 150 mM NaCl at pH 7.3. Prior to MS analysis, the fractions 
were lyophilized and redissolved in 10 μL water.  
The samples for MALDI-MS were prepared using the dried droplet method with freshly prepared 
sinapinic acid (10 mg/mL in acetontrile/H2O/trifluoroacetic acid = 50/50/0.1) as matrix. The 
protein samples and matrix were mixed 1 : 5 v/v and a 1 μL aliquot of the mixture was loaded 
onto the stainless steel MALDI target. The procedure was repeated three times. 
 
 
LC–ICP-DRC-MS 
The metal-free chromatographic system consisted of an AS 50 autosampler (including a custom 
made temperature control device), the ICS-3000 DP Dual pump system and the Chromeleon 
Chromatography Management System (Version 6.40), all from Dionex (Sunnyvale, California, 
USA). Injected samples were filtered in-line using a 0.45 µm PEEK filter located in front of the 
columns. The ICP-MS sample introduction system consisted of a PFA-nebulizer (CPI 
International, Amsterdam, Netherlands) and a cyclonic spray chamber. The ICP-MS used was a 
quadrupole-based system equipped with a dynamic reaction cell (ELAN DRC-II, PE SCIEX, 
Ontario, Canada) and oxygen (purity 4.5, Linde Gas GmbH, Vienna, Austria) was used as 
reaction gas.  
Size exclusion chromatographic separation was achieved using a BioSuiteTM 125 column (300 × 
4.6 mm UHR SEC, 4 µm particle diameter) from Waters (Milford, Massachusetts, USA). The 
SEC eluent, containing 150 mM NaCl and 20 mM Tris-HCl, pH 7.4, was delivered at a flow rate 
of 350 µL·min-1. A TSK-DEAE-NPR column (particle diameter 2.5 µm, TOSOH Bioscience 
GmbH, Stuttgart, Germany) made of PEEK (30 × 2 mm, Grom Chromatography GmbH, 
Rottenburg-Hailfingen, Germany) was used for anion exchange chromatography. The mobile 
phase was delivered by a gradient pump at a flow rate of 0.35 mL min-1 and consisted of water 
(A), 150 mM NaCl + 20 mM Tris, pH 7.4 (B) and 500 mM NaCl + 20 mM Tris, pH 7.4 (C). The 
initial composition was A/B 80/20, linear gradient elution was started simultaneously to switching 
of the transfer valve and ran to 100% C within 10 min. A more detailed description of the SEC-
IC–ICP-MS experimental set-up is given elsewhere.26 ICP-MS operation parameter are 
summarized in Table 1.  
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 Table 1. ICP-MS operational parameters 
Parameter  LC–ICP-DRC-MS CZE–ICP- MS 
Nebulizer PFA nebulizer 
CETAC CEI-100 
microconcentric nebulizer 
Spray chamber Cyclon - 
Nebulizer gas flow, L min-1 1.0  1.14 
Auxiliary gas flow, L min-1 1.275  0.4 
Plasma gas flow, L min-1 15  15 
ICP RF power, W 1300 1500 
O2 flow rate, mL min
-1 0.8  - 
RPQ 0.3 (SO), 0.6 (Ru) - 
Measured isotopes 48SO, 101Ru, 102Ru 34S, 72Ge, 101Ru, 102Ru 
Scan mode Peak hopping - 
Sampler Ni (0.1 mm orifice) 
Skimmer Ni (0.4 mm orifice) 
 
 
CZE–ICP-MS 
CZE experiments were performed with an HP3D CE system (Agilent, Waldbronn, Germany) 
interfaced to an Agilent 7500ce ICP-MS with a CETAC CEI-100 microconcentric nebulizer. 
Capillaries of 60 cm total length (75 μm ID) were used (Polymicro Technologies, Phoenix, AZ, 
USA) for all experiments. Capillary and sample tray were thermostatted at 37 °C. Injections 
were performed by applying a pressure of 25 mbar for 4 s, and a constant voltage of -20 kV. 
Prior to the first use, the capillary was flushed at 1 bar with 0.1 M HCl, water, 0.1 M NaOH and 
again with water (10 min each). After this treatment the capillary was coated modifying the 
procedure described by Kelly et al. by subsequently rinsing with 1% PB solution containing 
3v/v% ethylene glycol for 30 min at 50 mbar and water for 15 min at 1 bar.42 Before each 
injection, the capillary was purged for 3 min both with water and the background electrolyte 
(BGE; 50 mM formic acid). The operational values for the CZE–ICP-MS analyses are shown in 
Table 1. The nebulizer was employed in self-aspiration mode with the sheath liquid (50 mM 
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 formic acid with 20 ppb Ge) closing the electrical circuit and spraying a fine aerosol. Analyses 
were only started if a sufficiently stable signal (RSD 72Ge < 5%) was attained. 
 
 
SEC fractionation and subsequent LC-ESI-TOFMS and MALDI-MS analysis 
The samples were fractionated with a Dionex Ultimate 3000 system. The size exclusion column 
for the separation was a Waters Biosuite 125 4 μm UHR SEC, 4.6 × 300 mm. The conditions 
were set to a flow rate of 350 μl min-1 of 20 mM Tris buffer containing 150 mM NaCl at pH 7.3. 
After a pre-run the collection, windows were set to collect fractions A (6.2–7.0 min), B (7.0–7.8 
min), C (7.8–8.6 min) and D (8.6–9.4 min). The compounds were detected by UV spectroscopy 
at 215, 254 and 280 nm. 
 
The analysis via LC-ESI-TOF-MS was carried out on an Agilent 6210 TOF-MS in combination 
with an Agilent 1200 SERIES HPLC system (Agilent, Waldbronn, Germany). The reversed 
phase column for the separation was an Ascentis Express C18 HPLC (Sigma Aldrich, 
Bellefonte, USA; column dimensions: 2.1 × 50mm). The injection volume was 2 µL of the 
collected fractions and the flow rate was set to 600 µL min-1. Gradient elution was implemented 
starting with an aqueous phase containing 0.1% formic acid and 5% acetonitrile. The acetonitrile 
concentration was increased to 60% within 5 min followed by a further increase to 80% within 2 
min. Afterwards the column was re-equilibrated within 2 min.  
MALDI MS analyses were performed on an AXIMA-LNR instrument (Shimadzu Biotech-Kratos 
Analytical, Manchester, UK). The AXIMA-LNR was equipped with a pulsed nitrogen laser with a 
wavelength of 337 nm and a pulse width (FWHM) of about 4 ns and an integrated 1 GHz 
recorder. Analysis of the proteins was performed in linear mode with positive ionization at an 
acceleration voltage of 20 kV. Mass spectra were acquired by averaging 100 single laser shots 
and the spectra were recorded in the range from 30000 to 150000 m/z. For data processing and 
acquisition Kratos software version 2.3.5 was used. 
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 Results and Discussion 
 
In order to study the plasma protein distribution of the Ru compound KP1339 in an in vivo setup, 
three groups of mice were treated with the pharmaceutical formulation of 40 (M40), and 
50 mg/kg (M50) and the data was compared to an untreated control group. The mice were 
sacrificed after 1 d (M40-1, M50-1) or after 7 days (M40-7). Plasma was obtained from the 
collected blood samples and the total Ru content in the M40-1 and M50-1 mouse blood plasma 
was determined by flow injection ICP-MS to be much higher than in M40-7 (Table 2). This was 
expectable based on results collected during a pharmacokinetic study accompanying a clinical 
phase I trial for the structurally related bis(indazole)-ruthenium compound KP1019.31,43 The data 
were cross-validated with data obtained after microwave assisted digestion and the results are 
in good agreement.  
 
Table 2. Total Ru concentrations in plasma. 
Mouse Dose Time µg Ru / g plasma 
M40-1a 
40 mg/kg 1d 
22 
M40-1b 28 
M40-1c 20 
M40-7a 
40 mg/kg 7d 
1.1 
M40-7b 1.4 
M40-7c 1.8 
M50-1a 
50 mg/kg 1d 
23 
M50-1b 22 
M50-1c 22 
 
 
LC–ICP-MS 
In a semiquantitative determination of albumin using size exclusion chromatography (SEC)–
ICP-MS monitoring of the 48SO trace (Figure 2), the amount of protein in the 60–80 kDa fraction 
of the M50-1 plasma (22 ± 6 g/L), which contains mainly albumin (and ca. 5% transferrin), was 
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 estimated to be lowered by 2–2.5 times, as compared to the untreated control (54 ± 1 g/L) and 
the M40-1 (47 ± 7 g/L) and M40-7 mouse plasma samples (44 ± 4 g/L). The concentration of 
protein was determined using inorganic sulfur standards for external calibration by flow injection 
or by employing HSA standards. Both approaches proved to be valid, revealing comparable 
results, but the use of albumin or drug-albumin adducts in SEC–ICP-MS and SEC-IC–ICP-MS 
allowed omitting the extra flow injection step in the analytical work flow. 
 
 
Figure 2. SEC-ICP-MS analysis (
48
SO traces) of mouse plasma samples M40-7a and M50-1c ; The peak 
at 8 min represented the 60-80 kDa fraction containing the transporter proteins Tf, transferrin; and MSA, 
mouse serum albumin.  
 
 
All mouse plasma samples contained as major component the protein fraction constituted 
primarily by albumin. However, at a dosage of 50 mg/kg KP1339, SEC-ICP-MS measurement 
revealed significantly changed relative distribution of the proteins (given by the sulfur peaks). At 
this dosage, not only a decrease in albumin content (peak at 8 min) along with a decrease of 
total protein content was observed in the mouse plasma, but also a shift towards higher 
molecular weight species. Two protein fractions increased to about 15% each, namely a fraction 
of proteins eluting at the size exclusion limit of the used SEC column corresponding to protein 
sizes > 150 kDa, and a fraction corresponding to 100–130 kDa proteins. Size ladder 
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 experiments had shown that immunoglobulin and ferritin would elute at the time of the first SEC 
fraction. The latter fraction could represent an albumin dimer, since the peak was also found in 
albumin standards. Figure 3 shows the relative distribution of the three serum protein SEC 
fractions. At a dose of 40 mg/kg KP1339, the protein distribution was similar within the standard 
uncertainty, independent of the time of termination of the experiment. 
 
 
Figure 3. Changes in the relative protein distribution found in the plasma samples M40-1, M40-7 and 
M50-1 as compared to the control group M0.  
 
 
Ru analysis by SEC–ICP-MS revealed that the decreased protein concentration and the 
changed serum protein distribution were related to an altered KP1339 protein binding pattern 
upon dosage increase from 40 to 50 mg/kg (Figure 4). Whereas in the case of the M40 mouse 
plasma samples the vast majority of the Ru was attached to 60-80 kDa fraction (90–95%), a 
broader distribution was found in the M50-1 group: the majority was still found at the 
albumin/transferrin fraction (ca. 60%), followed by a pronounced adduct formation with proteins 
> 100 kDa. The recovery rates for Ru with the used SEC column were satisfying ranging at 
70%, whereas albumin is recovered quantitatively (tested with albumin standards).44 For the 
mouse plasma samples M40-7, the concentration of Ru found attached to plasma proteins was 
significantly lower than in the M50-1 and M40-1 samples. This fact was in agreement to the data 
obtained by total Ru quantification of the plasma samples (Table 2) and expectable considering 
the longer time for in vivo processing of the protein adducts.  
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Figure 4. 
101
Ru traces recorded by SEC–ICP-MS for mouse plasma samples M40-1a, M40-7a and M50-
1c. 
 
 
One possible explanation for these observations could be the agglomeration of serum albumin 
at KP1339 concentrations exceeding a certain dosage. Therefore experiments were carried out 
aiming at the characterization of the formed higher molecular weight species assumed to be 
agglomerated albumin-drug adducts. For this purpose an automated off-line SEC fraction 
collection was implemented. Samples of mice treated with a single dose of 50 and 60 mg/kg 
were investigated and sacrificed after 1 day. Figure 5 shows the SEC fractions, which were 
collected and subsequently analyzed by SEC-ICP-MS to confirm the quality of the fractionation, 
and by LC-TOF-MS and MALDI-MS to determine the molar masses of the proteins present in 
the collected fraction. As can be seen in Figure 5, the M60-1 sample contains a higher content 
of MSA agglomerates as compared to the M50-1 case (compare Figure 4), but no differences in 
the albumin fraction were observed. 
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Figure 5. SEC fractionation of the M60-1 sample (M60-1_A, B, C and D); shown is the UV trace at  
215 nm.  
 
 
SEC-ICP-MS analysis of fractions M60_1_B, C and D revealed single peaks confirming the 
quality of fractionation. The analysis by LC-TOF-MS resulted for fractions C and D in mass 
spectra containing multiply charged protein ion patterns which were mathematically 
deconvoluted to give the molar masses of albumin. However, no proteins were identified in 
fraction B using the same approach. Most interestingly, mass spectra of fraction A contained 
again peaks assignable to albumin, similar to the data obtained for fractions C and D. However, 
in an off-line SEC-SEC-ICP-MS experiment not a single protein peak at 6–7 min was observed, 
but a similar distribution of proteins as without fractionation (Figure 6). These results point 
towards the fact that fraction A could contain agglomerated albumin-drug adducts, which were 
denatured during reversed phase LC-TOF-MS and already partly degraded via simple dilution 
as occurring in an SEC-SEC-ICP-MS experiment. Moreover, these assumptions were further 
strengthened by MALDI-MS studies. All collected fractions of a M60-1 mouse plasma sample 
were analyzed under identical conditions and compared to an HSA standard. In all four 
fractions, albumin was detectable, however, proteins with a mass of approximately 130 kDa 
were identified in fraction M60-1_B (Figure 7), which are neither present in the control mouse 
nor the other fractions. The molecular weight of these species indicates the formation of dimeric 
MSA aggregates. These data also fit nicely the molecular mass expectable from the retention 
times in the SEC experiment.  
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Figure 6. 
48
SO trace recorded in an SEC-SEC-ICPMS run of fraction M60-1_A. 
 
 
 
 
 
 
Figure 7. MALDI-mass spectra of fractions A–D collected from a M60-1 plasma sample. 
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 SEC-IC-ICP-MS determination 
Finally, the drug adduct formation in the 60-80 kDa fraction was analyzed on a quantitative 
basis following a two dimensional native separation scheme in combination with ICP-MS 
detection. The validity of the approach has been shown in the past.26 As a key advantage, this 
method allows the separation of albumin and transferrin. In this work, the two-dimensional 
separation was achieved off-line. The LOD for transferrin was determined as 0.11 mg/mL and 
the LOQ as 0.36 mg/mL with regard to the sulfur signal (48SO), whereas Ru limits of detection 
are lower by at least 1 order of magnitude. For all investigated samples the transferrin-KP1339 
adduct was < LOD. Table 3 summarizes the obtained quantitative results for the albumin-
KP1339 adducts. 
 
CZE–ICP-MS 
Capillary electrophoresis has been used for a long time in metallodrug research and in this 
study a method involving the use of PB-coated capillaries was directly compared to the SEC-
IC–ICP-MS method described afore. External calibration was used with samples ranging from 
0.5–3 eq. of KP1339 per HSA and as assessed by CZE–ICP-MS the binding was quantitative 
and yielded a linear calibration curve (Figure 8).  
 
Figure 8. Calibration graph obtained for the analysis of HSA/KP1339 standards by CZE–ICP-MS. 
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 The LOD and LOQ were determined for the Ru-to-HSA ratio as 0.22 and 0.66, respectively. In 
contrast to the SEC-IC–ICP-MS method, the concentration of albumin was measured by 
recording the 34S trace. Due to the background of the 34S trace caused by the interferences of 
16O18O, 16O17O1H and 15N16O1H, only the trace of the most abundant protein in plasma, albumin 
(MSA contains 44 sulfur atoms45) was followed.  
The electropherograms of the M40 and M50 mouse plasma samples contain two peaks in the 
Ru trace after treatment with KP1339 (Figure 9). The peak with the higher migration time 
corresponds to the KP1339–albumin adduct, whereas the second peak is assumed to stem in 
accordance to the LC data from albumin aggregates. Integration of the peaks demonstrates that 
the majority of the ruthenium drug is bound in vivo to albumin. The molar ratios of Ru/S for the 
KP1339-MSA adducts found with CZE-ICP-MS are summarized in Table 3 and compared to the 
results collected by SEC-IC-ICP-MS. The Ru/S ratios found with CZE technique are slightly 
higher than those obtained with SEC-IC–ICP-MS, but are still in good accordance taking into 
account the low sensitivity for 34S (natural abundance 4.21%). In the plasma samples M40-1 
and M40-7 almost 80 and 70%, respectively, of the total observed Ru content was found as 
albumin adduct, whereas the M50-1 samples contain significantly lower amounts of Ru attached 
to albumin (about 50%).  
 
 
Figure 9. Electropherogram of the mouse plasma sample M40-1b. Shown are the traces of 
102
Ru and 
34
S 
(for MSA detection).  
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 Table 3. Experimentally determined KP1339/MSA molar ratios.  
Mouse Dose Ru/MSA a 
CE–ICP-MS SEC(-IC)–ICP-MS 
M40-1a 40 mg/kg 0.83 0.72 
M40-1b 0.88 0.71 
M40-1c 0.84 0.94 
M40-7a 40 mg/kg 0.15 0.04 
M40-7b 0.12 0.04 
M40-7c 0.15 0.05 
M50-1a 50 mg/kg 0.93 0.70 
M50-1b - b 0.80 
M50-1c 0.77 0.81 
a 
The total combined uncertainties were estimated as 15%; 
b
 The 
volume of the plasma sample was too small to analyze it with all 
available methods. 
 
 
 
 
Conclusions 
 
Hyphenated methods, such as LC– and CE–ICP-MS approaches, are essential in metallomics 
research, especially when performing analyses in in vivo samples. The speciation analysis of 
metallodrugs in plasma samples obtained from mice is of major interest to identify essential 
parts of the mode of action, i.e., the transport of the drugs through the bloodstream.  
CZE– and 1D and 2D LC–ICP-MS methods were implemented in order to analyze plasma 
samples collected from mice treated with different amounts of the ruthenium-indazole anticancer 
complex KP1339 for 1 or 7 days. In general, the LC-based method was more sensitive, whereas 
the CZE approach is considerably quicker. The studies revealed a significant effect of the 
dosage on the total protein content and the species formed. In addition to the expected proteins, 
MSA agglomerates were identified, as shown by LC-TOF-MS and MALDI-MS after fractionation 
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 of plasma samples. Furthermore, the protein and the drug-protein adduct distributions varied in 
dependence of the dose; for example, after treatment with 50 mg/kg the albumin contents along 
with the total protein content decreased significantly. Both, LC- and CZE-based ICP-MS 
experiments demonstrated that the majority of Ru was attached to albumin and good agreement 
was achieved for the molar ratio of Ru/MSA. In future, the developed methodology will be 
applied for the pharmacokinetic analysis of both in vivo samples collected from mice and 
eventually for accompanying experiments to clinical trials. 
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 Abstract 
 
The ruthenium complex KP1339 is a promising anticancer agent, currently undergoing clinical 
trials. In order to get insight into the distribution and accumulation throughout a living organism, 
KP1339 was administered intravenously in non-tumor bearing nude BALB/c mice and the Ru 
content in blood cells and plasma, bone, brain, colon, kidneys, liver, lung, muscle, spleen, 
stomach and thymus was determined at several time points. The Ru concentration in blood cells 
and plasma was found to increase slightly within the first hours of analysis, with the Ru 
concentration being 3-times higher in plasma compared to blood cells. The plasma samples 
were subjected to analysis by capillary zone electrophoresis (CZE) and size exclusion/anion 
exchange chromatography (SEC-IC) both coupled to inductively coupled plasma-mass 
spectrometry (ICP-MS) and a large majority of the total Ru content was found attached to mouse 
serum albumin (MSA). Within 1 h, the peak ratio of approximately 1.2–1.5 Ru per albumin 
molecule is reached which declines to about 1 Ru per albumin molecule within 24 h. Beside the 
MSA adduct a higher molecular weight species is observed probably stemming from MSA 
conjugates. In addition, the tissue samples were mineralized by microwave digestion and 
analyzed for their Ru content. The highest Ru levels were found in colon, lung, liver, kidney and 
thymus. The peak Ru concentrations in these tissues were reached 1–6 h after administration 
and decline slowly over time. Additionally, the NCI’s anticancer drug discovery screen for the 
parent compound KP1019 indicated high activity against leukemia. The high accumulation of 
KP1339 in the thymus and the high activity of KP1019 against leukemia make the two Ru drugs 
interesting candidates against lymphoblastic leukemia. 
 
 
 
 
Introduction 
 
Ruthenium compounds are considered the most likely candidates for the next generation of 
metal-based anticancer drugs and the Ru(III) complexes KP1019 {indazolium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)]} and NAMI-A {imidazolium trans-
[tetrachloride(DMSO)(imidazole)ruthenate(III)]} (Figure 1) have finished clinical phase I trials [1-
3].  
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Figure 1. The structures of KP1019 {trans-[tetrachloridobis(1H-indazole)ruthenate(III)]} and NAMI-A 
{imidazolium trans-[tetrachloride(DMSO)(imidazole)ruthenate(III)]}.  
 
 
The clinical and preclinical data indicate significant pharmacological differences between the 
different ruthenium compounds. Certain ruthenium compounds such as NAMI-A do not exhibit 
direct cytotoxicity in tumor cells and are considered only as anti-metastatic agents [4]. In contrast 
to these compounds, the bisindazole complex KP1019 and its analogues showed preclinical 
activity in several in vivo models against primary tumors and metastases. Most notable is the 
tumor-inhibiting potency in an autochthonous colorectal carcinoma of the rat, which resembles 
colon cancer of humans [5,6], and in more than 50 primary explanted human tumors, with a 
response rate of more than 80% of the tumor models [2]. In the KP1019 phase I clinical study, 
five of six patients experienced disease stabilization for 8–10 weeks, accompanied by only mild 
and non-drug-related toxic side effects [2,3]. The limitation in the application of KP1019 in the 
clinical trials was the low solubility and therefore the study endpoint was not reachable. 
Therefore, the sodium analogue of KP1019, called KP1339 {sodium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)]}, was selected for further development. KP1019 and KP1339 were found 
to share similar reactivity to proteins [7], modes of action and activity pattern [8,9]. These recent 
mechanism of action studies confirm that KP1019 and KP1339 differ from other ruthenium and 
platinum compounds. The primary target and mechanism of apoptosis induction for KP1019 and 
KP1339 appear to be cytosolic proteins and not DNA adduct formation. These studies indicate 
that KP1019 and KP1339 are novel apoptosis inducing agents. 
The interaction of KP1019 and KP1339 with serum proteins is supposed to contribute to the 
selective transport to the tumor, being probably also related to the low adverse effects as 
compared to metal anticancer agents. KP1019 is almost exclusively bound to proteins in the 
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 blood stream as shown both in vitro and in vivo [10-20]. Both major serum proteins, albumin and 
transferrin (Tf), represent potential binding partners. EPR studies revealed rapid non-covalent 
binding to the hydrophobic binding domains of HSA, followed by slow conversion to covalent 
interactions [20]. In contrast, the same experimental setup revealed covalent binding to apo-Tf. 
Competitive experiments with these two proteins indicated that less than 20% of the overall Ru 
content was bound to Tf in an equimolar mixture of Tf and HSA. When raising the HSA : Tf ratio 
to a physiologically relevant 10 : 1 ratio, this fraction declined to 2%. In the plasma samples of 
patients of the KP1019 clinical phase I trial, 80–90% of the Ru species were attached to HSA 
and the concentration of the KP1019-Tf adduct was below the quantification limit, but was 
estimated to be less than 1% of the total KP1019 content. The pharmacokinetic profile for 
humans comprises a small volume of distribution, low clearance and long half-life in blood 
plasma [8]. Renal excretion of Ru was very low, as secondary peaks were observed in the 
concentration-time curves, and biliary excretion might play a role in the overall elimination of 
ruthenium from plasma.  
In order to understand the biodistribution of the drug candidate KP1339, non-tumor bearing mice 
were treated with the ruthenium compound and the Ru content was determined by ICP-MS in 
different tissues. Furthermore, CZE and LC both coupled to ICP-MS were employed to 
investigate the in vivo binding partner of KP1339 in the blood stream after i.v. administration. 
The collected data are compared to those of a pharmacokinetic study accompanying the clinical 
trial of KP1019, the parent compound of KP1339, and discussed with regard to data obtained 
within the NCI (National Cancer Institute, USA) anticancer drug discovery screening program.  
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 Experimental 
 
Animal treatment and sample preparation 
The drug biodistribution study was carried out with nude BALB/c mice in groups of 3 mice each 
sacrificed after approximately 0.1, 1, 3, 6, 12 and 24 h. KP1339 was injected into the tail vein in 
a single dose of 40 mg/kg in citrate-saline buffer (5 mM citrate, 0.9% NaCl, pH 3.45) and blood, 
internal organs and tissues were harvested immediately after the animals were sacrificed at the 
given time points. Blood was taken from the heart and added to heparin-containing Eppendorf 
tubes and centrifuged (2500 rpm for 5 min), and liver, spleen, kidneys, stomach, colon, muscle, 
bone, lung, thymus and brain were collected. Animal handling was in accordance with standard 
animal keeping practice and regulation, animals were treated humanely and with regard for 
alleviation of suffering throughout the study. 
 
Tissue metal content 
Instrumentation. The Ru content in the tissue was determined by ICP-MS (Agilent 7500ce, 
Waldbronn, Germany), equipped with a CETAC ASX-520 autosampler (Neuss, Germany), a 
Scott double pass spray chamber, and a MicroMist nebulizer. The 101Ru and 102Ru isotopes as 
well as 115In as internal standard were recorded. Instrument control and data analysis were 
carried out using Agilent ChemStation software (G1834B). The instrument parameters were 
optimized daily using a 1 μg L-1 tuning solution (Agilent) containing 7Li, 89Y and 205Tl in 2% HNO3. 
Doubly charged ions and oxide levels were minimized by using 70Ce/140Ce and 156CeO/140Ce and 
were typically < 2.5%. The instrument was calibrated daily using Ru standards of 0.5 - 22 ng 
Ru/mL in 3.5% HNO3 spiked with 0.5 ppb In as internal standard (CPI International, Santa Rosa, 
CA, USA). The LOD and LOQ were determined as 0.98 and 2.98 ng/L.  
Sample preparation. Tissue and blood cell sample aliquots of 10–50 mg were digested with 
1 mL nitric acid (65% HNO3 p.a. from Sigma Aldrich, further purified with a quartz sub-boiling 
system from Milestone-MLS GmbH, Leutkirch, Germany) and 1 mL water in a microwave system 
(Milestone-MLS GmbH, Leutkirch, Germany). The samples were diluted with water to reach an 
end mass of approximately 10 g. Every sample contained 0.5 ppb In as internal standard. 
 
 
Plasma analysis/ Plasma metal content and metal distribution in plasma 
 
Instrumentation. The ICP-MS used was a quadrupole-based system equipped with a 
dynamic reaction cell (ELAN DRC-II, PE SCIEX, Ontario, Canada). Oxygen (purity 4.5, 
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 Linde Gas GmbH, Vienna, Austria) was used as reaction gas and the 102Ru and 32S16O 
traces were recorded. The ICP-MS sample introduction system consisted of a PFA-
nebulizer and a cyclonic spray chamber. For 2D SEC-IC-ICP-MS determinations a 
Meinhard nebulizer, ICP-MS operation parameters are given elsewhere [21].  
The metal-free chromatographic system used consisted of an AS 50 autosampler (including a 
custom made temperature control device), an ICS-3000DP dual pump system and the 
Chromeleon Chromatography Management System (Version 6.40), all from Dionex (Sunnyvale, 
California, USA). The metal content in the plasma samples was assessed by flow injection 
analysis. In case of LC-ICP-MS determination, chromatographic separation was achieved using 
a BioSuiteTM 125 column (300 × 4.6 mm UHR SEC, 4 µm particle diameter) from Waters 
(Milford, Massachusetts, USA). The SEC eluent containing 150 mM NaCl and 20 mM Tris-HCl, 
pH 7.4 was delivered at a flow rate of 350 µL·min-1 and directly transferred to the ICP-MS 
introduction system. 
Sample preparation. For both type of analysis, the samples were diluted by a factor of 20 
in 150 mM NaCl. For the 2D-SEC–IC–ICP-MS determination a dilution factor of 10 was 
applied. 
 
CZE–ICP-MS 
Instrumentation. CZE experiments were performed with an HP3D CZE system (Agilent, 
Waldbronn, Germany) interfaced to an Agilent 7500ce ICP-MS with a CETAC CEI-100 
microconcentric nebulizer. For all experiments capillaries of 60 cm total length (75 μm ID) were 
used (Polymicro Technologies, Phoenix, AZ, USA). Capillary and sample trays were 
thermostatted at 25 °C. Injections were performed by applying a pressure of 25 mbar for 4 s, 
and a constant voltage of –30 kV. Prior to the first use, the capillary was flushed at 1 bar with 
0.1 M HCl, water, 0.1 M NaOH and again with water (5 min each). After this treatment the 
capillary was coated by rinsing with 1% PB solution containing 3v/v% ethylene glycol for 30 min 
at 50 mbar and water for 15 min at 1 bar [22,23]. Before each injection, the capillary was purged 
for 2 min with NaOH, water and the background electrolyte (BGE). The operational values for 
the CZE–ICP-MS interface are shown in Table 1. The nebulizer was employed in self-aspiration 
mode with the sheath liquid closing the electrical circuit and spraying a fine aerosol. Analyses 
were only started if a sufficiently stable signal (RSD 72Ge < 5%) was attained. 
Sample preparation. For calibration, four sets of standards (incubated for 3 h at 37 °C in 10 mM 
phosphate buffer containing 100 mM NaCl at pH 7.4 in order to simulate physiological 
conditions) at four different stoichiometries, namely at molar KP1339/HSA ratios of 0.5, 1, 2 and 
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 3 were utilized. The concentration of HSA was kept constant at 100 μM. Human serum as well 
as the plasma samples were diluted 1 : 3 with the incubation buffer before analysis. 
 
Table 1. ICP-MS operational parameters 
Parameter  LC–ICP-DRC-MS CZE–ICP-MS 
Nebulizer PFA nebulizer 
CETAC CEI-100 
microconcentric nebulizer 
Spray chamber Cyclon - 
Nebulizer gas flow, L min
-1
 1.0  1.14 
Auxiliary gas flow, L min
-1
 1.275  0.4 
Plasma gas flow, L min
-1
 15  15 
ICP RF power, W 1300 1500 
O2 flow rate, mL min
-1
 0.8  - 
RPQ 0.3 (SO), 0.6 (Ru) - 
Measured isotopes 
48
SO, 
101
Ru, 
102
Ru 
34
S, 
72
Ge,
 101
Ru, 
102
Ru
 
Scan mode Peak hopping - 
Sampler Ni (0.1 mm orifice) 
Skimmer Ni (0.4 mm orifice) 
 
 
 
 
NCI/DPT cytotoxicity tests and COMPARE analysis 
The protocol for the determination of cytotoxicity on the 60 cell line panel can be found at 
http://dtp.nci.nih.gov/branches/btb/ivclsp.html. The cell line panel comprises subpanels of 
leukemia, melanoma, and cancers of lung, colon, brain, ovary, renal, breast and prostate. The 
Developmental Therapeutics Program (DTP) homepage can be accessed at 
http://dtp.cancer.gov/.  
A COMPARE analysis was performed using KP1019 as a seed, and the analysis was carried out 
as described at the Developmental Therapeutics Program webpage 
(http://www.dtp.nci.nih.gov/docs/compare/compare.html).  
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 Results and Discussion 
 
The pharmacokinetics and tissue distribution of drug compounds have a major influence on their 
therapeutic efficacy and adverse effects. In order to study the accumulation and biodistribution 
for the drug candidate KP1339, the Ru content was determined in nude BALB/c mice after i.v. 
administration of a single dose of 40 mg/kg. The i.v. route was chosen in order to allow the 
compounds to experience conditions similar to those observed in humans and to provide cleaner 
pharmacokinetic profiles without the complication of the absorption phase [24]. The mice were 
sacrificed 0.1, 1, 3, 6, 12 and 24 h after injection. Blood, liver, spleen, kidneys, stomach, colon, 
muscle, bone, lung, thymus and brain were collected from each mouse and stored at –80 °C 
until microwave digestion and analysis for the Ru content. In addition, the blood was centrifuged 
to separate plasma which was analyzed for the Ru distribution among the blood plasma 
components.  
 
Analysis of mouse blood samples 
The total Ru content in plasma and in blood cells was determined by flow injection ICP-MS 
(Figure 2). The Ru concentration in both compartments was found to increase slightly within the 
first hours of analysis. In plasma the Ru concentration is 3-times higher than in the blood cells. 
After approximately 2.5 h the Ru content reaches a maximum and starts to decrease slowly to 
reach 50% of the peak concentration after circa 24 h. Similar pharmacokinetics were found for 
the parent compound KP1019 in humans during a clinical trial in which the Ru peak 
concentration in the plasma was reached approximately 2.5 h after drug administration [8]. The 
pharmacokinetics of the Ru compounds KP1019 and KP1339 in plasma differ significantly from 
the classical picture obtained after i.v. administration but are conform with a two-compartment 
pharmacokinetic model. 
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Figure 2. Ruthenium concentration in plasma and blood cells after administration of a single dose of 
40 mg/kg KP1339. 
 
 
 
Serum proteins including albumin and Tf are thought to play a crucial role in the transport, 
delivery and storage of certain anticancer metallodrugs, including KP1019 and KP1339 
[3,26,27]. For determining the distribution of KP1339 between serum proteins in the mouse 
plasma samples, both capillary electrophoretic and chromatographic methods were coupled to 
ICP-MS. The electropherograms of the mouse plasma measured by CZE-ICP-MS contain two 
peaks in the Ru traces after treatment with KP1339. The peak with the higher migration time 
corresponds to the KP1339-MSA adduct, whereas the first peak is assumed to stem from MSA 
aggregates (Figure 3). In all plasma samples approximately 70% of the total content was 
detected attached to MSA. The high Ru load of MSA is probably also responsible for the long 
half-life of the drug. Similar results were obtained in a SEC–ICP-MS study with the majority of 
KP1339 bound to MSA and higher molecular weight species stemming from MSA conjugates. 
The presences of MSA conjugate was confirmed by collecting the SEC fractions off-line and 
performing orthogonal reversed phase separations in combination with ESI-TOF-MS 
determination [21].  
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Figure 3. Ru traces recorded for a mouse plasma sample collected 24 h after injection. Shown are the 
traces of 
102
Ru and 
34
S (the latter for MSA detection). 
 
 
 
The molar ratios of Ru/S for the KP1339-MSA adducts were determined by both CZE–ICP-MS 
and SEC–ICP-MS. For calibration, a set of standards containing KP1339 and human serum 
albumin at molar ratios of 0.5, 1, 2 and 3 were used and the concentration of the protein was 
kept constant (50 µM). Both methods delivered high linearity for the standard set and good 
agreement with calibration using inorganic standards was achieved. Analysis of the mouse 
plasma samples with both methods delivered essentially the same results within the standard 
errors (Figure 4). In general, the Ru/S ratios measured with the CZE setup are slightly higher 
than those obtained by SEC-IC–ICP-MS, but are still in good accordance to those determined 
with the LC method. The shape of the curves resembles widely the one obtained for the total Ru 
levels in plasma (Figure 2), with an increased level of ruthenation found after 1 h in comparison 
to the sample taken after 5 min. The peak ratio measured after 1 h was at approximately 1.2–1.5 
Ru per albumin molecule and started to decline to about 1 after 24 h.  
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Figure 4. Comparison of the molar ratios of Ru per MSA molecule measured by SEC–ICP-MS and CZE–
ICP-MS. 
 
 
 
Tissue distribution of KP1339 
The in vivo tissue distribution of KP1339 in non-tumor-bearing mice was determined by 
measuring the Ru content in bone, brain, colon, kidney, liver, lung, muscle, spleen, stomach and 
thymus by ICP-MS. Before analysis 10–50 mg of the organ samples were digested with nitric 
acid (34%) in a microwave digestion system.  
Several trends are extractable from the data set: the highest Ru levels were found in colon, lung, 
liver, kidney and thymus (Figure 5). As expected, the organ samples taken from the animals 
sacrificed within 5 min after administration contained low levels of Ru (Table 2). Over time Ru 
concentration increased in all tissues analyzed with the exception of the brain, which might be 
related to the low potential of the drug compound to cross the blood brain barrier. In case of 
bone, colon, liver, lung, kidney, muscle, stomach and thymus samples, the peak Ru 
concentration were reached 1–6 h after administration (paralleling the total Ru levels in blood 
plasma) and declined slowly over time whereas in the spleen the concentrations increased 
slightly (from about 9.5 to 14.6 μg/g Ru after 1 and 24 h, respectively).  
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Figure 5. Ru content in liver, colon, thymus, lung and kidney ca. 0.1, 1, 3, 6, 12 and 24 h after intravenous 
administration of KP1339. The values are the average of data collected from samples taken from three 
animals at each time point, and the bars indicate the standard deviations. 
 
Table 2. Organ distribution of Ru in non-tumor bearing mice treated with KP1339. 
 µg Ru / g tissue 
Time / h 0.1 1 3 6 12 24 
bone 4.99 
a 
9.17 ± 1.17 8.03 ± 1.09 9.46 ± 2.39 5.40 ± 2.43 7.77 ± 0.87 
brain 0.58 ± 0.31 0.61 ± 0.28 0.44 ± 0.11 0.48 ± 0.08 0.37 ± 0.02 0.61 ± 0.08 
colon 3.21 ± 1.47 15.48 ± 5.08 5.19 ± 1.06 9.48 ± 0.97 8.53 ± 1.32 14.26 ± 4.09 
lung 8.31 ± 2.21 33.19 ± 11.84 30.17 ± 7.66 18.62 ± 3.42 23.20 ± 2.04 24.92 ± 0.33 
liver 7.99 ± 0.9 36.02 ± 19.24 27.87 ± 9.34 29.02 ± 16.80 24.42 ± 4.11 26.86 ± 2.17 
kidney 7.65 ± 2.38 21.90 ± 6.49 31.41 ± 4.42 24.03 ± 8.03 23.35 ± 7.56 21.47 ± 3.97 
muscle 0.99 
a 
7.94 ± 2.72 13.60 ± 2.70 5.40 ± 2.47 3.86 ± 0.83 5.67 ± 1.31 
spleen 2.87 ± 0.13 9.54 ± 2.08 10.30 ± 5.54 11.09 ± 4.69 10.13 ± 2.77 14.63 ± 4.41 
stomach 7.07 ± 5.20 7.66 ± 1.59 9.99 ± 0.31 5.85 ± 1.59 5.85 ± 0.98 7.38 ± 3.53 
thymus 8.77 ± 0.65 40.24 ± 22.50 43.14 ± 6.53 31.86 ± 12.45 22.85 ± 5.41 20.44 ± 4.61 
a
 only a single sample was available. 
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 The high Ru levels measured in the liver and the kidneys were expected due to the role of these 
organs in clearance and excretion. Furthermore, relatively high Ru concentrations were found in 
the lungs, which is most probably related to the high blood flow through this tissue. Similar 
observations were made in in vivo biodistribution experiments with the anticancer complexes 
imidazolium trans-[tetrachloride(1H-imidazole)(dimethylsulfoxide-κS)ruthenate(III)] (NAMI-A) and 
imidazolium trans-[tetrachloridebis(1H-imidazole)ruthenate(III)] (KP418) and were explained by 
the high affinity of these compounds to collagen [27,28]. Furthermore, the colon is among the 
five organs with the highest Ru level which appears promising considering its potential in the 
treatment of colorectal cancer [2].  
A point of particular note is the surprising high Ru concentrations found in the thymus. The 
thymus gland is a specialized organ in the immune system and its main function is the 
processing and maturation of T-lymphocytes or T-cells. T-lymphocytes are the body’s immune 
system and protect the body by producing antibodies that stop the invasion of foreign agents, 
bacteria and viruses. In this experiments nude BALB/c mice were used, which differ from normal 
mice by a genetic mutation in the Foxn1 gene that causes a very small thymus with abnormal 
architecture lacking cortical and medullary domains, resulting in an inhibited immune system due 
to T-cell deficiency. There is no intrinsic defect of thymocytes (T-cell precursors) in nude mice, 
but the thymocytes are specifically blocked at both the DN1 and DP differentiation stages, 
express constitutively low TCR, and just very few SP thymocytes develop and immigrate into the 
periphery [28]. Literature data indicate that Ru(III) complexes with N-donor ligands can act as 
immunosuppressants and inhibit the antigen-independent phase of T-cell proliferation at 
nanomolar concentrations [29-31]. Based on these data, it appears as KP1339 could have 
potential in the treatment of lymphoblastic leukemia.  
Moreover, for the parent compound KP1019 (NSC-666158) particular activity against leukemia 
was observed in an NCI screening against a 60 cell line panel in the concentration range of  
10-4–10-8 M (Figure 6). Especially CCRF-CEM and MOLT-4 cells were sensitive to the 
compound and both stem from T-lymphoblasts of patients with acute lymphoblastic leukemia. In 
a mean graph derived from the GI50 values (50% growth inhibition; Figure 6), the vertical line 
represents the mean GI50 value of the compound against all cell lines and bars extending to the 
right or left represent relative cellular sensitivity or insensitivity, respectively. From that 
representation it is obvious that the leukemia cell line panel is most sensitive to the treatment 
with the Ru drug candidate, whereas in other subpanels cell lines are included that are not 
sensitive to KP1019.  
The NCI 60 cell line panel screening data was further subjected to a COMPARE analysis, in 
order to get further insight into the mode of action of KP1019 as compared to other anticancer 
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 drugs. Therefore, KP1019 was used as a seed in the COMPARE analysis and related to the 
activity pattern of established anticancer agents and developmental drugs (for details see the 
standard agent database with 170 compounds including compounds with established modes of 
action at http://www.dtp.nci.nih.gov/docs/cancer/searches/standard_agent_table.html). Analysis 
of the Pearson correlation coefficients (P) obtained for a series of compounds revealed no 
correlation better than 0.627 (Table 3). Correlation coefficient values <0.6 are not considered to 
be significant. Therefore, the mode of action of the Ru complex appears to be different from 
those of established drugs, including those of other metal-based anticancer agents.  
 
 
Figure 6. GI50 mean graph derived of the data obtained from the NCI screening program for KP1019 
against a 60 cell line panel; the numbers in parenthesis are the GI50 values in the respective cell line (µM).  
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Table 3. Results obtained using KP1019 as the seed compound in a COMPARE analysis based 
on the NCI Anticancer Drug Screen database. 
Rank Correlation * Name NSC.NO. 
1 0.627 ** AT-125 (acivicin) 163501 
2 0.606 ** aclacinomycin A 208734 
3 0.576 N,N-dibenzyldaunomycin 268242 
4 0.534 hydrazine sulfate 150014 
5 0.533 actinomycin D 3053 
6 0.525 anguidine 141537 
7 0.524 N,N-dibenzyldaunomycin 268242 
8 0.506 DUP785 (brequinar) 368390 
9 0.501 S-trityl-L-cysteine 83265 
* Pearson correlation coefficients.  
** Values > 0.6 are significant.  
 
 
 
Conclusions 
 
The accumulation and biodistribution are important factors for drugs to exhibit their activity in the 
desired tissue and also cause unwanted side effects. Adverse effects are a major issue in 
cancer chemotherapy, in particular in case of treatment with low specificity small molecule 
drugs. In the case of KP1019 and KP1339, drug candidates based on the Ru(indazole)2, clinical 
trials demonstrated minor drug-related toxicity which is often attributed to the mode of action, 
which involves binding to proteins and activation in the tumor. The high affinity of KP1339 to 
proteins was confirmed in an in vivo study in mice and a large portion of the Ru was found 
attached to albumin and albumin aggregates. With regard to tissue distribution, the highest 
concentrations were found in colon, lung, liver, kidney and thymus. In particular the high 
amounts of Ru in the thymus are interesting in the light that the parent compound KP1019 
showed high activity in the leukemia cell subpanel of the NCI 60 cell line panel. Especially, the 
marked activity of KP1019 in T-lymphoblasts and the high accumulation of KP1339 in the 
thymus make such Ru drugs interesting candidates against lymphoblastic leukemia. 
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Research Article
Biodistribution of anti-diabetic Zn(II)
complexes in human serum and in vitro
protein-binding studies by means of
CZE–ICP-MS
Application of modern analytical technology for studying the fate of metallodrugs after
administration to the blood is of utmost importance for drug development. Zn(II)
compounds are under development as insulin-enhancing drugs with potential use in the
treatment of diabetes. In comparison to the well-established vanadium compounds,
especially the lower risk of adverse effects due to the essentiality of the element in
biological processes is advantageous. Herein, CZE–ICP-MS studies on the interaction of
Zn(II)-maltolato, -2-picolinato and -2,6-dipicolinato complexes with human serum
proteins are discussed and modeling calculations were conﬁrmed by experimental
results. Studies with human serum reveal preference for HSA over other less abundant
proteins and serum components.
Keywords:
Anti-diabetic Zn(II) complexes / CE / ICP-MS / Protein Interactions / Speciation in
blood serum DOI 10.1002/elps.200900212
1 Introduction
Diabetes mellitus (DM) is a disease from which people suffer
all over the world, and with a continuously increasing
number of patients, especially in the industrialized world. It
is considered as a syndrome of disordered metabolism
resulting in abnormal high blood glucose level (hyperglyce-
mia) due to defects in either insulin secretion or insulin
action. There are three forms of DM: the insulin-dependent
type 1, the non-insulin-dependent or adult-onset type 2 and
the gestational DM. Type 1 is an autoimmune disease
caused by a lack of the insulin hormone due to the
destruction of insulin-producing b-cells, and it is therefore
treated by insulin replacement administered as daily
injection. Type 2 DM is characterized by insulin resistance,
i.e. lack of proper answer of the cells to the presence of
insulin. This kind of DM can be usually treated by a well-
controlled use of drugs, which are able to increase the
quantity of secreted insulin or the sensitivity of target organs
to insulin, or to decrease the rate of glucose absorption from
the gastrointestinal (GI) tract. The available drugs for DM
type 2 are mostly oral hypoglycemic agents such as
biguanide, sulfonylurea, thiazolidinediones and a-glucosi-
dase inhibitors. Since these anti-hyperglycemic chemicals
do not yield satisfactory results for all patients, there are
efforts on the development of new anti-diabetic drugs with
high efﬁcacy and with no or minor adverse effects [1, 2].
In recent years, metal complexes and organometallic
compounds have gained considerable interest for medicinal
applications [3–5]. Cu, Cr, Mo, V, Zn, Mn, etc. species were
found to exhibit insulin-enhancing activity [2, 6–8] and
vanadium compounds in the oxidation states IV and V are
among the most effective representatives [6–8]. More than
100 vanadium complexes have been developed and tested
both in vitro and in vivo [7–10], out of which bis(ethylmal-
tolato)oxovanadium(IV) (Fig. 1) has completed phase I
clinical trials and has advanced to phase II studies [11].
In addition to the V compounds, anti-diabetic Zn(II)
complexes have gained considerable interest for the treat-
ment of DM in the last few years [7]. They were found less
effective than the vanadium complexes [7, 10], but may be
introduced more easily into the medical treatment due to
the fact that Zn(II) is an essential metal ion, less toxic and
better bioavailable. Zn is a cofactor for more than 200
biologically important enzymes (which are particularly
involved in protein synthesis) and plays a key role in the
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synthesis and action of insulin. Moreover, Zn supple-
mentation has also demonstrated a protective effect in DM
type 2 animal models [12].
Fugono et al. have developed numerous Zn(II)
complexes and some of the complexes bearing, e.g. maltol
(mal) or 6-methyl-picolinic acid ligands were found to be
active in KK-Ay mice when administered orally [13]. The
effective Zn(II) complexes have a favorable effect not merely
on the blood glucose level, but on the concentrations of
adipocytokines such as free fatty acids, resistin, leptin,
adiponectin, etc. and also on obesity and the systolic blood
pressure [14]. The mode of action of anti-diabetic Zn(II)
complexes is still not completely understood: Most probably
they act at different sites of insulin signaling due to the
activation of tyrosine kinase (of the insulin receptor),
phosphatidyl inositol-3 kinase, phosphodiesterase enzymes
and glucose transporters, and due to the inhibition of the
protein tyrosine phosphatase [14]. Furthermore, these drug
candidates are regarded as prodrugs. Hence the active forms
are assumed to differ from the administered species as a
consequence of biotransformation processes in different
biological environments such as the GI tract, blood serum or
the cytosol. According to recent studies, the carrier ligand
determines mainly the absorption from the GI tract and it
may be partly or completely displaced by suitable endogen-
ous metal ion binders in the human serum [15, 16].
Improved knowledge about the Zn(II) speciation in
serum might contribute to a better understanding of the
transport processes in vivo. Previous results obtained in vitro
using ultraﬁltration–ICP-atomic emission spectroscopy and
modeling calculations on artiﬁcial serum showed that Zn(II)
is mostly bound to the high molecular mass (HMM) fraction
of the serum, and the binding toward HSA is predominant
[16, 17]. However, analysis of real blood serum should
provide more detailed information about the Zn(II) distri-
bution in the case of insulin-enhancing metal complexes.
Among the different separation techniques, CZE exhibits
high resolution, fast and efﬁcient separation of metal-
containing species of biomolecules [18]. CZE hyphenated to
an ICP-MS provides a powerful tool to detect metal ions
with high sensitivity and is perfectly suited for analyzing
biological samples [19–21].
Herein, the biodistribution of Zn(II) complexes of mal,
2-picolinic acid (pic) and 2,6-dipicolinic acid (dipic), which
exhibit anti-diabetic effects [14, 22], in human serum
samples is described. A CZE–ICP-MS method was devel-
oped for analyzing such samples under conditions main-
taining metal-protein bonds.
2 Materials and methods
2.1 Instrumentation
CZE experiments were performed with an HP3D CZE
system (Agilent Technologies, Waldbronn, Germany) inter-
faced to an Agilent 7500ce ICP-MS with a CETAC CEI-100
microconcentric nebulizer. For all experiments capillaries of
60 cm total length (75-mm id) were used (Polymicro
Technologies, Phoenix, AZ, USA). Injections were
performed by applying a pressure of 25 mbar for 4 s, and
constant voltages of 15 or 30 kV were used for Tris or
carbonate buffer as BGE, respectively. Prior to the ﬁrst use,
the capillary was ﬂushed at 1 bar with 0.1 M HCl, water,
0.1 M NaOH and again with water (10 min each). Before
each injection, the capillary was purged for 2 min both with
water and the BGE followed by applying a voltage of 30 kV
for 30 s and ﬂushed for 1 min with BGE again. The cleaning
procedure included purging with 0.1 M HCl, water and
0.1 M NaOH (each for 2 min). The operational values for the
CZE–ICP-MS interface are shown in Table 1. The nebulizer
was employed in self-aspiration mode with the sheath liquid
closing the electrical circuit and spraying a ﬁne aerosol.
Analyses were only started if a sufﬁciently stable signal
(RSD 72Geo5%) was attained.
2.2 Reagents and solutions
A 0.1M ZnCl2 stock solution was prepared by the dissolu-
tion of ZnCl2 (Reanal) in a deﬁned amount of HCl (0.007 M)
and its Zn concentration was determined by complexometry
via the EDTA complex. NaOH, HCl and NH4HCO3 were
obtained from Fluka; mal, pic and dipic (puriss) were
from Sigma Aldrich, as were HSA (approximately 99%,
fraction V), apotransferrin (apoTf; approximatelyZ98%)
and human serum. The concentrations of the protein
solutions were estimated from their UV absorption:
e280 nm(apoTf)5 92300M
1 cm1 and e280 nm(HSA)5
36850 M1cm1 [23, 24]. The ICP-MS tuning solution
Table 1. ICP-MS conditions
Sampler Ni (0.1 mm oriﬁce)
Skimmer Ni (0.4 mm oriﬁce)
Plasma RF power, W 1500
Isotopes recorded 34S, 72Ge, 64Zn, 66Zn
Nebulizer gas ﬂow rate, L/min 1.14
Sheath liquid 20 mM Tris with 20 ppb Ge or 10 mM
ammonium bicarbonate with 20 ppb Ge
BGE 20 mM Tris or 10 mM ammonium carbo-
nateFigure 1. Structure of the vanadium compound BEOV (AKP-020),
undergoing in clinical trials [11].
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containing Li, Y, Ce, Tl and Co in 2% HNO3 (each
10 mg/L) as well as the Ge standard were obtained from
Agilent Technologies. High purity water used throughout
this work was obtained from a Millipore Synergy 185 UV
Ultrapure Water system (Molsheim, France).
2.3 Sample preparation
The Zn(II) complexes were synthesized in situ: A ZnCl2
solution was added to the ligand in 1 mM Tris buffer or in
20 mM carbonate buffer (both pH 7.4). Depending on the
denticity of the ligand (bidentate or tridentate) and the
conditional stability constants of the formed complexes (at
pH 7.4), the ratio ZnCl2 ligand was varied (for dipic 1:2, for
mal and pic from 1:2 to 1:6). For in vitro studies on the
binding of the Zn compounds toward HSA and apoTf,
samples containing 0.1 mM of ZnCl2, 0.2 mM of the ligand
and 0.1 mM of the serum proteins were prepared in 1 mM
Tris buffer or 20 mM carbonate buffer. For the HSA–Zn-
dipic titration, 100 mM HSA was mixed with 50–300 mM
[Zn(dipic)2]
2 in carbonate buffer for 24 h. The samples for
the competitive binding studies contained 100 mM of HSA,
apoTf and Zn(II) and 200 mM dipic in carbonate buffer and
were kept for 24 h at 251C. The human serum was diluted
1:4 with the incubation buffer and the mixtures were
incubated at 251C for 24 h prior to the analysis. The
experiments were repeated at least three times.
2.4 Data processing and calculations
Modeling calculations on the speciation of the Zn(II)-
complexes in an artiﬁcial serum containing HSA, human
serum transferrin (Tf), a2-macroglobulin (a2M) as HMM
and L-cysteine (Cys), L-histidine (His), citric acid (cit) as low
molecular mass (LMM) serum components were performed
using the computer program PSEQUAD [25] based on the
stability constants taken from Refs. [16, 17, 26–29] at
physiological pH and at 251C in the presence of HCO3
. The
other LMM components of the serum were omitted from
the modeling calculations because of their negligible Zn(II)-
binding abilities [30]. The concentrations of the serum
components used for the calculations were equivalent to
those in the diluted blood serum [31].
The CZE–ICP-MS data was recorded using the Chem-
Station software bundle (Agilent Technologies), data analy-
sis was performed using Microsoft Excel 2003.
3 Results and discussion
Zn(II) is present at relatively low concentration in the human
blood serum (the normal level is appr. 10–15 mM [31, 32]).
When anti-diabetic Zn(II)-complexes are administered in
animal DM type 2 models, the Zn(II) level was increased
signiﬁcantly to 100–200 mM [13]. HSA, a2M and Tf as HMM
components, and Cys and His as LMM components are
considered as the most efﬁcient Zn(II) binders according
to their blood concentrations and Zn(II)-binding abilities
[16, 17, 26–29, 31, 32]. HSA is the most abundant serum
protein (630 mM) with a molecular weight of appr. 67 kDa; it is
negatively charged at physiological pH and has a key role in
transport and/or storage processes of fatty acids, Cu(II),
Ni(II), toxic metabolites (e.g. bilirubin) or drugs [18, 33, 34].
HSA is able to bind Zn(II) with conditional binding constants
in the range of logK’5 7.1–7.9. The binding site is situated at
the interface of domains I and II, which consists of two His-
nitrogen atoms (His-67, His-247), two carboxylate-oxygen
donor atoms (Asn-99, Asp-249) and a water molecule in the
coordination sphere, and the Zn center adopts a distorted
trigonal bipyramidal geometry [26, 34]. a2M is a fairly large
protein with 720 kDa, but found at much lower concentration
in the blood than albumin (2–6 mM), and with conditional
formation constants of logK1’5 7.49 and logK2’5 5.12 it has
also considerable Zn(II)-binding properties [29, 35–37].
Another possible Zn(II) binder is the 79kDa iron transport
protein Tf (37 mM in serum), but 30% of the binding sites are
occupied by Fe(III) ions in the serum [27, 33]. The Zn(II)-
binding constants are logK1’5 7.8 and logK2’5 6.4 (15mM
NaHCO3) [27] and the presence of the synergistic HCO3
 is
also considered important.
Literature data show that most of the total serum Zn(II)
is bound to the serum proteins (appr. 98%) and HSA is the
primary target (80–90%) [32, 35, 37], followed by a2M (5-
15%) [35–37]. However, the role of Tf is under discussion
[36, 38] and also a minority of Zn(II) is circulating unbound
or attached to LMM components (considered as the mobile
portion of the metal ion).
In the case of anti-diabetic VO(IV) complexes the
knowledge of the binding constants, characterizing their
interactions with the HMM and LMM components of
the blood serum, allows to calculate the distribution of
VO(IV) among the various serum constituents. It was found
that under physiological conditions in serum, Tf is the
primary VO(IV) transporter and the binding ability of HSA
is practically negligible, as conﬁrmed by HPLC–ICP-MS
analyses [39].
Zn(II) complex formation with mal, pic and dipic
results predominantly in bis species in aqueous solution at
physiological pH (see Fig. 2 for the structures) [22, 40], as
demonstrated by the concentration distribution curves (for
the Zn(II)-dipic system see Fig. 3). The bidentate mal and
pic coordinate via (O,O) and (N,O) donor sets, respectively,
to form [ZnA(H2O)4]
1, [ZnA2(H2O)2], [ZnA3]
 and
[ZnA2(H2O)(OH)]
 octahedral complexes (‘‘A’’ stands for
the fully deprotonated form of the ligands). Dipic is able to
coordinate in a tridentate mode through the (N,O,N) donor
atoms and forms the bis complex [ZnA2]
2, which is
predominant in a wide pH range [22]. Conditional constants
of the bis complexes of mal, pic and dipic are 8.13, 9.52 and
12.77, respectively, at physiological pH. The tridentate dipic
forms a signiﬁcantly more stable complex with Zn(II) as
compared to the bidentate ligands mal and pic [22].
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The migration behavior of the Zn(II) complexes was
determined by CZE–ICP-MS with 1,2-dibromoethane as a
neutral EOF marker. The species distribution of Zn(II)–li-
gand systems is highly dependent on the pH (see Fig. 3): At
physiological pH the octahedral complex [Zn(dipic)2]
2 is
the dominant species at a metal ion-to-ligand ratio of 1:2 and
according to the expectations, a negatively charged species
was observed in the electropherogram (Fig. 4). In the case of
the bidentate ligands (mal and pic), the octahedral coordi-
nation sphere of the neutral bis complexes is not saturated,
hence coordinated water molecules can be substituted by,
e.g. separation buffer components. To shift the equilibrium
to tris complexes, migrating then in the CZE mode slower
than the EOF, the metal to ligand ratio was increased from
1:2 to 1:6 in the incubation solutions, since the extent of the
formation of the negatively charged [ZnA3]
 species is
higher at elevated ligand concentrations. In the case of the
Zn(II)-mal system at a metal-to-ligand ratio of 1:2, no clear
peaks were identiﬁed. When raising the ratio to 1:6, the
neutral bis complex [Zn(mal)2(H2O)2] was detected in addi-
tion to a negatively charged tris species. Incubation of Zn(II)
with an excess of pic resulted exclusively in a negatively
charged complex, most probably [Zn(pic)3]
.
3.1 Interaction with HSA
To characterize the interaction between HSA and the Zn(II)-
complexes with mal or dipic as ligands, samples containing
100 mM HSA, 100 mM ZnCl2 and 200 mM of the ligand were
prepared in 20mM carbonate buffer (BGE: 10mM carbonate
solution at pH 7.4) or 1mM Tris buffer (BGE: 20mM Tris)
and analyzed after an incubation time of 24 h at 251C to
ensure equilibrium conditions. Quantiﬁcation of non-metal-
containing proteins by ICP-MS is only accessible via analysis
of the sulfur content. Polyatomic isotope interference from
atmospheric gas and biological material can, however, cause
serious errors in detection of sulfur. The most abundant 32S
isotope (94.93%) suffers from polyatomic interferences,
such as 16O16O, which cannot be resolved by conventional
quadrupole instruments. The second most abundant isotope
34S (4.29%) is interfered mainly by 16O18O and 16O17O1H, but
quantiﬁcation is still possible to a certain extent [41].
Figure 5 shows an electropherogram for the Zn(II)-dipic
system in carbonate buffer, and approximately 60% of
the total observed Zn content are bound to HSA. The
second peak in the 64Zn trace of the electropherogram was
assigned to the parent complex [Zn(dipic)2]
2, based on the
migration time and the absence of a sulfur peak. Switching
Figure 2. Structural formulae
of the predominant species in
aqueous solution at physiolo-
gical pH: (A) [Zn(mal)2(H2O)2],
(B) [Zn(pic)2(H2O)2], and (C)
[Zn(dipic)2]
2.
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Figure 3. Concentration distribution curves for complexes
formed in the Zn(II)–dipic system at 1:2 metal ion to ligand
ratio; cZn(II)5 0.1mM.
Figure 4. Comparison of the electropherograms of the Zn(II)-
mal-system (1:6) (A), Zn(II)-pic system (1:6) (B) and Zn(II)-dipic-
system (1:2) (C) after 24 h in carbonate buffer at pH 7.4. Shown
are the traces of 64Zn and 81Br (EOF marker; 100 mM).
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the incubation/separation system to Tris buffer causes no
signiﬁcant changes. Under these conditions, appr. 55% of
the total observed Zn content was found bound to HSA,
whereas for Zn(II)-mal almost quantitative binding was
observed. Modeling calculations on the Zn(II) distribution
in the Zn(II)-ligand-HSA system were performed using
equivalent conditions as for the CZE–ICP-MS measure-
ments and based on the stability constants of the Zn(II)-
ligand complexes, Zn(II)-binding ability of HSA and the
HSA-ligand interactions [16, 17, 26] at equimolar ratio of the
metal complex and HSA. Calculations show that in the case
of dipic equimolar amounts of Zn are bound to the carrier
ligand dipic and in a Zn(II)-HSA-ligand ternary complex. In
contrast, the weak ligand mal is able to maintain merely
appr. 6% of Zn(II) in a binary complex and the large
majority of the Zn was found attached to HSA. These
calculations are in good agreement to the experimental data.
Titration experiments with a constant amount of HSA
(100 mM) with [Zn(dipic)2]
2 (from 50–300 mM; incubation
time: 24 h) were performed. These studies show at low
Zn(II)-dipic to HSA ratios that the majority of the Zn(II) is
bound to albumin, whereas at increasing concentrations,
[Zn(dipic)2]
2 becomes the predominant species in solution.
The experimentally obtained results were compared with the
calculated distribution and relatively good agreement was
obtained (Fig. 6).
To characterize the binding kinetics for the reaction of
[Zn(dipic)2]
2 with HSA, samples containing 100 mM HSA,
100 mM ZnCl2 and 200 mM dipic were prepared in carbonate
buffer and again analyzed by CZE–ICP-MS. Time resolved
studies monitoring the peak area for the HSA adduct
demonstrate that the binding of Zn(II) to HSA is very quick
and already completed when the ﬁrst data point was recor-
ded (approximately 5 min after the start of the incubation).
3.2 Interaction with Tf
The same method as described for the analysis of the
Zn-HSA system was transferred to the Zn-apoTf system
(100 mM apoTf, 100 mM ZnCl2, 200 mM dipic) and the Zn(II)-
binding ability of apoTf was characterized. Incubation
of apoTf with [Zn(dipic)2]
2 causes a partial carrier ligand
displacement. In the presence of apoTf in carbonate buffer as
incubation medium approximately 46% of the total observed
Zn content is bound to apoTf (Fig. 7). The binding of Zn(II)
to apoTf is strongly inﬂuenced by the incubation buffer: In
Tris buffer nearly no interaction of Zn(II) with apoTf was
observed and only 4% of the total Zn(II) content was found
attached to apoTf after an incubation time of 24 h.
Hydrogencarbonate appears to act as a synergistic ion
necessary for Zn(II) binding [42]. To study the role of
hydrogen carbonate, the same set of samples was prepared
in 1 mM Tris buffer containing 500 mM NaHCO3 (incuba-
tion for 24 h) and the sample was analyzed using 20 mM
Tris buffer or 10 mM carbonate buffer as BGE. When using
Tris buffer as BGE, 20% of the total Zn(II) content was
bound to apoTf, whereas with the carbonate buffer 50% of
the Zn content was found attached to apoTf. These results
demonstrate the importance of the choice of the BGE and
Figure 5. Electropherogram of [Zn(dipic)2]
2 incubated for 24 h
with HSA in carbonate buffer. Shown are the traces of 64Zn
and 34S (for HSA detection). Peak identiﬁcation: 1 –HSA adduct,
2 – [Zn(dipic)2]
2; Conditions: see Section 2.
Figure 6. Titration of HSA with [Zn(dipic)2]
2 (incubated for
24 h). Legend: & [Zn-dipic]exp, & [Zn-dipic]calc,  S[Zn-HSA]exp,
J S[Zn-HSA]calc; S[Zn-HSA] stands for the summed concentra-
tions of the binary and ternary species [Zn-HSA] and [Zn-HSA-
dipic], respectively. Conditions: see Section 2.
Figure 7. Electropherogram of [Zn(dipic)2]
2 incubated for 24 h
with apoTf in carbonate buffer. Shown are the traces of 64Zn and
34S (for apoTf detection). Peak identiﬁcation: 1 – apoTf adduct;
2 – [Zn(dipic)2]
2; Conditions: see Section 2.
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furthermore when using Tris as BGE, in addition to the
adduct peak, broad peaks and an unstable baseline were
visible in the electropherogram, most probably indicating
the presence of mixed ligand species.
3.3 Competitive serum protein binding
Selective binding to a single protein after intravenous
administration might be an option for exploiting a transport
mechanism, e.g. known for Tf, causing enrichment of drugs
in the desired tissue [43]. Therefore, competitive binding
between HSA and apoTf was studied and it was found that,
in contrast to VO(IV)-based insulin-enhancing complexes,
HSA is the preferred binding partner at equimolar ratio
of HSA to apoTf (42 versus 50 sulfur atoms (http://
www.expasy.org/, ExPASy Proteomics Server, Swiss Institute
for Bioinformatics): 64% of Zn(II) is bound to HSA, 25%
to apoTf peak and the rest to the carrier ligand (Fig. 8);
however, the peaks of the proteins are slightly overlapping
and therefore no exact quantiﬁcation is possible.
3.4 Interaction with proteins in human serum
To study the binding behavior of the Zn(II) complexes to
serum proteins under more realistic conditions, serum
samples were incubated with the Zn(II) compounds
(0.1 mM; serum diluted with buffer; 1:4; 24 h; at 251C; see
caption of Fig. 10 for exact concentrations of the serum
components). CZE–ICP-MS analysis revealed for the
complexes with the dipic ligand that most of the Zn(II)
was bound to HSA (approximately 70%), as identiﬁed via
the 34S trace. A minor amount of Zn(II) was still
coordinated to dipic or other buffer components; however,
no Zn(II) was detected at Tf (Fig. 9). This result might be
explained by the low concentration of Tf in serum and also
the iron-binding sites of transferrin are partly occupied by
Fe(III), competing for the same binding site as Zn(II) [27].
Serum incubation with [Zn(mal)2(H2O)2] and [Zn(pic)2
(H2O)2] gives similar electropherograms, however nearly
quantitative binding to HSA was observed.
Modeling calculations on the Zn(II) distribution in
serum samples containing 100 mM of anti-diabetic bis
complex were performed according to the conditions of
the CZE–ICP-MS measurements. Formation of binary
complexes [Zn(II)1carrier ligands; Zn(II)1LMM compo-
nents], mixed-ligand species [Zn(II)1carrier ligands1LMM
compounds] and the interactions between serum proteins
and Zn(II) and between HSA and the carrier ligands were
considered [16, 17, 26–29]. The modeling calculations for the
Zn(II) distribution in artiﬁcial serum and with the most
important HMM and LMM components (HSA, Tf, Cys, His,
cit) showed that most of the Zn(II) is bound to the HMM
fraction, mostly to HSA (Fig. 10) [16, 17]. At equimolar
concentration of the bis complex and HSA, dipic is
able to maintain Zn(II) at higher concentration in the
LMM fraction compared to the binary ligands owing to its
high potency to bind Zn(II). It was also revealed that HSA-
ligand interaction affects the metal ion distribution. The
results of the modeling calculation were also conﬁrmed
Figure 8. Electropherogram of [Zn(dipic)2]
2 incubated for 24 h
with apoTf and HSA at a ratio of 1:1:1 in carbonate buffer. Shown
are the traces of 64Zn and 34S (for HSA and apoTf detection).
Peak identiﬁcation: 1 – apoTf adduct; 2 – HSA adduct and
3 – [Zn(dipic)2]
2; Conditions: see Section 2.
Figure 9. Electropherogram of [Zn(dipic)2]
2 incubated for 24 h
with serum in carbonate buffer. Shown are the traces of 64Zn and
34S (for HSA and Tf detection). Peak identiﬁcation: 1 – Tf; 2 – HSA
adduct and 3 – [Zn(dipic)2]
2; Conditions: see Section 2.
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Figure 10. Calculated Zn(II) speciation in the blood serum.
Sample concentration of the anti-diabetic complex: c([Zn
(ligand)2]) 100 mM; of the relevant serum components: c(HSA)
158 mM; c(Tf) 6.3 mM; c(a2M) 1.5 mM; c(cit) 25 mM; c(His) 19 mM;
c(Cys) 8 mM (pH5 7.40; T5 251C).
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experimentally by ultraﬁltration–ICP-atomic emission
spectroscopy studies [16]. HSA has a higher capacity to bind
Zn(II) than a2M at elevated Zn(II) concentration, due to its
much higher concentration and accordingly a higher
number of available binding sites.
4 Concluding remarks
Zn(II) complexes are promising candidates as insulin-
enhancing drugs for the treatment of diabetes. Zn(II)
complexes with mal, pic and dipic ligands were prepared
in situ and their reaction with human serum proteins
was studied by means of CZE hyphenated to ICP-MS.
As compared to the tridentate ligand dipic, the bidentate
metal binders mal and pic form less stable complexes
with Zn(II) and accordingly higher amounts of Zn were
detected at both HSA and apoTf. Competitive experiments
with HSA and apoTf revealed signiﬁcant preference for
HSA over apoTf at equimolar incubation ratios. However,
under serum conditions, HSA is by far the preferred
binding partner for all three Zn(II)-ligand systems. Model-
ing calculations based on solution speciation studies
and stability constants of binary and ternary Zn-ligand
(-biomolecule) systems can give a good estimation of the
distribution of such bioelements in biological ﬂuids, with
kinetic factors and the time course of these metal transport
processes potentially having a signiﬁcant inﬂuence on this
picture. Attempts to correlate the experimental data for the
distribution of Zn(II) in the serum with calculated results
demonstrated overall good agreement of data obtained by
calculations and experiments. Such metal ion distribution
results can be used for designing carrier compounds with
the desired chemical characteristics for obtaining ideal
transport properties and mobility features.
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10.9 million people are worldwide diagnosed with cancer every year [1]. By the time cancer is 
diagnosed most of the patients have already infected lymph nodes and metastases. In these 
cases complete eradication by surgery is nearly impossible and chemotherapy is necessary. 
The three approved Pt drugs, cisplatin, carboplatin and oxaliplatin, are among the few metal-
based compounds in contemporary medical oncology [18, 19]. They have improved 
chemotherapy significantly [49, 132, 133] but their administration is accompanied by severe 
side effects as well as intrinsic and acquired resistance. The resistance is explained by 
enhanced repair of Pt-DNA adducts or enhanced tolerance to these adducts [32-36], 
detoxification by reaction with intracellular thiols [38-40] and by lower intracellular drug 
concentration due to reduced drug uptake and enhanced efflux [29-31]. All three compounds 
are administrated intravenously and therefore serum proteins are the first possible binding 
partners for these complexes. It was found that 65% to 98% of cisplatin in the blood plasma 
is bound to proteins within a day after administration [44, 134]. The literature about the 
binding of Pt-antitumor agents to serum proteins is contradictory and it seems that this 
interaction is important for both drug activity and toxicity. Through the irreversible binding of 
cisplatin to plasma proteins it is believed that the formation of Pt-protein adducts competes 
with formation of cyctotoxic Pt-DNA lesions, and results in a reduction of the efficacy of Pt 
antitumor agents [135-138]. On the other side there are also reports that indicated the 
effectiveness of cisplatin-HSA complexes in the treatment of patients with various types of 
tumors [139]. These studies demonstrated that the tumor Pt concentration was considerably 
higher after cisplatin-HSA administration than after conventional cisplatin therapy. 
Furthermore, it was shown that the response of hypo-albuminemic patients to cisplatin 
therapy is poor [140, 141]. Pt anticancer drugs are used in the clinic for more than 30 years 
and despite the controversy about the interaction of cisplatin, carboplatin and oxaliplatin with 
plasma proteins clinical trials concerning this issue just started in 2005 [142]. 
Due to the resistance and severe side effects of the anticancer drugs used nowadays in the 
clinics there is an intensive search for new and better tolerated drugs. Based on the 
pathophysiology of cancer cells it is important to design new, targeted anticancer drugs and 
investigate their modes of action for further optimization. In this thesis, CE and ICP-MS as 
well as a hyphenated approach of both have been used to study the influence of the 
lipophilicity on the anticancer activity of Pt complexes and for the characterization of the 
interaction of metal-based drugs with serum proteins. 
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One way to improve contemporary chemotherapy is to enhance the intracellular drug 
concentration in tumor cells [143-145]. Therefore the relationship between lipophilicity, 
accumulation of anticancer drugs in tumor cells and cytotoxicity was investigated closer. The 
lipophilicity of a compound is a useful parameter for an efficient screening of new drug 
candidates and was determined for various anticancer Pt complexes by the shake-flask 
method as well as indirectly by MEEKC. A linear correlation between the log P and log k 
values obtained by the shake-flask method and MEEKC, respectively, was only observable 
as long the Pt complexes varied only slightly in their structure. Due to the simplicity and 
automation of MEEKC as compared to the shake-flask method further studies on the 
correlation of log P and log k appear attractive. Moreover, in order to establish a more 
general rule, a broader series of compounds is required. Because of the limitation of 
conventional MEEKC technique to UV/vis active compounds, the hyphenation of MEEKC to 
ICP-MS was established. Log k values obtained by ICP-MS detection were very similar to the 
values obtained with UV/vis detection. Initial performance tests revealed slightly higher 
sensitivity for the ICP-MS system as compared to UV/vis. However, MEEKC-UV/vis was 
more stable in terms of operation, and high linearity of the calibration curve was obtained 
without addition of an internal standard. Further improvements of the MEEKC-ICP-MS 
system are necessary, especially with regard to peak shape and this could broaden the area 
of application of the method. With the aim of gaining a deeper insight into the mechanism of 
action of anticancer Pt complexes and in order to understand the structure-activity 
relationships, the lipophilicity was correlated to the redox potentials, in vitro antiproliferative 
activity and cellular accumulation. The cytotoxic properties of the studied Pt compounds 
correlate well with the lipophilicity as well as the accumulation of the compounds in tumor 
cells, but are not caused by differences in the reduction potentials.  
The relationship between lipophilicity and cellular uptake of Pt compounds was also 
investigated by analysis of in vivo samples. In contrast to cisplatin and carboplatin, the 
cellular uptake of oxaliplatin is mainly based on passive diffusion and less dependent on 
facilitated transport by the copper influx transporter CTR1 [19, 56]. Therefore, oxaliplatin and 
its methyl derivatives KP1691 and KP1537 were chosen for the in vivo studies. Organ 
samples from tumor-bearing mice, collected 1 and 6 h post-injection, were analyzed for 
biodistribution and accumulation in the tumor. The complex KP1691 had the fastest 
accumulation rate in all analyzed tissue samples but also a fast efflux was observed. In 
contrast, the Pt tumor content in the KP1537 group was similar to that of oxaliplatin 6 h after 
administration. A closer look at Pt tumor levels indicates that for KP1537 no changes were 
found between the samples taken 1 and 6 h post-injection, whereas in the oxaliplatin group 
an increase was seen. It would be interesting to perform the same experiments but over a 
longer time and see if the Pt content further increases for oxaliplatin. Considering that 
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neurotoxicity is a central problem of clinical oxaliplatin applications [50], the lower 
accumulation of KP1537 in the sciatic nerve makes it a promising oxaliplatin follower.  
A further focus of my PhD thesis was the interaction of metal complexes with serum proteins 
as well as their biodistribution. For metal-based drugs the interaction with serum proteins is 
thought to be important for their activity and better accumulation in cells [84-86]. For that 
reason a better understanding of the formation and reactivity of metal-protein adducts could 
help in defining the therapeutic profile of these drugs and improve treatment strategies. A 
CZE-ICP-MS technique was optimized to study the in vitro binding of diverse anticancer Ru 
complexes and antidiabetic Zn compounds with the serum proteins HSA and Tf. Both 
classes of metal complexes showed a high affinity toward HSA. The experimental data for 
the Zn compounds were confirmed by theoretical calculations. The findings for the Ru 
complexes are interesting considering the accumulation of HSA in malignant tissue due to 
anatomical pathophysiology of tumor blood vessels that facilitates the transport of 
macromolecules into tumor tissue combined with an absent or defective lympathic drainage 
system. In the case of the Ru complex KP1339, the in vitro results were verified by in vivo 
experiments in non-tumor bearing nude BALB/c mice. Additionally, to the serum protein 
interaction also the accumulation of KP1339 in different tissues was investigated. The 
highest Ru levels were found in colon, lung, liver, kidney and thymus. Until now KP1339 was 
considered a promising drug candidate against colon cancer [73] but the high accumulation 
in lung and thymus makes this compound also interesting for the treatment of lung cancer 
and lymphoblastic leukemia. Further investigations in this direction are desirable. 
In conclusions, this thesis indicates how important preclinical studies are and how they can 
aid in the prediction of the activity of a compound. Simple parameters like e.g. lipophilicity 
can help in the screening of drug candidates but there is a need for better techniques. 
Furthermore, in vitro experiments can only give limited information and animal tests are 
required to consider important factors such as bioavailability, -distribution and 
pharmacokinetics. All these joint efforts have potential to enhance drug development in 
future. 
 
109
 110
  
References 
5. References 
 
1. Cancer Research UK, Mortality from cancer worldwide. 
www.info.cancerresearchuk.org, last update 25/09/2009. 
2. German Cancer Research Center, Atlas of cancer mortality; comparison with other 
causes of death. www.dkfz.de, last update 26/10/2010. 
3. German Cancer Research Center, Atlas of cancer mortality; leading causes of cancer 
deaths. www.dkfz.de, last update 23/05/2007. 
4. Cancer Research UK, Trends in cancer mortality-UK statistics. 
www.info.cancerresearchuk.org, last update 01/04/2010. 
5. American Cancer Society, What is cancer. www.cancer.org, last update 22/03/2010. 
6. American Cancer Society, Cancer causes: theories throughout history. 
www.cancer.org, last update 22/03/2010. 
7. M. J. Atkinson and S. Tapio, Tumorgenesis. The impact of tumor biology on cancer 
treatment and multidisciplinary strategies 2009: p. 2-15. 
8. B. Alberts, Lehrbuch der molekularen Zellbiologie, 2002: p. 1317. 
9. T. Sjöblom, et al., The Consenous Coding Sequences of Human Breast and Colorectal 
Cancers. Science, 2006. 314: p. 268-274. 
10. R. C. Smart, Chemical Cancerogenesis. A Textbook of Modern Toxicology, 2004. 
11. P. Hainaut and M. Hollstein, p53 and human cancer: The first ten thousand mutations. 
Advances in Cancer Research, Vol 77, 2000. 77: p. 81-137. 
12. A. Hamai, et al., Immune surveillance of human cancer: if the cytotoxic T-lymphocytes 
play the music, does the tumoral system call the tune? Tissue Antigens, 2010. 75: p. 1-
8. 
13. D. Hanahan and R. A. Weinberg, The Hallmarks of Cancer. Cell, 2000. 100: p. 57-70. 
14. J. H. Mao, et al., Stochastic modelling of tumorgenesis in p53 deficient mice. British 
Journal of Cancer, 1998. 77(2): p. 243-252. 
15. German Cancer Research Center, Atlas of Cancer Mortality; Trends by age range. 
www.dkfz.de, last update 06/11/2007. 
16. V. T. DeVita and E. Chu, A history of cancer chemotherapy. Cancer Res, 2008. 
68(21): p. 8643-53. 
17. J. F. Kelvin and L. B. Tyson, What is cheotherapy and how is it given? One hundred 
questions and answers about cancer treatment side effects, 2005: p. 8. 
18. M. Galanski, et al., Recent developments in the field of tumor-inhibiting metal 
complexes. Curr Pharm Des, 2003. 9(25): p. 2078-89. 
19. L. Kelland, The resurgence of platinum-based cancer chemotherapy. Nature Reviews 
Cancer, 2007. 7(8): p. 573-584. 
20. B. Rosenberg, L. Vancamp, and T. Krigas, Inhibition of Cell Division in Escherichia 
Coli by Electrolysis Products from a Platinum Electrode. Nature, 1965. 205: p. 698-9. 
21. B. Rosenberg, et al., Platinum-induced filamentous growth in Escherichia coli. J 
Bacteriol, 1967. 93(2): p. 716-21. 
22. M. Peyrone, Über die Einwirkung des Ammoniaks auf Platinchlorid. Annalen der 
Chemie und Pharmacie, 1844. 51: p. 1-29. 
23. G. B. Kauffman, et al., Michele Peyrone (1813-1883), Discoverer of Cisplatin. 
Platinum Metals Rev., 2010. 54(4): p. 250-256. 
24. T. Boulikas and M. Vougiouka, Recent clinical trials using cisplatin, carboplatin and 
their combination chemotherapy drugs (Review). Oncology Reports, 2004. 11(3): p. 
559-595. 
25. L. H. Einhorn, Curing metastatic testicular cancer. Proc Natl Acad Sci U S A, 2002. 
99(7): p. 4592-5. 
111
  
References 
26. A. M. Fichtinger-Schepman, et al., cis-Diamminedichloroplatinum(II)-induced DNA 
adducts in peripheral leukocytes from seven cancer patients: quantitative 
immunochemical detection of the adduct induction and removal after a single dose of 
cis-diamminedichloroplatinum(II). Cancer Res, 1987. 47(11): p. 3000-4. 
27. F. P. T. Hamers, W. H. Gispen, and J. P. Neijt, Neurotoxic Side-Effects of Cisplatin. 
European Journal of Cancer, 1991. 27(3): p. 372-376. 
28. Drug Information online, Cisplatin Side Effects. www.drugs.com. 
29. D. J. Stewart, et al., Platinum Concentrations in Human Autopsy Tumor Samples. 
American Journal of Clinical Oncology-Cancer Clinical Trials, 1988. 11(2): p. 152-
158. 
30. D. P. Gately and S. B. Howell, Cellular accumulation of the anticancer agent 
cisplatin: a review. Br. J. Cancer, 1993. 67: p. 1171-1176. 
31. K. Katano, et al., Acquisition of resistace to cisplatin is accompanied by changes in 
the cellular pharmacology of copper. Cancer Res., 2002. 62: p. 6559-6565. 
32. D. Fink, The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 
1996. 56: p. 4881-4886. 
33. S. Johnson, et al., Relationship between platinum-DNA adduct formation and removal 
and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer 
cells. Cancer Res., 1994. 54: p. 5911-5916. 
34. K. V. Ferry, T. C. Hamilton, and S. W. Johnson, Increased nucleotide excision repair 
in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol., 
2000. 60: p. 1305-1313. 
35. I. Y. Chang, et al., Small interfering RNA-induced suppresion of ERCC1, enhances 
sensitivity of human cancer cells to cisplatin. Biochem.Biophys.Res.Commun., 2005. 
327: p. 225-233. 
36. E. Reed, ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res., 
2005. 11: p. 6100-6102. 
37. E. R. Jamieson and S. J. Lippard, Structure, recognition, and processing of cisplatin-
DNA adducts. Chemical Reviews, 1999. 99(9): p. 2467-2498. 
38. P. Mistry, et al., The relationships between glutathione, glutathione-S-transferase and 
cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell 
lines. Br. J. Cancer, 1991. 64: p. 215-220. 
39. A. D. Lewis, J. D. Hayes, and C. R. Wolf, Glutathione and glutathione-dependent 
enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after 
the onset of drug resistance: intrisic differences and cell cycle effects. Carcinogenesis, 
1988. 9: p. 183-1287. 
40. S. L. Kelland, et al., Overexpression of metallothionein confers resistance to 
anticancer drugs. Science, 1988. 241: p. 1813-1815. 
41. D. Lebwohl and R. Canetta, Clinical development of platinum complexes in cancer 
therapy: an historical perspective and an update. European Journal of Cancer, 1998. 
34(10): p. 1522-1534. 
42. M. Galanski, M. A. Jakupec, and B. K. Keppler, Update of the preclinical situation of 
anticancer platinum complexes: Novel design strategies and innovative analytical 
approaches. Current Medicinal Chemistry, 2005. 12(18): p. 2075-2094. 
43. F. M. Muggia, Overview of Carboplatin - Replacing, Complementing, and Extending 
the Therapeutic Horizons of Cisplatin. Seminars in Oncology, 1989. 16(2): p. 7-13. 
44. L. Pendyala and P. J. Creaven, In Vitro Cytotoxicity, Protein Binding, Red Blood Cell 
Partitioning, and Biotransformation of Oxaliplatin. Cancer Research, 1993. 53: p. 
5970-5976. 
112
  
References 
45. A. K. Holzer, G. H. Manorek, and S. B. Howell, Contribution of the major copper 
influx transporter CTR1to the cellular accumulation of cisplatin, carboplatin and 
oxaliplatin. Molec. Pharmacol., 2006. 70: p. 1390-1394. 
46. H. Bing, et al., Oxaliplatin, fluorouracil and leucovorin (FOLFOX) as first-line 
chemotherapy for metastatic or recurrent colorectal cancer patients. Chinese Journal 
of Clinical Oncology, 2007. 4(6): p. 397-400. 
47. S. Giachetti, et al., Phase III multicenter randomized trial of oxaliplatin added to 
chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic 
colorectal cancer. J. Clin. Oncol., 2000. 18: p. 136-147. 
48. A. de Gramont, et al., Leucovorin and fluorouracil with or without oxaliplatin as first-
line treatment in advanced colorectal cancer. J. Clin. Oncol., 2000. 18: p. 2938-2947. 
49. R. M. Goldberg, et al., A key clincial phase III study showing significantly improved 
survival with oxaliplatin, fluorouracil/leucovorin (FOLFOX regimen) in patients with 
previously untreated metastatic colorectal canccer. J. Clin. Oncol., 2004. 22: p. 23-29. 
50. M. W. Saif and J. Reardon, management of oxaliplatin-induced peripheral 
neutropathy. Therapeutics and Clinical Risk Management, 2005. 1(4): p. 249-258. 
51. M. D. Hall, et al., Basis for design and development of Platinum(IV) anticancer 
complexes. J. Med. Chem., 2007. 50(15): p. 3403-3411. 
52. C. N. Sternberg, et al., Phase III trial of satraplatin, an oral platinum plus prednisone 
vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 
2005. 68(1): p. 2-9. 
53. M. R. Reithofer, et al., Tuning of lipophilicity and cytotoxic potency by structural 
variation of anticacer platinum(IV)complexes. Journal of Inorganic Bichemistry, 
2011. 105(1): p. 46-51. 
54. L. R. Kelland, An update on satraplatin: the first orally available platinum anticancer 
drug. Exp.Opin. Invest. Drugs, 2000. 9: p. 1373-1382. 
55. A. P. Silverman, et al., 2.4-A crystal structure of the asymmetric platinum complex 
[Pt(ammine)(cyclohexylamine)] bound to a dodecamer DNA duplex. J. Biol.Chem., 
2002. 277: p. 49743-49749  
56. G. Samimi and S. B. Howell, Modulation of the cellular pharmacology of JM118, the 
major metabolite of satraplatin, by copper influx and efflux transporters. Cancer 
Chemother. Pharmacol., 2006. 57: p. 781-788. 
57. S. Y. Sharp, P. M. Rogers, and L. R. Kelland, Transport of cisplatin and Bis-acetato-
ammine-dichlorocyclohexylamine-platinum(IV) (JM216) in human ovarian carcinoma 
cell lines: identification of a plasma membrane protein associated with cisplatin 
resistance. Clin.Cancer Res., 1995. 1: p. 981-989. 
58. A. Kozubik, et al., High effectiveness of platinum(IV) complex with adamantylamine 
in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer 
cells in vitro. Biochem. Pharmacol., 2005. 69(3): p. 373-383. 
59. J. Turanek, et al., New platinum(IV) complex with adamantylamine ligand as a 
promising anti-cancer drug: comparison of in vitro cytotoxic potential towards 
A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) 
complexes. Anti-Cancer Drugs, 2004. 15(5): p. 537-543. 
60. Y. K. Yan, et al., Organometallic chemistry, biology and medicine: ruthenium arene 
anticancer complexes. Chemical Communications, 2005(38): p. 4764-4776. 
61. N. Katsaros and A. Anagnostopoulou, Rhodium and its compounds as potential agents 
in cancer treatment. Critical Reviews in Oncology Hematology, 2002. 42(3): p. 297-
308. 
62. G. A. Woldemariam and S. S. Mandal, Iron(III)-salen damages DNA and induces 
apoptosis in human cell via mitochondrial pathway. J. Inorg. Biochem., 2008. 102(4): 
p. 740-747. 
113
  
References 
63. D. S. Dwyer, K. Gordon, and B. Jones, Ruthenium Red potently inhibits immune 
responses both in vitro and in vivo. Int J Immunopharmacol, 1995. 17(11): p. 931-40. 
64. R. A. Sanchez-Delgado, et al., Toward a novel metal-based chemotherapy against 
tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new 
ruthenium- and rhodium-chloroquine complexes. J Med Chem, 1996. 39(5): p. 1095-
99. 
65. C. S. Allardyce and P. J. Dyson, Ruthenium in medicine:Current clinical uses and 
future prospects. Platinum Metals Review, 2001. 45(2): p. 62-69. 
66. M. J. Clarke, The Potential of Ruthenium in anticancer pharmaceuticals. Inorganic 
Chemistry in Biology and Medicine, 1980: p. 157-180. 
67. M. Gielen and E.R.T. Tiekink, Perspectives of Ruthenium complexes in Cancer 
Therapy Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of 
Metals in Medicine, 2005. 
68. J. M. Rademaker-Lakhai, et al., A Phase I and pharmacological study of the platinum 
polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with 
solid tumors. Clin Cancer Res, 2004. 10(10): p. 3386-95. 
69. E. S. Antonarakis and A. Emadi, Ruthenium-based chemotherpeutics: are they ready 
for prime time? Cancer Chemotherapy and Pharmacology, 2010. 66(1): p. 1-9. 
70. M. Cocchietto, et al., Primary tumor, lung and kidney retention and antimetastasis 
effect of NAMI-A following different routes of administration. Investigational New 
Drugs, 2003. 21(1): p. 55-62. 
71. P. J. Dyson and G. Sava, Metal-based antitumour drugs in the post genomic era. 
Dalton Trans., 2006(16): p. 1929-1933. 
72. P. Heffeter, et al., Intracellular protein binding patterns of the anticancer ruthenium 
drugs KP1019 and KP1339. JBIC, J. Biol. Inorg. Chem., 2010. 15(5): p. 737-748. 
73. C. G. Hartinger, et al., From bench to bedside - preclinical and early clinical 
development of the anticancer agent indazolium trans-[tetrachlorobis(1H-
indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006. 100(5-6): p. 
891-904. 
74. C. Scolaro, et al., In vitro and in vivo evaluation of ruthenium(II)-arene PTA 
complexes. J. Med. Chem., 2005. 48(12): p. 4161-4171. 
75. W. Forth, et al., Allgemeine und Spezielle Pharmakologie und Toxikologie. 6. Auflage 
Mannheim; Leipzig; Wien; Zürich BI-Wiss.-Verlag, 1992: p. 3. 
76. E. Oberdisse, E. Hackenthal, and K. Kuschinsky, Pharmakologie und Toxikologie. 3. 
Auflage Springer-Verlag, 2002: p. 4. 
77. Institut für Biochemische Pharmakologie Universität Innsbruck, Pharmakokinetik. 
1994: p. 1-18. 
78. Merck, Clinical Pharmacology, Introduction. 
http://www.merckmanuals.com/professional/sec20/ch303/ch303a.html, last update 
11/2007. 
79. Merck, Clinical Pharmacology, Absorption. 
http://www.merckmanuals.com/professional/sec20/ch303/ch303b.html, last update 
11/2007. 
80. S. Chillistone and J.  Hardman, Factors affecting drug absorption and distribution. 
Anaesthesia and Intensive Care Medicine, 2008. 9(4): p. 167-171. 
81. H. P. Rang, M. M. Dale, and J. M. Ritter, Absorption and distribution of drugs. 
Pharmacology & Therapeutics, 1999: p. 68. 
82. M. J. Banker and T. H. Clark, Plasma/serum protein binding determinations. Curr. 
Drug. Metab., 2008. 9(9): p. 854-9. 
114
  
References 
83. J.J.H.M. Lohman, F.W.H.M. Merkus, and K.H. Rahn, Plasma protein binding of 
drugs. Implications for therapeutic drug monitoring. Pharmacy world & science, 
1986. 8(6): p. 302-304. 
84. L. Hongyan, S. Hongzhe, and M. Q. Zhong, The role of the transferrin-transferrin-
receptor system in drug delivery and targeting. Trends in Pharmacological Sciences, 
2002. 23(5): p. 206-209. 
85. F. Kratz, Albumin, a versatile carrier in oncology. International Journal of Clinical 
Pharmacology and Therapeutics, 2010. 48(7): p. 453-455. 
86. G.Stehle, et al., Plasma protein (albumin) catabolism by the tumor itself-implications 
for tumor metabolism and the genesis of catechexia. Crit. Rev. Oncol., 1997. 26: p. 
77-100. 
87. Merck, Clinical Pharmacology, Metabolism. 
http://www.merckmanuals.com/professional/sec20/ch303/ch303e.html, last update 
09.2007. 
88. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski, The price of innovation: new 
estimates of drug development costs. Journal of Health Economics, 2003. 22(2): p. 
151-185. 
89. P. M. Lorosso, Phase 0 clinical trials:an answerto drug development stagnation? J. 
Clin.Oncol., 2009. 27: p. 2586-2588. 
90. US Department of Health and Human Services Food and Drug Administration, 
Clinical trials of medical treatment. http://www.fda.gov, last update 01/04/2010. 
91. aCCeSSCR, www.aCCeSSCr.com.au/upload/Image/Drugdeveolpment, 2007. 
92. US Department of Health and Human Services Food and Drug Administration, The 
critical path:making medical products better, faster and cheaper. 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm061234.htm, last 
accessed:29/07/2010. 
93. A. McNaught and A. Wilksinson, IUPAC Compendium of Chemical Terminology, 
Royal Society of Chemistry, Cambridge, UK, 1997. 
94. H. H. Lauer and G. P. Rozing, High Performance Capillary Electrophoresis. 2010, 
2nd. ed. 
95. J. W. Jorgenson and K. D. Lukacs, Capillary Zone Electrophoresis. Science, 1983. 
222(4621): p. 266-272. 
96. J. W. Jorgenson and K. D. Lukacs, Zone Electrophoresis in Open-Tubular Glass-
Capillaries. Analytical Chemistry, 1981. 53(8): p. 1298-1302. 
97. A. Shafaati, Capillary Electrophoresis. 
mnpc.congress.sums.ac.ir:8080/mnpc/ppt/Dr.shafaati.ppt, 01.05.2005. 
98. P. Camilleri, Capillary Electrophoresis, Theory and Practice. 1998, . 2nd. ed. 
99. Capillary electrophoresis, www.answers.com/topic/capillary-electrophoresis. 
100. K. D. Altria, Background theory and applications of microemulsion electrokinetic 
chromatography. Journal of Chromatography A, 2000. 892(1-2): p. 171-186. 
101. R. Ryan, et al., Advances in the theory and application of MEEKC. Electrophoresis, 
2010. 31(5): p. 755-767. 
102. Y. Henchoz, et al., High-throughput log P determination by MEEKC coupled with UV 
and MS detections. Electrophoresis, 2010. 31(5): p. 952-964. 
103. H. Wan, M. Ahman, and A. G. Holmen, Relationship between Brain Tissue 
Partitioning and Microemulsion Retention Factors of CNS Drugs. J. Med. Chem., 
2009. 52(6): p. 1693-1700. 
104. C. N. Yin, et al., Rapid determination of water- and fat-soluble vitamins with 
microemulsion electrokinetic chromatography. Journal of Chromatography A, 2008. 
1193(1-2): p. 172-177. 
115
  
References 
105. S. Lucangioli, et al., A capillary electrophoretic system based on a novel 
microemulsion for the analysis of coenzyme Q10 in human plasma by electrokinetic 
chromatography. Electrophoresis, 2009. 30(11): p. 1899-1905. 
106. Y. H. Cao, et al., Comparison of microemulsion electrokinetic chromatography with 
high-performance liquid chromatography for fingerprint analysis of resina draconis. 
Analytical and Bioanalytical Chemistry, 2008. 392(5): p. 1003-1010. 
107. T. F. Jiang, et al., Separation and Determination of Nitrofuran Antibiotics in Turbot 
Fish by Microemulsion Electrokinetic Chromatography. Analytical Sciences, 2009. 
25(7): p. 861-864. 
108. R. Thomas, A Beginner's Guide to ICP-MS Part I. Spectroscopy Tutorial, 2001. 16(4): 
p. 38-42. 
109. K. Cottingham, ICPMS: It's Elemental. Analytical Chemistry, 2004: p. 35-38. 
110. Agilent Technologies, The Principles of ICP-MS. http://www.chem.agilent.com/en-
US/Products/Instruments/atomicspectroscopy/icp-ms/pages/gp455.aspx. 
111. Perkin Elmer SCIEX, The 30-Minute Guide to ICP-MS. 
112. R. Thomas, p.-. A Beginner's Guide to ICP-MS. Part III: The Plasma Source. 
Spectroscopy Tutorial, 2001. 16(6): p. 26-30. 
113. R. Thomas, A Beginner's Guide to ICP-MS Part IV: The Interface Region. 
Spectroscopy Tutorial, 2001. 16(7): p. 26-34. 
114. R. Thomas, A Beginner's Guide to ICP-MS Part V: The Ion Focusing System. 
Spectroscopy Tutorial, 2001. 16(9): p. 38-44. 
115. R. Thomas, A Beginner's Guide to ICP-MS Part VI: The Mass Analyzer. Spectroscopy 
Tutorial, 2001. 16(10): p. 44-48. 
116. Georg-August-Universität Göttingen, Massenspektrometrie und Ionenbeschleuniger. 
https://lp.uni-goettingen.de/get/text/5338. 
117. J. W. Olesik, J. A. Kinzer, and S. V. Olesik, Capillary Electrophoresis Inductively-
Coupled Plasma Spectrometry for Rapid Elemental Speciation. Analytical Chemistry, 
1995. 67(1): p. 1-12. 
118. X. B. Yin, Y. Li, and X. P. Yan, CE-ICP-MS for studying interactions between metals 
and biomolecules. Trac-Trends in Analytical Chemistry, 2008. 27(6): p. 554-565. 
119. G. Alvarez-Llamas, et al., Comparison of two CE-ICP-MS interfaces based on 
microflow nebulizers: application to cadmium speciation in metallothioneins using 
quadrupole and double focusing mass analyzers. J. Anal. At. Spectrom., 2002. 17(7): 
p. 655-661. 
120. D. Schaumloffel and A. Prange, A new interface for combining capillary 
electrophoresis with inductively coupled plasma-mass spectrometry. Fresenius Journal 
of Analytical Chemistry, 1999. 364(5): p. 452-456. 
121. C. Moller, et al., Comparison of two CE-ICP-MS interfaces and quantitative 
measurements of carboplatin in plasma samples using an internal standard. J. Anal. 
At. Spectrom., 2009. 24(9): p. 1208-1212. 
122. S.Y. Lin, et al., Speciation of selenium compounds by open tubular capillary 
electrochromatography-inductively coupled plasma mass spectrometry. 
Electrophoresis, 2006. 27: p. 4257-4265. 
123. B. Michalke and P. Schramel, Application of capillary zone electrophoresis-
inductively coupled plasma mass spectrometry and capillary isoelectric focusing-
inductively coupled plasma mass spectrometry for selenium speciation. Journal of 
Chromatography A, 1998. 807(1): p. 71-80. 
124. A. K. Bytzek, et al., The first example of MEEKC-ICP-MS coupling and its 
application for the analysis of anticancer platinum complexes. Electrophoresis, 2010. 
31(7): p. 1144-1150. 
116
  
References 
125. M. Dole, L.L. Mack, and R.L. Hines, Molecular Beams of Macroions. Journal of 
Chemical Physics, 1968. 49(5): p. 2240. 
126. M. Yamashita and J. B. Fenn, Electrospray Ion-Source - Another Variation on the 
Free-Jet Theme. Journal of Physical Chemistry, 1984. 88(20): p. 4451-4459. 
127. M. Yamashita, M. and J. B. Fenn, Negative-Ion Production with the Electrospray Ion-
Source. Journal of Physical Chemistry, 1984. 88(20): p. 4671-4675. 
128. C. M. Whitehouse, et al., Electrospray Interface for Liquid Chromatographs and Mass 
Spectrometers. Analytical Chemistry, 1985. 57(3): p. 675-679. 
129. J. B. Fenn, et al., Electrospray Ionization for Mass-Spectrometry of Large 
Biomolecules. Science, 1989. 246(4926): p. 64-71. 
130. E. Hoffmann and V. Stroobant, Mass spectrometry, Principles and Applications. 
Wiley VCH, Weinheim, 2002. 
131. The University of Bristol School of Chemistry, Electrospray Ionisation. 
http://www.chm.bris.ac.uk/ms/theory/esi-ionisation.html,, last update 20.01.2004. 
132. D. Machover, et al., Two consecutive phase II studies of oxaliplatin (L-OHP) for 
treatment of patients with advanced colorectal carcinoma who were resistant to 
previous treatment with fluoropyrimidines. Ann. Oncol., 1996. 7: p. 95-98. 
133. F. Levi, et al., A chronopharmacologic phase II clinical trial with 5-fluorouracil, 
folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. 
High antitumour effectiveness against metastatic colorectal cancer. Cancer 1992. 69: 
p. 893-900. 
134. J. Will, A. Dirk, and W. S. Sheldrick, Characterisation of Cisplatin Binding Sites in 
Human Serum Proteins Using Hyphenated Multidimensional Liquid Chromatography 
and ESI Tandem Mass Spectrometry. Chem. Med. Chem, 2008. 3: p. 1696-1707. 
135. S. Urien and F. Lokiec, Population pharmacokinetics of total and unbound plasma 
cisplatin in adult patients. Br. J. Clin. Pharmacol., 2004. 57(6): p. 756-763. 
136. T. Peleg-Shulman, Y. Najajreh, and D. Gibson, Interaction of cisplatin and transplatin 
with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-
protein adducts of cisplatin and transplatin towards biological nucleophils. J. Inorg. 
Biochem., 2002. 91: p. 306-311. 
137. K. Takahashi, et al., Antitumor activity and toxicity of serum protein-bound platinum 
formed from cisplatin. Jpn. J. Cancer Res., 1985. 2: p. 68-74. 
138. W. C. Cole and W. Wolf, Preparation and metabolism of a cisplatin/serum protein 
complex. Chem. Biol. Interactions, 1980. 30: p. 223-235. 
139. J. D. Holding, et al., Phase I trial of a cisplatin-albumin complex for the treatment of 
cancer of the head and neck. Br. J. Clin. Pharmacol., 1992. 33(1): p. 75-81. 
140. J. D. Holding, et al., Disposition and tumour concentrations of platinum in 
hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and 
neck. Br. J. Clin. Pharmacol., 1991. 32: p. 173-179. 
141. E. Espinosa, et al., Serum albumin and other prognostic factors to response and 
survival in patients with advanced non-small cell lung cancer. Lung Cancer, 1995. 
12(3): p. 67. 
142. Alberta Health Services, Cisplatin, Carboplatin, and Oxaliplatin interactions with 
plasma proteins. 
http://clinicaltrials.gov/ct2/show/NCT00131586?term=NCT00131586&rank=1, last 
update 22.09.2008. 
143. D. J. Stewart, et al., Platinum Concentrations in Human Autopsy Tumor Samples. 
American Journal of Clinical Oncology-Cancer Clinical Trials, 1988. 11(2): p. 152-
158. 
144. L.Yang, E. B. Douple, and H. Wang, Irradiation enhances cellular uptake of 
carboplatin. Int. J. Radiation Oncology Biol. Phys., 1995. 33(3): p. 641-646. 
117
  
References 
145. S. A. Abramkin, et al., {(1R,2R,4R)-4-Methyl-1,2-
cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin 
Derivative Showing Improved Anticancer Activity in Vivo. J. Med.Chem., 2010. 
 
 
 
 
 
 
 
Ich habe mich bemüht, sämtliche Inhaber der Bildrechte ausfindig zu machen und ihre 
Zustimmung zur Verwendung der Bilder in dieser Arbeit eingeholt. Sollte dennoch eine 
Urheberrechtsverletzung bekannt werden, ersuche ich um Meldung bei mir. 
 
 
 
 
 
 
 
 
 
 
118
  
Curriculum Vitae 
6. Curriculum Vitae 
 
Dipl.-Chem. Anna Katharina Bytzek 
 
 
PERSONAL DATA 
           Date of Birth   April 1, 1982                                                     
Place of Birth   Beuthen (Poland) 
Nationality  German 
Civil status  unmarried 
Tel                             +43-1-4277-52666 
E-mail                        anna.bytzek@univie.ac.at 
 
 
EDUCATION 
11.2007-now PhD Study of Chemistry at the University of Vienna, Austria 
Specialization: Bioinorganic Chemistry  
“Studies on the biophysical properties and biotransformation of metal-
based drugs” 
02.-10.2007 Diploma-Thesis at the University of Kaiserslautern, Germany 
Specialization: Bioinorganic Chemistry  
“Untersuchungen der elektronischen und strukturellen Eigenschaften 
sowie der Reaktivität von Catecholat-, Semichinonat-und Benzo-   
chinonant-komplexen” 
04.-08.2006 Studies at the University of Barcelona, Spain 
Specialization: Molecular Magnetism 
08.2004 Intermediate Diploma in Chemistry (Bachelor degree equivalent) at 
the University of Kaiserslautern, Germany 
10.2002 Begin of studies at the University of Kaiserslautern, Germany 
Field of study: Chemistry 
1989 – 2002 Elementary and Grammar school, Germany 
 
 
 
119
  
Curriculum Vitae 
 
PROFESSIONAL SKILLS AND RESEARCH INTERESTS 
Biological Inorganic Chemistry, Molecular Magnetism, Coordination and 
Organometallic Chemistry, Medicinal Chemistry, Biodistribution of Anticancer 
Compounds, Bioanalytical Chemistry (Mass Spectrometry, Capillary Electrophoresis)  
 
 
AWARDS AND FELLOWSHIPS 
2004  Award of the GdCh for Intermediate Degree 
12.3.2008 Forschungsstipendium der Universität Wien 
„Wechselwirkung von Metallkomplexen mit Biomolekülen“ 
 
 
LANGUAGE SKILLS 
German native language 
English fluently 
Polish  fluently 
Spanish mediocre 
French  high school level 
 
 
PUBLICATIONS IN SCIENTIFIC JOURNALS 
Biodistribution of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)] (KP1339) 
Bytzek A.K., Koellensperger G., Keppler B.K., Hartinger C.G. 
Status: in preparation 
 
LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug 
candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in 
mouse plasma 
Bytzek A.K., Boeck K., Hann S., Keppler B.K., Hartinger C.G., Koellensperger G. 
Status: in preparation 
 
120
  
Curriculum Vitae 
The first example of MEEKC-ICP-MS coupling and its application for the analysis of 
anticancer platinum complexes 
Bytzek A.K., Reithofer M.R., Galanski M., Groessl M., Keppler B.K., Hartinger C.G. 
Status: published in Electrophoresis, 2010, 31, 1-7. (Cover article) 
 
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer 
platinum(IV) complexes 
Reithofer M.R., Bytzek A.K., Valiahdi S.M., Kowol C.R., Groessl M., Hartinger C.G., Jakupec M.A., 
Galanski M., Keppler B.K. 
Status: published in Journal of Inorganic Biochemistry, 2010, 105, 46-51. 
 
Improved in vitro and in vivo activity of novel methyl-substituted oxaliplatin analogs: 
impact of stereoisomerism 
Jungwirth U., Gojo J., Bytzek A.K., Koerner W., Heffeter P., Jakupec M.A., Galanski M., Hartinger 
C.G., Keppler B.K., Berger W. 
Status: in preparation 
 
KP1537- an oxaliplatin analog with reduced side effects 
Jungwirth U., Xanthos D., Bytzek A.K., Heffeter P., Hartinger C.G., Keppler B.K., Sandkühler J., 
Berger W. 
Status: in preparation. 
 
Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-
binding studies by means of CZE-ICP-MS 
Bytzek  A.K., Enyedy E.A., Kiss T., Keppler B.K., Hartinger C.G. 
Status: published in Electrophoresis, 2009, 30, 4075-4082. 
 
The serum protein binding of pharmacologically active gallium(III) compounds 
assessed by hyphenated CE-MS techniques 
Groessl M., Bytzek A., Hartinger C.G 
Status: published in Electrophoresis, 2009, 30, 2720-2727. 
 
Physiochemical studies and anticancer potency of ruthenium(η6-p-cymene) 
complexes containing antibacterial quinolones 
Kljun J., Bytzek A.K., Kandioller W., Bartel C., Jakupec M.A., Hartinger C.G., Keppler B.K., Turel I. 
Status: accepted in Organometallics  
121
  
Curriculum Vitae 
Cellular uptake, DNA interaction and protein binding studies of active trans-platinum 
anticancer compounds  
Bartel C., Bytzek A., Scaffidi-Domianello Y.Y., Hartinger C.G., Jakupec M.A., Kukushkin V. Y., 
Galanski M., Keppler B.K. 
Status: in preparation 
 
Mechanistic insights into the unexpected rearrangement of tosylated flavones to 
aminoaurones.  
Kandioller W., Kubanik  M., Bytzek A., Jakupec M.A., Arion V.B., Keppler B.K., Hartinger C.G. 
Status: submitted to Tetrahedron 
 
From hydrolytically labile to hydrolytically stable RuII-arene anticancer complexes with 
carbohydrate-derived co-ligands 
Hanif M., Meier S.M., Kandioller W., Bytzek A., Hejl M., Hartinger C.G., Nazarov A.A., Arion V.B., 
Jakupec M.A., Dyson P.J., Keppler B.K. 
Status: published in Journal of Inorganic Biochemistry, 2011, 105, 224-231. 
 
Strategies for the covalent conjugation of a bifunctional chelating agent to albumin: 
Synthesis and characterization of potential MRI contrast agents 
Kundu A., Peterlik H., Krssak M., Bytzek A.K., Pashkunova-Martic I., Arion V.B., Helbich T.H., Keppler 
B.K. 
Status: published in Journal of Inorganic Biochemistry, 2011, 105, 250-255. 
 
 
POSTER PRESENTATIONS 
 
The application of MEEKC-ICP-MS for the determination of octanol-water partition 
coefficients of anticancer platinum complexes  
Bytzek A.K., Galanski M., Hartinger C.G., Keppler B.K.  
Winter Conference on Plasma Spectrochemistry. Fort Myers, Florida, USA 2010.  
 
Metabolism of organometallic Ru compounds with antimetastatic activity  
Bytzek A.K., Hartinger C.G., Dyson P., Keppler B.K. 
European Winter Conference on Plasma Spectrochemistry. Graz, Austria 2009.  
 
 
 
122
  
Curriculum Vitae 
ORAL PRESENTATIONS 
 
The first example of MEEKC-ICP-MS coupling and its application for the analysis of 
anticancer platinum complexes 
Bytzek A.K., Galanski M., Keppler B.K., Hartinger C.G.   
MassSpec-Forum-Vienna-2010, Vienna, Austria 2010.  
 
Further studies of bis(carboxylate)platinum(IV) compounds: Correlation between 
lipophilicity, reduction potential, cellular accumulation and cytotoxicity 
Reithofer M R., Bytzek A.K.,Valiahdi S.M, Kowol Ch.R., Groessl M., Galanski, M., Hartinger C. G., 
Jakupec M.A., Keppler, B.K.,   
240th ACS National Meeting, Boston, MA, USA 2010.  
 
 
 
 
123
